===== DISCHARGE NOTE =====
note_id=14679785-DS-26 | hadm_id=20250603

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___.
 
Chief Complaint:
admitted for re-induction with ___
 
Major Surgical or Invasive Procedure:
Temp CVL ___
Temp CVL suture change ___

 
History of Present Illness:
HISTORY OF PRESENTING ILLNESS: ___ is a ___ man with
intermediate risk cytogenetics and favorable risk molecular
stratification (normal karyotype, FLT3 negative, NPM1 positive,
IDH2 positive, RAD21 positive, CEBPA (negative) presenting to
initiate therapy for now relapsed disease.

REVIEW OF SYSTEMS: No acute issues since recent discharge and
clinic visit. He still does not believe that his AML has
relapsed. Wonders if he took the additional HIDAC cycle if that
would have made a difference. He has not had any fevers, chills,
rigors, sweats, or localizing infectious symptoms. He denies any
headache, vision changes, dizziness, lightheadedness, nausea,
vomiting, abdominal pain, diarrhea, constipation, easy bruising,
joint swelling, skin rash, or any other complaints on a 10-point
review.

 
Past Medical History:
TREATMENT COURSE:
-------------------
___ INITIAL BMBX  AML
___ Consented to  protocol ___  INDUCTION DAUNOrubicin  (90 mg/m2)  Cytarabine  (100
mg/m2)  (RHP: +NPM1, +IDH2,+ RAD21)
___  D+14 BMBx ablated, 
___  D+26 remission, NPM1 negative
___ C1D1 HIDAC
--___ admitted for fever
--___ CT showed perianal abscess, drained, improved with
antibiotics
--___ - C2D1 HIDAC, complicated by fevers and rash after 4 
of
6 doses attributed to possible cytarabine syndrome, all resolved
with higher dexamethasone premedication. also received neulasta
on D9
--___ - C3D1 HIDAC, complicated by neutropenic fever, 
empiric
antibiotics without complications or infectious source
--___ - taken off of active study protocol (control arm) due
to patient preference to avoid frequent visits and tests;
consented to be followed by the study for survival/outcome data
- ___ - initiation of therapy for relapsed AML on trial
___

PAST MEDICAL HISTORY: AML as above

 
Social History:
___
Family History:
Mother had lung cancer
Father had some type of metastatic cancer extensively involving
the bones
No history of any hematologic disorders including leukemia or
lymphoma
 
Physical Exam:
ADMISSION PHYSICAL EXAMINATION:
___ 1605 Temp: 97.8 PO BP: 122/73 HR: 70 RR: 18 O2 sat: 99%
O2 delivery: RA 
GENERAL: Well-appearing adult man sitting comfortably in no 
acute
distress. Pleasant, conversant and interactive.
HEENT: Anicteric sclerae. Mucous membranes are moist and pink. 
no
petechiae, purpura, or exudates. No erythema in oropharynx.
LYMPHATICS:  No tenderness in right cervical region
PULMONARY: Lungs are clear bilaterally. No wheezing, rales or
rhonchi
HEART: RRR, no murmurs, rubs or gallops.
ABDOMEN: Soft, nontender, nondistended. No palpable masses or
hepatosplenomegaly.
EXTREMITIES:  Without any edema.
ACCESS: R Temp CVL

DISCHARGE PHYSICAL EXAMINATION:
___ 1206 Temp: 99 PO BP: 126/77 HR: 60 RR: 18 O2 sat: 100%
O2 delivery: RA 
GENERAL: NAD, lying in bed, pleasant and cooperative. 
HEENT: sclera are clear, conjuctivae anicteric. Mucous membranes
are moist, pink and intact. No petechiae, purpura, or exudates.
No OP lesions. 
PULMONARY: CTAB. No wheezing, rales, crackles or rhonchi.
Respirations are even and unlabored
HEART: RRR, normal S1/S2, no S3/S4, no murmurs, rubs or gallops
ABDOMEN: Normoactive BS. Soft, NTND. No masses or HSM. 
Rectum: Minimal induration on his left gluteal cleft. There is
still overlaying erythema but significantly improved. Skin
remains intact, non-tender on palpation.
EXTREMITIES: WWP. No edema, cyanosis or clubbing 
SKIN: Scattered faint petechiae on shins bilaterally
ACCESS: R Temp CVL-CDI. No erythema, tenderness or drainage.

 
Pertinent Results:
ADMISSION LABS
-----------------

___ 03:24PM   PLT SMR-VERY LOW* PLT COUNT-48*
___ 03:24PM   HYPOCHROM-1+* ANISOCYT-OCCASIONAL 
POIKILOCY-OCCASIONAL MACROCYT-NORMAL MICROCYT-NORMAL 
POLYCHROM-NORMAL OVALOCYT-OCCASIONAL
___ 03:24PM   NEUTS-4* BANDS-0 ___ MONOS-1* EOS-6 
BASOS-0 ___ MYELOS-0 BLASTS-37* AbsNeut-0.13* 
AbsLymp-1.72 AbsMono-0.03* AbsEos-0.20 AbsBaso-0.00*
___ 03:24PM   WBC-3.3* RBC-2.66* HGB-8.6* HCT-25.2* MCV-95 
MCH-32.3* MCHC-34.1 RDW-16.9* RDWSD-56.6*
___ 03:24PM   TSH-3.9
___ 03:24PM   ALBUMIN-3.9 CALCIUM-8.5 PHOSPHATE-3.7 
MAGNESIUM-2.1
___ 03:24PM   ALT(SGPT)-26 AST(SGOT)-20 ALK PHOS-57 TOT 
BILI-0.4
___ 03:24PM   GLUCOSE-81 UREA N-13 CREAT-0.8 SODIUM-141 
POTASSIUM-3.8 CHLORIDE-104 TOTAL CO2-26 ANION GAP-11
___ 12:00AM   PLT SMR-VERY LOW* PLT COUNT-48*
___ 12:00AM   HYPOCHROM-NORMAL ANISOCYT-NORMAL 
POIKILOCY-NORMAL MACROCYT-NORMAL MICROCYT-NORMAL 
POLYCHROM-NORMAL
___ 12:00AM   NEUTS-12* BANDS-0 ___ MONOS-3* EOS-8* 
BASOS-0 ATYPS-2* ___ MYELOS-0 BLASTS-35* AbsNeut-0.25* 
AbsLymp-0.88* AbsMono-0.06* AbsEos-0.17 AbsBaso-0.00*
___ 12:00AM   WBC-2.1* RBC-2.68* HGB-8.6* HCT-25.8* MCV-96 
MCH-32.1* MCHC-33.3 RDW-17.0* RDWSD-58.3*
___ 12:00AM   ALBUMIN-3.8 CALCIUM-8.2* PHOSPHATE-2.2* 
MAGNESIUM-2.0 URIC ACID-3.6
___ 12:00AM   ALT(SGPT)-25 AST(SGOT)-19 LD(LDH)-191 ALK 
PHOS-52 TOT BILI-0.3
___ 12:00AM   GLUCOSE-143* UREA N-11 CREAT-0.7 SODIUM-142 
POTASSIUM-4.4 CHLORIDE-108 TOTAL CO2-24 ANION GAP-10

DISCHARGE LABS:

___ 12:00AM BLOOD WBC-2.4* RBC-2.49* Hgb-7.4* Hct-22.2* 
MCV-89 MCH-29.7 MCHC-33.3 RDW-14.1 RDWSD-44.7 Plt Ct-70*
___ 12:00AM BLOOD Neuts-69 Bands-4 ___ Monos-7 Eos-0* 
___ Metas-1* AbsNeut-1.75 AbsLymp-0.46* AbsMono-0.17* 
AbsEos-0.00* AbsBaso-0.00*
___ 12:00AM BLOOD Glucose-91 UreaN-6 Creat-0.8 Na-142 
K-3.2* Cl-105 HCO3-26 AnGap-11
___ 12:00AM BLOOD ALT-34 AST-33 LD(LDH)-185 AlkPhos-115 
TotBili-0.6
___ 12:00AM BLOOD Albumin-3.1* Calcium-7.8* Phos-3.2 Mg-1.___ is a ___ man with intermediate
risk AML presenting to initiate therapy for relapsed disease 
with
MEC-R per ___. Course c/b febrile neutropenia with infectious
work-up revealing + clostridium difficile and CoNs from
peripheral culture x1 on ___ (thought to be likely 
contaminant)
and presumed perirectal cellulitis.

ACUTE CONDITIONS
--------------------

#Relapsed AML: evidence of relapsed disease, now enrolled in
protocol ___: Phase 2 Study of Mitoxantrone, Etoposide, and
Cytarabine(MEC) plus Lenalidomide for the Treatment of Adult
Patients with Relapsed or Refractory Acute Myeloid Leukemia. He
was initiated on Lenalidomide outpatient on ___ (Day 1).
Prior to admission, he was cytoreduced with hydrea 1g BID which
is no longer needed given MEC initiation. He is currently in his
nadir but has evidence of counts recovery. Pre-transplant
work-up: Echo, PFTs, EKG, CXR, and panorex (to evaluate for
dental caries given history of periodontal disease). 
-Mitoxantrone* 18 mg IV DAILY on Days 4, 5, 6, 7 and 8.
___ and ___ mg/m2) 
-Etoposide* 223 mg IV DAILY on Days 4, 5, 6, 7 and 8. ___ and ___ mg/m2) 
-Cytarabine* 2230 mg IV DAILY on Days 4, 5, 6, 7 and 8.
___ and ___ 

-Lenalidomide 50mg daily Days ___, now completed
-Added ACV on ___ for VZV/HSV prophylaxis
-Fungal prophylaxis with posaconazole initiated ___ after
MEC completion
-Tentative plan for pre-transplant dental extraction as
outpatient on ___ 
-Day 35 marrow: ___ (results pending) 

#Febrile Neutropenia:
#Perianal discomfort: 
 Last fever on ___. He had one bottle of blood culture on
___ (drawn peripherally) that grew coagulase negative
staphylococcus. ID consulted, thought to be likely due to skin
contamination during culture collection. He was started
empirically on cefepime, has been afebrile since. Positive C.
Diff detected ___ for which he initiated PO vancomycin (Day
1: ___. Of recent, in the setting of counts recovery, he was
noted to have increasing pain on his left gluteal cleft (had
prior abscess on the same site in ___. Given
neutropenia, we broadened his coverage to flagyl and vancomycin
IV. now on Cipro/flagyl per ID
-d/c home with Cipro/augmentin (patient cannot tolerate SE of 
flagyl) 
-u/s with small abscess collection, colorectal evaluated nothing 
to drain currently will f/u outpatient and monitor
-Continue surveillance of his L gluteal cleft pain currently no
pain

#Clostridium Difficile: positive assay on ___ with febrile
neutropenia work-up. Resolution of diarrhea with PO vancomycin. 
-Continue empirically for now on broad spectrum antibiotics 
-Continue PO Vancomycin (D1: ___ until 3days off po ABX

#Pancytopenia: His pancytopenia is most likely secondary to
recent MEC-Revlimid. Evidence of count recovery. Requiring less
frequent platelets and PRBC transfusions.  
-Continue with infectious prophylaxis as above 
-Transfuse if plts < 10 and/or hgb < 7 
-Monitor and trend
-Follow-up with results from BM biopsy 
-Neupogen administered with improved WBC ___ and ___

#Dysgeusia: Persistent bitter taste in mouth since beginning IV
Flagyl, which has resulted in decreased PO intake and 
exacerbated
weight loss (approximately 10kg since admission on ___. He
reports similar symptoms while taking flagyl on prior admission.
He states symptoms resolved with discontinuation. Will continue
to monitor, nutrition consulted, IVF as needed. 

#Malnutrition, mild: Patient with 9% weight loss in 1
month and ongoing poor appetite. Continue with nutrition 
support.
-Continue with diet as ordered, encourage PO intake as tolerated
-Encourage smoothies and frappes 
-Continue multivitamin w/ minerals
-Trend weights daily

#Bio-Psychosocial: He is coping fairly well with his newly
relapsed AML.  

#Marijuana Use: Reports using CBD oil and occasional vaporized
marijuana prior to admission. He is on fungal prophylaxis as
above. 

CHRONIC/RESOLVED CONDITIONS

#Vision change: Resolved. Transient episode of floater sensation
and blurry vision ___. This lasted approximately 15 minutes
then stopped. He had no numbness, tingling, or difficulty w/ 
word
finding at the time. Unclear etiology. No neurologic deficit on
exam. Given risk of CVA or TIA in the setting of high dose
Revlimid, we obtained MRI of head which showed no evidence of
infarction or hemorrhage. He has since completed his Revlimid
course per protocol. Monitor for reoccurrence. 

CORE MEASURES: 
----------------- 
#FEN: IVF prn/replete electrolytes/neutropenic diet & 
precautions
#DVT: None r/t thrombocytopenia  
#Access: R temp CVL placed ___
#HCP/Contact: ___   
#Code: Full Code

#Dispo: home f/u ___ or ___ or sooner if issues arise 
 
Medications on Admission:
The Preadmission Medication list is accurate and complete.
1. LORazepam 0.5-1 mg PO Q8H:PRN 
anxiety/nausea/vomiting/insomnia 
2. Vitamin D ___ UNIT PO DAILY 
3. Levofloxacin 500 mg PO Q24H 
4. Allopurinol ___ mg PO DAILY 
5. Lenalidomide 50 mg PO DAILY 
6. Hydroxyurea 1000 mg PO BID 
7. turmeric 1000 mg oral DAILY 
8. Multivitamins W/minerals 1 TAB PO DAILY 
9. ginger (Zingiber officinalis) 1 tab oral DAILY 

 
Discharge Medications:
1.  Acyclovir 400 mg PO Q12H 
RX *acyclovir 400 mg 1 tablet(s) by mouth twice a day Disp #*60 
Tablet Refills:*3 
2.  Amoxicillin-Clavulanic Acid ___ mg PO Q12H Duration: 10 Days 
 
3.  Ciprofloxacin HCl 500 mg PO Q12H 
RX *ciprofloxacin HCl 500 mg 1 tablet(s) by mouth twice a day 
Disp #*28 Tablet Refills:*0 
4.  Vancomycin Oral Liquid ___ mg PO QID  
5.  LORazepam 0.5-1 mg PO Q8H:PRN 
anxiety/nausea/vomiting/insomnia 
RX *lorazepam 0.5 mg ___ tabs by mouth every 8 hours as needed 
Disp #*30 Tablet Refills:*0 
6.  Multivitamins W/minerals 1 TAB PO DAILY  
7.  Vitamin D ___ UNIT PO DAILY  

 
Discharge Disposition:
Home
 
Discharge Diagnosis:
Relapsed AML
Pancytopenia 
Clostridium Difficile

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Mr. ___, 

You were admitted for your reinduction chemotherapy. While your 
counts were low you developed Clostridium Difficile and skin 
infection. You were treated with antibiotics and you improved. 
Continue your medications as prescribed and follow up with your 
oncologist. 
 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=14679785-DS-21 | hadm_id=21246101

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___.
 
Chief Complaint:
Febrile Neutropenia
 
Major Surgical or Invasive Procedure:
I&D of perianal abscess

 
History of Present Illness:
Mr. ___ is a ___ male with history of
intermediate-risk cytogenetics and favorable risk AML (normal
karyotype, FLT3-, NPM1+, IDH2+, RAD21+, CEBPA-) in ___ remission
after successful induction 7+3 chemotherapy who presented to
clinic C1D126 of HiDAC consolidation and admitted for febrile
neutropenia.

Patient presented to clinic for blood count check. He reports
feeling tired for the past few weeks. His labs were notable for
ANC 90, H/H 7.1/20.7, and Plt 16. He was transfused 1 unit PBRCs
and 1 unit platelets. 1 hour after receiving Tylenol
pre-medication for his platelets (developed hives on 2 most
recent platelet transfusions), his temp rose to 99.6 from 98.1.
He had blood and urine cultures. He was given cefepime 2g IV.
Decision was made to admit for febrile neutropenia.

On arrival to the floor, patient reports chills currently but no
fevers or chills at home. He denies headache, vision changes,
dizziness/lightheadedness, weakness/numbnesss, shortness of
breath, cough, hemoptysis, chest pain, palpitations, abdominal
pain, nausea/vomiting, diarrhea, hematemesis,
hematochezia/melena, dysuria, hematuria, and new rashes.

REVIEW OF SYSTEMS: A complete 10-point review of systems was
performed and was negative unless otherwise noted in the HPI.

 
Past Medical History:
PAST ONCOLOGIC HISTORY:
- ___: INITIAL BMBX  AML
- ___: Consented to  protocol ___:
- ___: INDUCTION DAUNOrubicin  (90 mg/m2)  Cytarabine  (100
mg/m2) (RHP: +NPM1, +IDH2,+ RAD21)
- ___: D+14 BMBx ablated, 
- ___: D+26 remission, NPM1 negative
- ___: C1D1 HIDAC

PAST MEDICAL HISTORY:
- AML, as above
 
Social History:
___
Family History:
Mother had lung cancer. Father had some type of
metastatic cancer extensively involving the bones. No history of
any hematologic disorders including leukemia or lymphoma.
 
Physical Exam:
ADMISSION PHYSICAL EXAM:
=========================
VS: Temp 99.1, BP 148/79, HR 85, RR 20, O2 sat 100% RA.
GENERAL: Pleasant man, in no distress, lying in bed comfortably.
HEENT: Anicteric, PERLL, OP clear.
CARDIAC: RRR, normal s1/s2, no m/r/g.
LUNG: Appears in no respiratory distress, clear to auscultation
bilaterally, no crackles, wheezes, or rhonchi.
ABD: Soft, non-tender, non-distended, positive bowel sounds.
EXT: Warm, well perfused, no lower extremity edema, erythema or
tenderness.
NEURO: A&Ox3, good attention and linear thought, CN II-XII
intact. Strength full throughout. Sensation to light touch
intact.
SKIN: No significant rashes.
ACCESS: Right chest wall port without erythema.

DISCHARGE PHYSICAL EXAM:
=========================
VS: 98.1 104 / 67 84 20 100 Ra  
GENERAL: Pleasant man, NAD, lying in bed comfortably.
HEENT: Anicteric, PERRL, OP clear.
CARDIAC: RRR, normal s1/s2, no murmurs, gallops, or rubs.
LUNG: Appears in no respiratory distress, clear to auscultation
bilaterally, no crackles, wheezes, or rhonchi.
ABD: Soft, non-tender, non-distended, positive bowel sounds.
RECTAL: clean incision site at perianal region at 11 o'clock
position with drainage
EXT: Warm, well perfused, no lower extremity edema, erythema or
tenderness.
NEURO: A&Ox3. Strength full throughout. Sensation to light touch
intact.
SKIN: No significant rashes.
ACCESS: Right chest wall port without erythema. Nontender to
palpation. 
 
Pertinent Results:
ADMISSION LABS:
=================
___ 11:30AM BLOOD WBC-0.5* RBC-2.33* Hgb-7.1* Hct-20.7* 
MCV-89 MCH-30.5 MCHC-34.3 RDW-14.6 RDWSD-47.0* Plt Ct-16*
___ 11:30AM BLOOD Neuts-18* Bands-0 Lymphs-74* Monos-3* 
Eos-1 Baso-0 Atyps-4* ___ Myelos-0 AbsNeut-0.09* 
AbsLymp-0.39* AbsMono-0.02* AbsEos-0.01* AbsBaso-0.00*
___ 11:30AM BLOOD Hypochr-NORMAL Anisocy-NORMAL 
Poiklo-NORMAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL
___ 03:15PM BLOOD UreaN-10 Creat-0.8 Na-140 K-3.6 Cl-100 
HCO3-26 AnGap-14
___ 03:15PM BLOOD ALT-18 AST-13 AlkPhos-63 TotBili-0.6
___ 12:00AM BLOOD Calcium-8.5 Phos-3.7 Mg-1.5*

DISCHARGE LABS:
=================
___ 12:00AM BLOOD WBC-3.6* RBC-2.90* Hgb-8.9* Hct-25.8* 
MCV-89 MCH-30.7 MCHC-34.5 RDW-14.5 RDWSD-46.0 Plt ___
___ 12:00AM BLOOD Neuts-29* Bands-1 ___ Monos-39* 
Eos-0 Baso-0 ___ Metas-3* Myelos-0 AbsNeut-1.08* 
AbsLymp-1.01* AbsMono-1.40* AbsEos-0.00* AbsBaso-0.00*
___ 12:00AM BLOOD Hypochr-1+* Anisocy-NORMAL Poiklo-NORMAL 
Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL
___ 12:00AM BLOOD Glucose-101* UreaN-7 Creat-0.7 Na-138 
K-4.2 Cl-100 HCO3-23 AnGap-15
___ 12:00AM BLOOD ALT-29 AST-19 LD(LDH)-191 AlkPhos-73 
TotBili-0.2
___ 12:00AM BLOOD Albumin-4.0 Calcium-8.7 Phos-4.1 Mg-2.1

MICROBIOLOGY:
================
___ 3:15 pm BLOOD CULTURE

                            **FINAL REPORT ___

   Blood Culture, Routine (Final ___:    NO GROWTH. 

___ 4:00 pm BLOOD CULTURE      PERIPHERAL. 

                            **FINAL REPORT ___

   Blood Culture, Routine (Final ___:    NO GROWTH. 

___ 12:17 pm URINE      Source: ___. 

                            **FINAL REPORT ___

   URINE CULTURE (Final ___:    NO GROWTH. 

___ 7:25 pm BLOOD CULTURE      2 OF 2. 

                            **FINAL REPORT ___

   Blood Culture, Routine (Final ___:    NO GROWTH. 

___ 7:00 pm URINE      Source: ___. 

                            **FINAL REPORT ___

   URINE CULTURE (Final ___:    NO GROWTH. 

___ 6:08 pm BLOOD CULTURE      Source: Line-PORT. 

                            **FINAL REPORT ___

   Blood Culture, Routine (Final ___:    NO GROWTH. 

___ 10:37 pm BLOOD CULTURE      Source: Line-POC. 

                            **FINAL REPORT ___

   Blood Culture, Routine (Final ___:    NO GROWTH. 

IMAGING/RESULTS:
===================
CXR (___):
IMPRESSION:  
No focal consolidation. 

CXR (___):
IMPRESSION:  
No focal consolidation. 

CT ABD & PELVIS WITH CONTRAST (___):
IMPRESSION: 
1. Perianal fistula with a 2.1 x 1.5 cm abscess formation in the 
left gluteal cleft with the fistula entering the anus at 5 
o'clock position 
2. No other acute process in the abdomen or pelvis. 

CT CHEST W/ CONTRAST (___):
IMPRESSION:  
1.  No acute cardiopulmonary process. 
2.  Please see report performed on same day for detailed 
evaluation of the 
abdomen. 

 
Brief Hospital Course:
Mr. ___ is a ___ male with history of 
intermediate-risk cytogenetics and favorable risk AML (normal 
karyotype, FLT3-, NPM1+, IDH2+, RAD21+, CEBPA-) in ___ remission 
after successful induction 7+3 chemotherapy who presented to 
clinic C1D16 of HiDAC consolidation and admitted for febrile 
neutropenia. Patient was found to have a perianal fistula and 
abscess on CT scan which was drained by colorectal surgery.

# Febrile Neutropenia
# Perianal abscess 
Patient with ANC 90 on admission who developed low grade temp of 
99.6 in clinic. Patient had previously received acetaminophen 
for pRBC and platelet transfusion. Remained afebrile until 
evening of ___ when spiked to ___ while on Cefepime. Broadened 
with vancomycin and respiked on ___ to 102.7. ID consulted and 
recommended transition Cefepime to meropenem as patient 
previously spiked on Cefepime during prior hospitalization. CT 
torso on ___ showed perianal fistula with a 2.1 x 1.5 cm 
abscess formation in the left gluteal cleft. Colorectal surgery 
was consulted and performed a bedside I&D. Per ID, patient was 
transitioned to po cipro/Flagyl. He will need to complete a 7 
day course of antibiotics (last day ___. He was continued on 
Voriconazole 200mg BID for Aspergillus prophylaxis. Neutropenia 
improved during hospitalization, with ANC of 1080 at discharge. 

# AML
Intermediate-risk cytogenetics and favorable risk AML (normal 
karyotype, FLT3-, NPM1+, IDH2+, RAD21+, CEBPA-) in ___ remission 
after successful induction 7+3 chemotherapy and is currently in 
C1 of HiDAC consolidation. He did not require any transfusions 
while in the hospital. His home ciprofloxacin was initially held 
as he was started on broad spectrum antibiotics and he was 
started back on ciprofloxacin at time of discharge to treat his 
perianal abscess. He was continued on Voriconazole for 
Aspergillus prophylaxis. He is scheduled to be seen in clinic on 
___. At discharge, he was C1D23 HiDAC consolidation. 

Transitional Issues:
[] Will need to determine if patient needs to continue 
ciprofloxacin for prophylaxis after completing course for 
perirectal abscess

CODE: Full Code (confirmed)
EMERGENCY CONTACT HCP: ___ (ex-wife/HCP) 
___
(home) ___ (cell)
 
Medications on Admission:
The Preadmission Medication list is accurate and complete.
1. LORazepam 0.5-1 mg PO Q8H:PRN 
anxiety/nausea/vomiting/insomnia 
2. Vitamin D ___ UNIT PO DAILY 
3. Ciprofloxacin HCl 500 mg PO Q12H 
4. Voriconazole 200 mg PO Q12H 

 
Discharge Medications:
1.  MetroNIDAZOLE 500 mg PO Q8H 
RX *metronidazole 500 mg 1 tablet(s) by mouth three times a day 
Disp #*18 Tablet Refills:*0 
2.  Ciprofloxacin HCl 500 mg PO Q12H Duration: 7 Days  
3.  LORazepam 0.5-1 mg PO Q8H:PRN 
anxiety/nausea/vomiting/insomnia 
RX *lorazepam 0.5 mg 1 tab by mouth every eight (8) hours Disp 
#*30 Tablet Refills:*0 
4.  Vitamin D ___ UNIT PO DAILY  
5.  Voriconazole 200 mg PO Q12H  

 
Discharge Disposition:
Home
 
Discharge Diagnosis:
PRIMARY DIAGNOSES:
Febrile Neutropenia
Perianal Abscess
Acute Myeloid Leukemia

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Mr. ___,

It was a pleasure to take care of you at ___. 

WHY WAS I HERE?
You were admitted to the hospital because you had a low grade 
fever after receiving a blood transfusion.

WHAT WAS DONE WHILE YOU WERE IN THE HOSPITAL
- You continued to have fevers while in the hospital and was 
started on IV antibiotics.
- A CT scan of your abdomen showed that you had a perirectal 
fistula and abscess (small collection of pus)
- Surgery saw you and cut open the abscess to allow it to drain
- Your IV antibiotics were changed to oral antibiotics.

WHAT SHOULD I DO WHEN I GET HOME?
- You should continue to take your medications as prescribed, 
especially antibiotics
- You should follow up with Dr. ___ the surgeons as 
scheduled

We wish you the best!

Your ___ Care Team

 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=14679785-DS-32 | hadm_id=22693528

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___
 
Chief Complaint:
postive blood culture
 
Major Surgical or Invasive Procedure:
none
 
History of Present Illness:
Mr. ___ is a ___ year old man with history of relapsed AML 
treated with multiple rounds chemotherapy and MRD alloHSCT with 
MAC (D0 ___ complicated by steroid-refractory GI-GVHD, C. 
difficile colitis, CMV viremia, and recent VRE/E.coli bacteremia
with recent admission with multifocal pneumonia, progressive 
cavitary pulmonary nodules, and worsening lower extremity edema 
found to have aspergillosis despite prophylaxis with 
posaconazole with adequate levels, treated with isavuconazole. 
He
now presents for direct admission given positive blood cultures.

Upon arrival to the floor, he states that overall since his
discharge from the hospital on ___ he has been doing well. He
notes a chronic ongoing cough that has improved since his
discharge. He denies any fever, chills, abdominal pain, nausea,
or vomiting. He notes abdominal discomfort with associated pain
with urination and urinating frequently over the last few days.
He notes that his diarrhea has resolved and his stools are now
"solid." He is no longer taking loperamide PRN that he was
prescribed at time of his recent discharge, given resolution of
his diarrhea. 

He endorses a great appetite and believes he has gain a few
pounds since discharge. He notes stable lower extremity edema
that improves with leg elevation. He states taht his PICC in the
right upper extremity was removed several days ago, though per
OMR note PICC was removed on ___. He denies any rash in 
this
area, or other areas, or areas of skin breakdown. He denies any
orthopnea or PND. He has been doing work around the house
including laundry without exertional dyspnea or other symptoms.
He has been stretching daily at home and performing bicep curls.
He brings with him medications from home including Jakafi and
cresemba. He is accompanied by his daughter.  

Of note, he was admitted to the hospital on ___ with VRE and
E. Coli bacteremia thought to be secondary to translocation,
treated with IV ceftriaxone and daptomycin until ___.

Review of Systems:  
(+) Per HPI.
Denies fever, chills, night sweats, headache, vision changes,
rhinorrhea, congestion, sore throat, shortness of breath, chest
pain, abdominal pain, nausea, vomiting, diarrhea, constipation,
BRBPR, melena, hematochezia, hematuria. 

 
Past Medical History:
ONCOLOGIC HISTORY:
___ INITIAL BMBX  AML
___ Consented to  protocol ___  INDUCTION DAUNOrubicin  (90 mg/m2)  Cytarabine  (100
mg/m2)  (RHP: +NPM1, +IDH2,+ RAD21)
___  D+14 BMBx ablated, 
___  D+26 remission, NPM1 negative
___ C1D1 HIDAC
___ admitted for fever
___ CT showed perianal abscess, drained, improved with
antibiotics
___ - C2D1 HIDAC, complicated by fevers and rash after 4 
of 6 doses attributed to possible cytarabine syndrome, all
resolved with higher dexamethasone premedication. also received
neulasta on D9
___ - C3D1 HIDAC, complicated by neutropenic fever, 
empiric antibiotics without complications or infectious source
___ - taken off of active study protocol (control arm) due
to patient preference to avoid frequent visits and tests;
consented to be followed by the study for survival/outcome data
___ - initiation of therapy for relapsed AML on trial
___
----lenalidomide 50 mg D1-10
----MEC D4-8
___ - admitted for alloHSC transplant
- Flu/Bu ablation chemotherapy ___
- Allogeneic stem cell transplant ___
- Discharged ___ - Bone marrow biopsy w/no morphologic evidence of AML,
negative NPM1 and myeloid sequencing panels
---- COMPLICATIONS: neutropenic fever, c.diff colitis, SCoN
bacteremia, ___ abscess, steroid-refractory GI-GVHD, C. 
difficile colitis, CMV viremia, and recent VRE/E.coli bacteremia 


PAST MEDICAL HISTORY:
- Recurrent clostridioides colitis
- genital warts
- Hernia s/p mesh ___ years ago

 
Social History:
___
Family History:
Mother had lung cancer
Father had some type of metastatic cancer extensively involving
the bones
No history of any hematologic disorders including leukemia or
lymphoma
 
Physical Exam:
ADMISSION PHYSICAL EXAM
=================================== 
Vitals: ___ 1441 Temp: 98.4 PO BP: 134/87 HR: 104 RR: 18 O2
sat: 100% O2 delivery: Ra 
Gen: walking around the room, unpacking his bag, no acute
distress
NEURO: A&Ox3.
HEENT: No conjunctival pallor. No icterus. MMM. OP clear.  
NECK: JVP not elevated
LYMPH: No cervical or supraclav LAD
CV: Nl rate, regular rhythm. No MRG.   
LUNGS: No incr WOB. Scattered faint crackles in bilateral lung
fields. No wheezes, rales, or rhonchi.  
ABD: ND, nl bowel sounds, tender to palpation in the suprapubic
region 
EXT: warm and well-perfused. 1+ edema to the shins bilaterally
SKIN: Right upper extremity with areas of ecchymosis in the
entecubital fossae. No rash or erythema noted.

DISCHARGE PHYSICAL EXAM
See flow sheets for vitals
GEN: Pleasant. NAD
NEURO: A&Ox3, non-focal
HEENT: No conjunctival pallor. No icterus. MMM. OP clear.  
NECK: Supple. JVP not elevated
LYMPH: No cervical or supraclavicular LAD
CV: Nl rate, regular rhythm. No MRG.   
LUNGS: No incr WOB. CTA
fields. No wheezes, rales, or rhonchi.  
ABD: ND, nl bowel sounds. Tenderness to palpation in the
suprapubic region has now resolved 
EXT: WWP. 1+ edema to the shins bilaterally
SKIN: Right upper extremity with areas of ecchymosis in the
entecubital fossae. No rash or erythema.

 
Pertinent Results:
ADMISSION LABS
====================

___ 03:29PM   PLT SMR-VERY LOW* PLT COUNT-56*
___ 03:29PM   ANISOCYT-1+* POIKILOCY-1+* MACROCYT-1+* 
MICROCYT-1+* POLYCHROM-1+* SCHISTOCY-1+* RBCM-SLIDE REVI
___ 03:29PM   NEUTS-42 BANDS-4 ___ MONOS-4* EOS-0* 
___ METAS-6* MYELOS-5* NUC RBCS-1.6* AbsNeut-1.70 
AbsLymp-1.44 AbsMono-0.15* AbsEos-0.00* AbsBaso-0.00*
___ 03:29PM   WBC-3.7* RBC-2.30* HGB-7.8* HCT-24.7* 
MCV-107* MCH-33.9* MCHC-31.6* RDW-23.1* RDWSD-89.4*
___ 03:29PM   CALCIUM-8.0* PHOSPHATE-3.3 MAGNESIUM-1.3*
___ 03:29PM   ALT(SGPT)-33 AST(SGOT)-26 LD(LDH)-526* ALK 
PHOS-99 TOT BILI-0.2
___ 03:29PM   UREA N-18 CREAT-0.7 SODIUM-143 POTASSIUM-3.9 
CHLORIDE-107 TOTAL CO2-25 ANION GAP-11
___ 01:50PM   PLT SMR-VERY LOW* PLT COUNT-41*
___ 01:50PM   ANISOCYT-2+* POIKILOCY-1+* POLYCHROM-1+* 
OVALOCYT-1+* SCHISTOCY-1+* ACANTHOCY-1+* RBCM-SLIDE REVI
___ 01:50PM   NEUTS-53 BANDS-5 ___ MONOS-11 EOS-0* 
BASOS-0 ___ METAS-3* MYELOS-0 NUC RBCS-1.5* OTHER-0 
AbsNeut-1.97 AbsLymp-0.95* AbsMono-0.37 AbsEos-0.00* 
AbsBaso-0.00*
___ 01:50PM   WBC-3.4* RBC-2.09* HGB-7.0* HCT-22.3* 
MCV-107* MCH-33.5* MCHC-31.4* RDW-22.4* RDWSD-87.8*
___ 01:50PM   CALCIUM-7.8* PHOSPHATE-3.8 MAGNESIUM-1.2*
___ 01:50PM   ALT(SGPT)-32 AST(SGOT)-25 LD(LDH)-510* 
CK(CPK)-34* ALK PHOS-92 TOT BILI-0.2
___ 01:50PM   estGFR-Using this
___ 01:50PM   UREA N-18 CREAT-0.8 SODIUM-145 POTASSIUM-3.6 
CHLORIDE-108 TOTAL CO2-23 ANION GAP-14
___ 02:37PM URINE  MUCOUS-OCC*
___ 02:37PM URINE  RBC-19* WBC-7* BACTERIA-NONE YEAST-NONE 
EPI-0 TRANS EPI-<1
___ 02:37PM URINE  BLOOD-SM* NITRITE-NEG PROTEIN-30* 
GLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NORMAL PH-6.0 
LEUK-NEG
___ 02:37PM URINE  COLOR-Straw APPEAR-Clear SP ___

MICROBIOLOGY STUDIES
==========================
ENTEROCOCCUS SP..    PRELIMINARY SENSITIVITY. 
SENSITIVITIES: MIC expressed in MCG/ML
      ____________________________________________________
                             ENTEROCOCCUS SP.
                             |   
AMPICILLIN------------       R
VANCOMYCIN------------       R

Anaerobic Bottle Gram Stain (Final ___: 
GRAM POSITIVE COCCI IN PAIRS AND IN SHORT CHAINS. 
      
Aerobic Bottle Gram Stain (Final ___: 
GRAM POSITIVE COCCI IN PAIRS AND IN SHORT CHAINS.

IMAGING STUDIES
=======================
CT CHEST ___: Complete resolution of the multi-focal
pneumonia described immediate prior study. Short interval 
density
and mild size increase in multiple bilateral peribronchovascular
solid and cavitating nodules as well as appearance of a new
nodule in the left lower lobe. Non-resolving and new nodules
following treatment and the short interval progression raises 
concern for
lung involvement from primary disease. Tissue sampling is
strongly recommended to rule out this possibility. 

CT A/P ___: No acute findings within the abdomen or pelvis. 

Interval improvement in previously demonstrated diffuse colonic
wall thickening with some persistent areas in the descending and
sigmoid colon. Mild thickening of the terminal ileum is overall
unchanged. Questionable asymmetric thickening of the right
lateral bladder wall. Recommend correlation with urinalysis.
Peripheral triangular hyperdensities throughout both kidneys
which may represent retained contrast from prior study on ___
due to renal dysfunction 

DISCHARGE LABS:
___ 09:43AM BLOOD WBC-3.8* RBC-2.69* Hgb-9.2* Hct-28.5* 
MCV-106* MCH-34.2* MCHC-32.3 RDW-21.7* RDWSD-83.8* Plt Ct-53*
___ 09:43AM BLOOD WBC-3.8* RBC-2.69* Hgb-9.2* Hct-28.5* 
MCV-106* MCH-34.2* MCHC-32.3 RDW-21.7* RDWSD-83.8* Plt Ct-53*
___ 09:43AM BLOOD Neuts-62 Bands-4 ___ Monos-6 Eos-0* 
___ Metas-3* Myelos-3* NRBC-1.1* AbsNeut-2.51 AbsLymp-0.84* 
AbsMono-0.23 AbsEos-0.00* AbsBaso-0.00*
___ 09:43AM BLOOD Glucose-107* UreaN-8 Creat-0.7 Na-133* 
K-4.1 Cl-93* HCO3-25 AnGap-15
___ 09:43AM BLOOD ALT-24 AST-22 LD(LDH)-539* AlkPhos-110 
TotBili-0.2
___ 09:43AM BLOOD Albumin-3.2* Calcium-8.2* Phos-4.1 Mg-1.9
 
Brief Hospital Course:
Mr. ___ is a ___ year old male with history of relapsed AML 
treated with multiple rounds chemotherapy and MRD allogeneic 
HSCT (D0 ___ complicated by steroid-refractory GI-GVHD, C. 
difficile colitis, CMV viremia, recent VRE bacteremia, E.coli 
bacteremia (thought to be ___ GI translocation, treated with IV 
ceftriaxone and daptomycin until ___ and multifocal 
pneumonia with progressive cavitary pulmonary nodules and 
worsening lower extremity edema found to have aspergillosis 
despite adequate levels of posaconazole prophylaxis treated now 
with isavuconazole. He presents for direct admission for GPC 
bacteremia speciated to VRE bacteremia.
SSESSMENT & PLAN: Mr. ___ is a ___ year old male with history
of relapsed AML treated with multiple rounds chemotherapy and 
MRD
allogeneic HSCT (D0 ___ complicated by steroid-refractory
GI-GVHD, C. difficile colitis, CMV viremia, recent VRE
bacteremia, E.coli bacteremia (thought to be ___ GI
translocation, treated with IV ceftriaxone and daptomycin until
___ and multifocal pneumonia with progressive cavitary
pulmonary nodules and worsening lower extremity edema found to
have aspergillosis despite adequate levels of posaconazole
prophylaxis treated now with isavuconazole. He presents for
direct admission for ___ bacteremia speciated to VRE bacteremia.

ACTIVE ISSUES
========================

#VRE BSI: Unclear source but suspect GI given presenting 
symptoms
(abdominal discomfort, dysuria, and urinary frequency). We
obtained a CT A/P to evaluate for GI pathology and it showed no
acute intra-abdominal process but noted asymmetric thickening of
the right lateral bladder wall as well as stable abnormalities.
UA did not show gross hematuria and pyuria but will obtain BK 
PCR
per urine and serum as well as correlative cytopathology. Of
note, BK urine ___ was markedly elevated (___) so 
may
be potential GI culprit. Pulmonary source is also possible but 
CT
Chest ___ showed resolution of multifocal pneumonia though
noted possible worsening of known cavitary pulmonary nodules.
Prior history of enterococcus faecium bacteremia was resistant 
to
ampicillin, penicillin, and vancomycin. Started on daptomcycin 
(received x1 dose on ___ but per ID
recommendations, we started linezolid ___ mg Q12 hours pending
sensitivity results.  When these became available transitioned 
back to 
dapto given risk of count suppression on linezolid.  There were 
no vegetations on TTE.  
Plan to continue Daptomycin 10 mg/kg IV Q24h for at least 14 day 
course
from date of first negative cultures ___ require 
longer course
given recurrent infection.  
-Appreciate ID recommendations

#RECENT MULTIFOCAL PNEUMONIA AND CAVITARY PULMONARY NODULES:
Patient is currently being treated with isavuconazole given c/f
aspergillus. Recent BAL ___ growing mold (described as a
contaminant but ID concerned about true mold infection). Repeat
chest CT ___ shows complete resolution of multifocal
pneumonia. Chest CT also shows short interval density and mild
size increase in multiple bilateral peribronchovascular solid 
and
cavitating nodules as well as appearance of a new nodule in the
left lower lobe with concern for lung involvement from primary
disease. In close discussion with ID, felt no need to pursue
biopsy and/or change antifungal therapy.  
-Continue isavuconazole 372mg daily
-Appreciate ID recommendations

#AML s/p allogeneic MRD HSCT (Day 0 = ___: 
#THROMBOYCTOPENIA:
AML initially with favorable mutational profile (normal
karyotype; FLT3 negative, NPM1 positive, IDH2 positive, RAD21
positive, CEBPA negative). He relapsed after chemo-consolidation
(7+3, 3C HIDAC & MEC/Revlimid) then underwent an MRD allogeneic
SCT as above. In remission following his transplant with slow
count recovery most likely due to valganciclovir. BMBX during
recent admission showed no evidence of recurrence w/ 100%
chimerism. His immunosuppression agents are:
-Continue Tacrolimus 0.5mg BID; No
adjustments in light of starting Jakafi. 
-Continue ruxolitinib 5mg PO BID
-Continue prednisone 10mg PO QD, tapering while on Jakafi
-Continue Valganciclovir 900mg PO QD; no need for ACV. CMV VL 
neg
could change to ACV. 
-Continue Bactrim SS PO QD
- f/u LENIs (potential source) 

CHRONIC ISSUES
========================

#MASSIVE ANASARCA: Prior LENIs without DVT. Repeat in setting of
infection.  Attributed to multifactorial low albumin due to
GI-GVHD and side effect of steroids. Improved with diuresis and
reduction in prednisone dosing. Significantly improved since 
most
recent admission. 

#GI GVHD: Remains on tacrolimus, prednisone, budesonide and 
Jakafi as above.   
-Continue ID prophylaxis with bactrim
-Continue PPI, vitamin D and folic acid supplementation

#CMV VIREMIA: He continues on valgancyoclovir 900 mg daily until
follow up with ID for full course duration to be determined 
-CMV vL ___ PND. If neg consider changing to ACV. 

#RECURRENT C-Diff COLITIS: Recent completion of oral vancomycin
___ with no further diarrhea. Of note, patient received 
fidaxomicin and dose of bezlotoxumab for prior treatment. 
-Trend for diarrhea recurrence. 

#PRIOR VRE & E.coli BACTEREMIA: He completed a course of
daptomycin and ceftriaxone for E. coli bacteremia, completed on
___. Both bacteremia attributed to a likely GI source
(microperforation or permeability of the bowel mucosa). See 
above
regarding new infection. 

#NICOTINE DEPENDENCE: nicotine patch while inpatient.  
 
 
Medications on Admission:
The Preadmission Medication list is accurate and complete.
1. Isavuconazonium Sulfate 372 mg PO DAILY 
2. Sulfameth/Trimethoprim SS 1 TAB PO DAILY 
3. PredniSONE 10 mg PO DAILY 
4. Budesonide 3 mg PO TID 
5. FoLIC Acid 1 mg PO DAILY 
6. LORazepam 1 mg PO BID: PRN anxiety 
7. multivitamin 1 tablet oral daily 
8. Pantoprazole 40 mg PO Q12H 
9. Nicotine Patch 21 mg/day TD DAILY 
10. ruxolitinib 5 mg oral BID 
11. Tacrolimus 0.5 mg PO Q12H 
12. ValGANCIclovir 900 mg PO Q24H 
13. Vitamin D ___ UNIT PO 1X/WEEK (WE) 

 
Discharge Medications:
1.  Acyclovir 400 mg PO Q8H 
RX *acyclovir 400 mg 1 capsule(s) by mouth three times a day 
Disp #*90 Tablet Refills:*0 
2.  Daptomycin 740 mg IV Q24H bacteremia  
3.  Budesonide 3 mg PO TID  
4.  FoLIC Acid 1 mg PO DAILY  
5.  Isavuconazonium Sulfate 372 mg PO DAILY  
6.  LORazepam 1 mg PO BID: PRN anxiety  
7.  multivitamin 1 tablet oral daily  
8.  Nicotine Patch 21 mg/day TD DAILY  
9.  Pantoprazole 40 mg PO Q12H  
10.  PredniSONE 10 mg PO DAILY  
11.  ruxolitinib 5 mg oral BID  
12.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  
13.  Tacrolimus 0.5 mg PO Q12H  
14.  Vitamin D ___ UNIT PO 1X/WEEK (WE)  

 
Discharge Disposition:
Home With Service
 
Facility:
___
 
Discharge Diagnosis:
Primary Diagnoses
======================
VRE Bacteremia
Cavitary pulmonary nodules secondary to aspergillosis

SECONDARY DIAGNOSIS
======================
-Acute myelogenous leukemia
-Graft versus host disease
-CMV reactivation

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Mr. ___,

You were admitted due to concern for blood stream infection. We 
did extensive infectious workup which showed bacteremia. We 
started you on antibiotics and your infection has cleared. You 
will continue on antibiotics as instructed. Please continue to 
take all of your medications as instructed.

Sincerely, 
Your ___ TEAM
 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=14679785-DS-31 | hadm_id=22727777

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___.
 
Chief Complaint:
progressive lower extremity edema, electrolyte
abnormalities, and abnormal imaging findings
 
Major Surgical or Invasive Procedure:
Bronchoscopy (___)

 
History of Present Illness:
Mr. ___ is a ___ year old male with history of relapsed AML
treated with multiple rounds of chemotherapy and MRD alloHSCT
with MAC (D0 ___, currently +301) complicated by
steroid-refractory GI-GVHD, C. difficile colitis, CMV viremia, 
BK
virus, and recent VRE/E.coli bacteremia presenting from clinic
with progressive lower extremity edema, electrolyte
abnormalities, and abnormal imaging findings. 

Mr. ___ was recently discharged from ___ after a prolonged
hospitalization for GI-GVHD flare, BK cystitis, incidental E.
coli bacteremia and VRE bacteremia, and pulmonary nodules with
positive BDG concerning for fungal infection. He was discharged
on a course of ceftriaxone and daptomycin with oral vancomycin
prophylaxis given history of C. dif (last scheduled dose
___ with plan to repeat CT CHEST on ___. 

Since discharge, he states that he has been feeling overall well
with stable diarrhea and improved form of stools. No fevers,
chills, or chest pain however does note upper respiratory
symptoms preceding new new cough productive of white sputum over
the last several days, and both of his children have had upper
respiratory symptoms recently, and has continued to smoke
cigarettes intermittently. Notably, he has continued to use
recreational marijuana. He has also noticed increasing 
difficulty
ambulating attributed to worsening proximal muscle weakness and 
increased lower extremity edema. 

On ___, Mr. ___ was seen in clinic by Dr. ___
noted to have worsening lower extremity edema, weakness and
fatigue. Labs were notable for Hg 7.9, WBC 8.2 (___ 6720), Plt
36, K 3.1, and Cr 0.8. CT CHEST (___) ordered to assess 
interval
changes in pulmonary nodules demonstrated new multifocal
pneumonia and redemonstration of multiple bilateral 
peribronchial
nodules, some demonstrating cavitation, with slight interval
increase in size of two nodules.
 
Past Medical History:
ONCOLOGIC HISTORY:
___ INITIAL BMBX  AML
___ Consented to  protocol ___  INDUCTION DAUNOrubicin  (90 mg/m2)  Cytarabine  (100
mg/m2)  (RHP: +NPM1, +IDH2,+ RAD21)
___  D+14 BMBx ablated, 
___  D+26 remission, NPM1 negative
___ C1D1 HIDAC
___ admitted for fever
___ CT showed perianal abscess, drained, improved with
antibiotics
___ - C2D1 HIDAC, complicated by fevers and rash after 4 
of 6 doses attributed to possible cytarabine syndrome, all
resolved with higher dexamethasone premedication. also received
neulasta on D9
___ - C3D1 HIDAC, complicated by neutropenic fever, 
empiric antibiotics without complications or infectious source
___ - taken off of active study protocol (control arm) due
to patient preference to avoid frequent visits and tests;
consented to be followed by the study for survival/outcome data
___ - initiation of therapy for relapsed AML on trial
___
----lenalidomide 50 mg D1-10
----MEC D4-8
___ - admitted for alloHSC transplant
- Flu/Bu ablation chemotherapy ___
- Allogeneic stem cell transplant ___
- Discharged ___ - Bone marrow biopsy w/no morphologic evidence of AML,
negative NPM1 and myeloid sequencing panels
---- COMPLICATIONS: neutropenic fever, c.diff colitis, SCoN
bacteremia, ___ abscess

REVIEW OF SYSTEMS: otherwise negative

PAST MEDICAL HISTORY:
- Recurrent clostridioides colitis
- genital warts
- Hernia s/p mesh ___ years ago
 
Social History:
___
Family History:
Mother had lung cancer
Father had some type of metastatic cancer extensively involving
the bones
No history of any hematologic disorders including leukemia or
lymphoma
 
Physical Exam:
ADMISSION PHYSICAL EXAM:
========================
VS: Reviewed in ___
General: appears comfortable, sitting upright in bed
HEENT: NC/AT, MMM, no oral lesions
Lungs: symmetric expansion, +expiratory wheezing, +inspiratory
rhonchi
Heart: RRR, no M/R/G, 2+ radial pulses bilaterally
Abdomen: soft, non-distended, non-tender, +minimal BS
Extremities: warm, ___ bilateral lower extremity edema
Skin: scattered superficial bruising on R/L forearms
Neuro: 
  - alert, oriented, appropriate, fluent
  - PERRLA, EOMI, CN intact
  - ___ shoulder, ___ tricep, ___ bicep, ___ hand grip
Psych: appropriate affect and judgement
Access: RUE PICC non-erythematous

DISCHARGE PHYSICAL EXAM:
========================
VS: 24 HR Data (last updated ___ @ 524)
    Temp: 98.5 (Tm 98.5), BP: 135/74 (123-158/63-86), HR: 75
(66-81), RR: 20 (___), O2 sat: 98% (97-100), O2 delivery: RA,
Wt: 169.1 lb/76.7 kg  
General: appears comfortable, sitting upright in bed
HEENT: NC/AT, MMM, no oral lesions
Lungs: symmetric expansion, +expiratory wheezing, +inspiratory
rhonchi, similar to day prior
Heart: RRR, no M/R/G
Abdomen: soft, non-distended, non-tender
Extremities: warm, 2+ bilateral lower extremity edema, improved
from day prior with elevation
Skin: scattered superficial bruising on R/L forearms
Neuro: alert, oriented, appropriate, fluent, moves all
extremities spontaneously without FND
Psych: appropriate
 
Pertinent Results:
INITIAL LABS
============
___ 11:30AM BLOOD WBC-8.2 RBC-2.27* Hgb-7.9* Hct-24.1* 
MCV-106* MCH-34.8* MCHC-32.8 RDW-21.1* RDWSD-80.5* Plt Ct-36*
___ 11:30AM BLOOD Neuts-76* Bands-6* Lymphs-12* Monos-3* 
Eos-0* ___ Metas-1* Myelos-2* NRBC-2.0* AbsNeut-6.72* 
AbsLymp-0.98* AbsMono-0.25 AbsEos-0.00* AbsBaso-0.00*
___ 07:30PM BLOOD ___ PTT-22.6* ___
___ 11:30AM BLOOD UreaN-26* Creat-0.8 Na-142 K-3.2* Cl-106 
HCO3-22 AnGap-14
___ 11:30AM BLOOD ALT-46* AST-30 LD(LDH)-625* AlkPhos-83 
TotBili-0.3
___ 11:30AM BLOOD Calcium-8.1* Phos-2.9 Mg-1.5*
___ 12:41AM URINE Color-Yellow Appear-Clear Sp ___
___ 12:41AM URINE Blood-NEG Nitrite-NEG Protein-30* 
Glucose-150* Ketone-NEG Bilirub-NEG Urobiln-NORMAL pH-6.5 
Leuks-NEG
___ 12:41AM URINE RBC-<1 ___ Bacteri-FEW* Yeast-NONE 
Epi-<1

MICROBIOLOGY
============
___ 12:21PM OTHER BODY FLUID FluAPCR-NEG FluBPCR-NEG

___ 12:41 am URINE      Source: ___. 

                            **FINAL REPORT ___

   URINE CULTURE (Final ___:    < 10,000 CFU/mL. 

___ 6:12 am SEROLOGY/BLOOD      Source: Line-PICC. 

                            **FINAL REPORT ___

   CRYPTOCOCCAL ANTIGEN (Final ___: 
      CRYPTOCOCCAL ANTIGEN NOT DETECTED. 
           (Reference Range-Negative). 
      Test performed by Lateral Flow Assay. 
      A negative serum does not rule out localized or 
disseminated
      cryptococcal infection. 
      Appropriate specimens should be sent for culture. 

CRYPTOCOCCAL ANTIGEN (Final ___: not detected

BRONCHOALVEOLAR LAVAGE (___)
   GRAM STAIN (Final ___: 
      1+    (<1 per 1000X FIELD):   POLYMORPHONUCLEAR 
LEUKOCYTES. 
      NO MICROORGANISMS SEEN. 
      This is a concentrated smear made by cytospin method, 
please refer to
      hematology for a quantitative white blood cell count, if 
applicable. 

   RESPIRATORY CULTURE (Final ___: 
      ~8000 CFU/mL Commensal Respiratory Flora. 

   LEGIONELLA CULTURE (Preliminary):    NO LEGIONELLA ISOLATED. 

   Immunofluorescent test for Pneumocystis jirovecii (carinii) 
(Final
      ___:    NEGATIVE for Pneumocystis jirovecii 
(carinii). 

   FUNGAL CULTURE (Preliminary):    NO FUNGUS ISOLATED. 

   NOCARDIA CULTURE (Preliminary): 
      NO NOCARDIA ISOLATED. 
      MOLD. 

   ACID FAST SMEAR (Final ___: 
      NO ACID FAST BACILLI SEEN ON CONCENTRATED SMEAR.

Respiratory Viral Culture (Final ___: 
      No respiratory viruses isolated. 
      Culture screened for Adenovirus, Influenza A & B, 
Parainfluenza type
      1,2 & 3, and Respiratory Syncytial Virus.. 
      Detection of viruses other than those listed above will 
only be
      performed on specific request. Please call Virology at 
___
      within 1 week if additional testing is needed. 

Respiratory Viral Antigen Screen (Final ___: 
      Less than 60 columnar epithelial cells;. 
      Inadequate specimen for DFA detection of respiratory 
viruses.. 
      Interpret all negative DFA and/or culture results from 
this specimen
      with caution.. 
      Negative results should not be used to discontinue 
precautions.. 
      Recommend new sample be submitted for confirmation.. 
      Refer to respiratory viral culture and/or Influenza PCR 
(results
      listed under "OTHER" tab) for further information.. 
      Reported to and read back by ___, MD (___), 
___ @
      13:14. 

IMAGING
=======
CXR (___):
The tip of the right PICC projects over the mid SVC. There is no 
focal consolidation, pleural effusion or pneumothorax 
identified. Patchy mid to lower lung opacities are present. 
Known cavitary and non cavitary lung nodules are not well 
visualized on this exam. IMPRESSION: The tip of the right PICC 
projects over the mid SVC. Patchy mid to lower lung opacities 
likely reflect multifocal pneumonia, better evaluated on the CT 
chest performed earlier today.

BILAT LOWER EXT VEINS (___):
1. No evidence of deep venous thrombosis in the right or left 
lower extremity veins. 2. Moderate right ___ cyst, not seen 
on the previous study.

OTHER RESULTS
=============
___ 11:30AM BLOOD  WBC-8.2 Lymph-12* Abs ___ CD3%-71 
Abs CD3-702 CD4%-14 Abs CD4-136* CD8%-58 Abs CD8-566 
CD4/CD8-0.24*
___ 08:55AM BLOOD tacroFK-6.7

DISCHARGE LABS
==============
___ 05:19AM BLOOD WBC-4.2 RBC-2.39* Hgb-7.9* Hct-24.6* 
MCV-103* MCH-33.1* MCHC-32.1 RDW-23.6* RDWSD-88.7* Plt Ct-37*
___ 05:19AM BLOOD Neuts-70 Bands-1 Lymphs-16* Monos-3* 
Eos-0* ___ Metas-4* Myelos-6* NRBC-2.9* AbsNeut-2.98 
AbsLymp-0.67* AbsMono-0.13* AbsEos-0.00* AbsBaso-0.00*
___ 07:30PM BLOOD ___ PTT-22.6* ___

___ 05:19AM BLOOD Glucose-113* UreaN-16 Creat-0.6 Na-142 
K-4.1 Cl-108 HCO3-26 AnGap-8*
___ 05:19AM BLOOD ALT-29 AST-20 LD(LDH)-534* AlkPhos-62 
TotBili-0.3
___ 05:19AM BLOOD Albumin-2.5* Calcium-7.8* Phos-3.1 Mg-1.7
___ 05:42AM BLOOD Hapto-204*
___ 06:12AM BLOOD CMV VL-NOT DETECT
 
Brief Hospital Course:
BRIEF HOSPITAL COURSE
=====================
Mr. ___ is a ___ year old mane with history of relapsed AML 
treated with multiple rounds chemotherapy and MRD alloHSCT with 
MAC (D0 ___ complicated by steroid-refractory GI-GVHD, C. 
difficile colitis, CMV viremia, and recent VRE/E.coli bacteremia 
who presented from clinic with multifocal pneumonia, progressive 
cavitary pulmonary nodules, and worsening lower extremity edema 
found to have aspergillosis despite prophylaxis with 
posaconazole with adequate levels and started on isavuconazole.

ACTIVE ISSUES
=============
# Multifocal pneumonia
Mr. ___ presented from clinic after CT CHEST (___) obtained 
to assess interval changes in cavitary lung lesions demonstrated 
new multifocal pneumonia. His only reported symptom was 
productive cough. He was empirically broadened from his home 
antibiotics specified below to meropenem with improvement in his 
cough. RVP negative. Induced sputum gram stain and PCP culture 
were negative. Fungal cultures pending. BCx all were negative. 
Bronchoscopy lavage samples positive for aspergillus 
galactomannan antigen on two different samples. He was 
discharged on isavuconazole and continued on prophylactic 
Bactrim with stable platelet count. 

# Cavitary pulmonary nodules
On his last admission, Mr. ___ was incidentally found to 
have multifocal lung lesions. Interval CT CHEST (___) 
demonstrated progression of these lesions with evidence of 
cavitation. Bronchoscopy lavage samples positive for aspergillus 
on two different samples. He was discharged on isavuconazole and 
continued on prophylactic Bactrim with stable platelet count.

# Lower extremity edema
Mr. ___ presented with worsening ___ lower extremity edema 
that improved significantly with elevation. LENIs without 
evidence of clot. Ultimately attributed to multifactorial low 
albumin due to GI-GVHD and side effect of steroids. Improved 
with diuresis with IV diuretics and reduction in prednisone 
dosing.

# AML s/p alloHSCT
# GI-GVHD
Mr. ___ was continued on his home tacrolimus, ruxolitinib, 
and budesonide. His prednisone was adjusted as specified below.

CHRONIC ISSUES
==============
# C. dif colitis - Mr. ___ was continued on his home 
prophylaxis of oral vanc that was scheduled to finish on 
___, last dose given before discharge.

# CMV viremia - Mr. ___ was continued on his home 
prophylaxis.

TRANSITIONAL ISSUES
===================
[] patient was able to regain insurance while inpatient and get 
needed medications, please continue to make sure he has enough 
of his meds at home
[] valganciclovir 900mg PO qd for 12 weeks per outpatient ID 
currently finishing week 9, stop after first week of ___ minutes spend on discharge planning
 
Medications on Admission:
The Preadmission Medication list is accurate and complete.
1. Atovaquone Suspension 1500 mg PO DAILY 
2. Budesonide 3 mg PO TID 
3. FoLIC Acid 1 mg PO DAILY 
4. LORazepam 1 mg PO BID:PRN anxiety 
5. Multivitamins 1 TAB PO DAILY 
6. Nicotine Patch 21 mg/day TD DAILY 
7. Pantoprazole 40 mg PO Q12H 
8. Posaconazole Delayed Release Tablet 300 mg PO DAILY 
9. Tacrolimus 0.5 mg PO QAM 
10. Tacrolimus 0.5 mg PO QPM 
11. ValGANCIclovir 900 mg PO DAILY 
12. Vitamin D ___ UNIT PO 1X/WEEK (WE) 
13. ruxolitinib 5 mg PO BID 
14. PredniSONE 15 mg PO DAILY 
15. CefTRIAXone 2 gm IV Q 24H 
16. Daptomycin 750 mg IV Q24H 
17. Vancomycin Oral Liquid ___ mg PO BID 
18. LOPERamide 2 mg PO QID:PRN Diarrhea 

 
Discharge Medications:
1.  Isavuconazonium Sulfate 372 mg PO DAILY  
2.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY 
RX *sulfamethoxazole-trimethoprim 400 mg-80 mg 1 tablet(s) by 
mouth once a day Disp #*30 Tablet Refills:*1 
3.  PredniSONE 10 mg PO DAILY 
RX *prednisone 10 mg 1 tablet(s) by mouth once a day Disp #*30 
Tablet Refills:*1 
4.  Budesonide 3 mg PO TID  
5.  FoLIC Acid 1 mg PO DAILY  
6.  LOPERamide 2 mg PO QID:PRN Diarrhea 
RX *loperamide 2 mg 2 ml by mouth four times a day Disp #*30 
Capsule Refills:*1 
7.  LORazepam 1 mg PO BID:PRN anxiety 
RX *lorazepam [Ativan] 1 mg 1 ml by mouth twice a day Disp #*30 
Tablet Refills:*1 
8.  Multivitamins 1 TAB PO DAILY 
RX *multivitamin [Daily Multi-Vitamin]  1 capsule(s) by mouth 
once a day Disp #*30 Tablet Refills:*3 
9.  Nicotine Patch 21 mg/day TD DAILY 
RX *nicotine 21 mg/24 hour one patch to skin once a day Disp 
#*30 Patch Refills:*0 
10.  Pantoprazole 40 mg PO Q12H 
RX *pantoprazole 40 mg 1 tablet by mouth twice a day Disp #*60 
Tablet Refills:*1 
11.  ruxolitinib 5 mg PO BID  
12.  Tacrolimus 0.5 mg PO QPM  
13.  Tacrolimus 0.5 mg PO QAM  
14.  ValGANCIclovir 900 mg PO DAILY 
RX *valganciclovir 450 mg 2 tablet(s) by mouth once a day Disp 
#*60 Tablet Refills:*1 
15.  Vitamin D ___ UNIT PO 1X/WEEK (WE) 
RX *ergocalciferol (vitamin D2) [Drisdol] 50,000 unit 1 
capsule(s) by mouth once weekly Disp #*12 Capsule Refills:*0 

 
Discharge Disposition:
Home
 
Discharge Diagnosis:
PRIMARY DIAGNOSIS
======================
- Multifocal pneumonia
- Cavitary pulmonary nodules secondary to aspergillosis
- Lower extremity edema

SECONDARY DIAGNOSIS
======================
- Acute myelogenous leukemia
- Graft versus host disease
- CMV reactivation
- ___ cyst

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Dear Mr. ___,  

WHY WERE YOU ADMITTED TO THE HOSPITAL?  
- You had swelling in your legs and abnormal imaging on your CT 
CHEST. 

WHAT WAS DONE WHILE YOU WERE IN THE HOSPITAL?  
- You were given antibiotics to treat your pneumonia
- You had a procedure known as a bronchoscopy performed to 
figure out why you had the abnormal lung findings
- Findings from the bronchoscopy showed that you are growing a 
fungus called aspergillus in your lungs and were given a new 
antifungal for that
 
WHAT DO YOU NEED TO DO WHEN YOU LEAVE THE HOSPITAL?  
- Take all of your medications as prescribed (listed below)  
- Follow up with your doctors as listed below  

Please see below for more information on your hospitalization. 
It was a pleasure taking part in your care here at ___. We 
wish you all the best,

- Your ___ Care Team  

 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=14679785-DS-27 | hadm_id=22989133

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___
 
Chief Complaint:
planned admission for alloHSC transplant
 
Major Surgical or Invasive Procedure:
RIJ Tunneled Triple Lumen Power Access Line  ___

AlloSCT: ___

 
History of Present Illness:
Mr ___ is a ___ year old man with relapsed AML, now admitted
for ablation chemotherapy and allogenic SCT. His AML was
diagnosed in ___ initially with favorable mutational profile
(normal karyotype; FLT3 negative, NPM1 positive, IDH2 positive,
RAD21 positive, CEBPA negative), however he relapsed 12 months
post last HIDAC. He underwent re-induction chemotherapy with
MEC-Lenalidomide ___ (course complicated by C. diff and
perianal abscess) and achieved complete remission with 
incomplete
count recovery based on D+35 BMBx. However his next-gen
sequencing still had detectable clone, indicating measurable
residual disease. He is now admitted for ablation chemotherapy
with Flu/Bu before allogenic stem cell transplant, planned for
___. Donor is the patient's brother. 

 
Vitals on ___ 1230 Temp: 97.4 PO BP: 119/69 HR: 72
RR: 18 O2 sat: 100% O2 delivery: RA Dyspnea: 0 RASS: 0 Pain
Score: ___ 

Upon arrival to the floor, he is feeling well, and denies any
cardiorespiratory or infectious symptoms. 

Review of Systems:  
(+) Per HPI. 
Denies fever, chills, night sweats, headache, vision changes,
rhinorrhea, congestion, sore throat, cough, shortness of breath,
chest pain, abdominal pain, nausea, vomiting, diarrhea,
constipation, BRBPR, melena, hematochezia, dysuria, hematuria. 
 
 
Past Medical History:
TREATMENT COURSE:
-------------------
___ INITIAL BMBX  AML
___ Consented to  protocol ___  INDUCTION DAUNOrubicin  (90 mg/m2)  Cytarabine  (100
mg/m2)  (RHP: +NPM1, +IDH2,+ RAD21)
___  D+14 BMBx ablated, 
___  D+26 remission, NPM1 negative
___ C1D1 HIDAC
--___ admitted for fever
--___ CT showed perianal abscess, drained, improved with
antibiotics
--___ - C2D1 HIDAC, complicated by fevers and rash after 4 
of
6 doses attributed to possible cytarabine syndrome, all resolved
with higher dexamethasone premedication. also received neulasta
on D9
--___ - C3D1 HIDAC, complicated by neutropenic fever, 
empiric
antibiotics without complications or infectious source
--___ - taken off of active study protocol (control arm) due
to patient preference to avoid frequent visits and tests;
consented to be followed by the study for survival/outcome data
- ___ - initiation of therapy for relapsed AML on trial
___

PAST MEDICAL HISTORY: AML as above

 
Social History:
___
Family History:
Mother had lung cancer
Father had some type of metastatic cancer extensively involving
the bones
No history of any hematologic disorders including leukemia or
lymphoma
 
Physical Exam:
ADMISSION PHYSICAL EXAM
=======================
Vitals: 24 HR Data (last updated ___ @ 1233)
    Temp: 97.4 (Tm 97.4), BP: 119/69, HR: 72, RR: 18, O2 sat:
100%, O2 delivery: RA, Wt: 212.5 lb/96.39 kg 
GENERAL:  Well-appearing adult man laying comfortably in no
acute distress, in good spirits.  Pleasant, conversant and
interactive.
HEENT:  Anicteric sclerae.  Mucous membranes are moist and pink.
no petechiae, purpura, or exudates. no erythema in oropharynx.
S/P extraction of two teeth #27, #28
LYMPHATICS:  no tenderness in right cervical region.
PULMONARY:  Lungs are clear bilaterally.
HEART:  Within normal rate and regular rhythm, no murmurs, rubs
or gallops.
ABDOMEN:  Soft, nontender, nondistended.  No palpable masses or
hepatosplenomegaly.
EXTREMITIES:  Without any edema.
SKIN: no petechiae, ecchymosis, or rashes
LINES: Tunneled RIJ

DISCHARGE PHYSICAL EXAM
=========================
24 HR Data (last updated ___ @ 607)
    Temp: 98.3 (Tm 98.3), BP: 100/61 (100-165/61-86), HR: 69
(61-81), RR: 19 (___), O2 sat: 97% (97-100), O2 delivery: Ra,
Wt: 193.4 lb/87.73 kg  
GENERAL: Resting comfortably in bed in NAD
HEENT:  Anicteric sclerae.  Mucous membranes are moist, intact
mucosa without exudate S/P extraction of two teeth #27, #28
LYMPHATICS:  no palpable cervical LAD
PULMONARY:  CTAB
HEART:  Within normal rate and regular rhythm, no murmurs, rubs
or gallops.
ABDOMEN:  Soft, nontender, non-distended
EXTREMITIES:  wwp, no edema.
SKIN: no petechiae, ecchymosis, or rashes
LINES: Tunneled RIJ, no erythema
 
Pertinent Results:
ADMISSION LABS
===============

___ 09:30AM BLOOD WBC-3.1* RBC-2.28* Hgb-7.3* Hct-22.7* 
MCV-100* MCH-32.0 MCHC-32.2 RDW-21.5* RDWSD-54.1* Plt ___
___ 09:30AM BLOOD Neuts-63.2 ___ Monos-4.2* Eos-3.2 
Baso-0.3 NRBC-1.6* Im ___ AbsNeut-1.97 AbsLymp-0.90* 
AbsMono-0.13* AbsEos-0.10 AbsBaso-0.01
___ 09:30AM BLOOD ___ PTT-26.9 ___
___ 09:30AM BLOOD UreaN-12 Creat-0.8 Na-143 K-3.9 Cl-107 
HCO3-24 AnGap-12
___ 09:30AM BLOOD ALT-23 AST-22 LD(LDH)-164 AlkPhos-113 
TotBili-0.3 DirBili-<0.2 IndBili-0.3
___ 09:30AM BLOOD TotProt-6.7 Albumin-4.3 Globuln-2.4 
Calcium-8.9 Phos-3.0 Mg-1.6 UricAcd-6.2

INTERVAL LABS
==============

___ 12:00AM BLOOD WBC-0.3* RBC-2.09* Hgb-6.8* Hct-20.0* 
MCV-96 MCH-32.5* MCHC-34.0 RDW-21.1* RDWSD-67.5* Plt Ct-13*
___ 12:00AM BLOOD Neuts-0* Lymphs-91* Monos-9 Eos-0* Baso-0 
AbsNeut-0.00* AbsLymp-0.27* AbsMono-0.03* AbsEos-0.00* 
AbsBaso-0.00*

DISCHARGE LABS
===============

___ 12:00AM BLOOD WBC-2.8* RBC-2.93* Hgb-9.5* Hct-29.4* 
MCV-100* MCH-32.4* MCHC-32.3 RDW-21.8* RDWSD-76.0* Plt ___
___ 12:00AM BLOOD Neuts-43.4 ___ Monos-28.0* 
Eos-0.7* Baso-1.1* Im ___ AbsNeut-1.21* AbsLymp-0.71* 
AbsMono-0.78 AbsEos-0.02* AbsBaso-0.03
___ 12:00AM BLOOD ___ PTT-26.8 ___
___ 12:00AM BLOOD Ret Aut-5.2* Abs Ret-0.15*
___ 12:00AM BLOOD Glucose-96 UreaN-10 Creat-0.8 Na-141 
K-4.1 Cl-106 HCO3-22 AnGap-13
___ 12:00AM BLOOD ALT-16 AST-17 LD(LDH)-227 AlkPhos-60 
TotBili-0.3
___ 12:00AM BLOOD TotProt-6.0* Albumin-3.9 Globuln-2.1 
Calcium-9.0 Phos-4.1 Mg-1.9
___ 09:08AM BLOOD tacroFK-14.9
___ 12:00AM BLOOD CMV VL-NOT DETECT

IMAGING/STUDIES
================
Tunneled line placement ___
FINDINGS: 
Patent right internal jugular vein. Final fluoroscopic image 
showing right IJ
approach triple-lumen powered tunneled catheter with tip 
terminating in the
right atrium.
 
IMPRESSION: 
Successful placement of a triple-lumen powered tunneled tunneled 
line via the
right internal jugular venous approach. The tip of the catheter 
terminates in
the right atrium. The catheter is ready for use.

ECG Normal sinus rhythm Nonspecific intraventricular block When 
compared with ECG of ___ 10:42, Criteria for Septal 
infarct are no longer present Electronically signed by MD ___, 
___ (___) on ___ 11:19:41 AM

MICRO
========
___. difficile PCR-FINAL {POSITIVE}; C. 
difficile Toxin antigen assay-FINAL {POSITIVE}INPATIENT

___ Cell - Blood CultureStem Cell ___ 
Culture-FINALINPATIENT

 
Brief Hospital Course:
PATIENT SUMMARY
============================
___ is a ___ man with relapsed intermediate risk AML 
s/p re-induction with MEC Lenalidomide per protocol ___ 
presenting for ablation chemotherapy, allogenic SCT on ___. 

ACUTE ISSUES
============================
# Relapsed AML: S/p re-induction on protocol ___ with 
Mitoxantrone, Etoposide, and Cytarabine(MEC) plus Lenalidomide. 
Has undergone pre-transplanbt workup s/p extraction ___, 
PFT DLCO 61%, ECHO LVEF 55%. Bone marrow biopsy +35 showed 
complete
remission with incomplete count recover, but next gen sequencing 
showed measurable residual disease. He underwent Flu/Bu ablation 
chemotherapy (___) and allogenic stem cell transplant 
___. He was started on prophylaxis with levofloxacin, 
bactrim, acyclovir, and fluconazole. Levofloxacin was stopped 
when ___ was near 500 and we started treatment for CDiff.

# C diff: last admission treated with vancomycin, finished 
course ___. Pt complained about loose stool without 
abdominal pain or cramping. Cdiff PCR and toxin were positive. 
Oral vanc 125mg PO QID was started on ___. For first 
recurrence then taper with 125 mg orally twice daily for 7 days 
(___), then 125 mg orally once daily for 7 days 
(___), then 125 mg orally every 2 for 8 weeks (___). 


CHRONIC/RESOLVED CONDITIONS
============================
# Marijuana Use: Reports using CBD oil and occasional vaporized 
marijuana prior to admission. 

# Prior perianal abscess: During last admission. s/p augmentin 
and cipro, follow up ultrasound with no focal fluid collection 
identified. 

TRANSITIONAL ISSUES: 
==================
[] New Meds:
Sulfameth/Trimethoprim SS 1 TAB PO DAILY START DAY +21: ___
Ursodiol 300 mg PO BID 
Tacrolimus 1 mg PO QPM 
Tacrolimus 0.5 mg PO QAM 
[] Changed Meds:
Acyclovir 400 mg PO Q8H (from q12H)
[] Discharge weight: 88.72 kg
[] Will need tacro level ___ AM before AM dose of tacro. 
Tacro goal ___. Last Level on ___: 14.9
[] C diff taper for first recurrence Vanc 125mg PO QID was 
started on (___), then 125 mg orally twice daily for 7 days 
(___), then 125 mg orally once daily for 7 days 
(___), then 125 mg orally every 2 days for 8 weeks 
(___). 
[] RIJ Tunneled Triple Lumen Power Access Line placed ___
[] CML VL ___ PENDING

 
Medications on Admission:
The Preadmission Medication list is accurate and complete.
1. LORazepam 0.5-1 mg PO Q8H:PRN 
anxiety/nausea/vomiting/insomnia 
2. Multivitamins W/minerals 1 TAB PO DAILY 
3. Vitamin D ___ UNIT PO DAILY 
4. Acyclovir 400 mg PO Q12H 
5. cannabidiol (CBD) extract ___ mg/mL oral uncertain 
6. Ascorbic Acid Dose is Unknown  PO Frequency is Unknown 

 
Discharge Medications:
1.  Fluconazole 400 mg PO Q24H 
RX *fluconazole 200 mg 2 tablet(s) by mouth Once daily Disp #*30 
Tablet Refills:*0 
2.  FoLIC Acid 1 mg PO DAILY 
RX *folic acid 1 mg 1 tablet(s) by mouth once daily Disp #*30 
Tablet Refills:*0 
3.  Multivitamins 1 TAB PO DAILY 
RX *multivitamin  1 tablet(s) by mouth once daily Disp #*30 
Tablet Refills:*0 
4.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY 
RX *sulfamethoxazole-trimethoprim 400 mg-80 mg 1 tablet(s) by 
mouth once daily Disp #*30 Tablet Refills:*0 
5.  Tacrolimus 1 mg PO QPM 
RX *tacrolimus 0.5 mg 2 capsule(s) by mouth At 10pm Disp #*60 
Capsule Refills:*0 
6.  Tacrolimus 0.5 mg PO QAM 
RX *tacrolimus 0.5 mg 1 capsule(s) by mouth At 10am Disp #*30 
Capsule Refills:*0 
7.  Ursodiol 300 mg PO BID 
RX *ursodiol 300 mg 1 capsule(s) by mouth Twice a day Disp #*60 
Capsule Refills:*0 
8.  Vancomycin Oral Liquid ___ mg PO QID 
RX *vancomycin 125 mg 1 capsule(s) by mouth 4 times a day Disp 
#*44 Capsule Refills:*0 
9.  Acyclovir 400 mg PO Q8H 
RX *acyclovir 400 mg 1 tablet(s) by mouth once a day Disp #*30 
Tablet Refills:*0 
10.  LORazepam 0.5-1 mg PO Q6H:PRN anxiety,nausea or vomiting if 
not relieved by ondansetron 
RX *lorazepam [Ativan] 0.5 mg 1 tablets by mouth every 6 hours 
Disp #*15 Tablet Refills:*0 
11.  Vitamin D ___ UNIT PO DAILY  

 
Discharge Disposition:
Home With Service
 
Facility:
___
 
Discharge Diagnosis:
Primary diagnosis:
==============
AML

Secondary diagnosis:
================
CDiff
Mucositis
History of perianal abscess

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Dear Mr. ___,   

It was a privilege caring for you at ___ ___ 
___.  

WHY WAS I IN THE HOSPITAL?  
- You were admitted for ablative chemotherapy and a stem cell 
transplant for your leukemia.  

WHAT HAPPENED TO ME IN THE HOSPITAL?  
- You received chemotherapy and the the stem cell transplant. 
- You were started on medications to prevent infection. 
- We monitored your blood counts, which were increasing at 
discharge
- You developed loose stool and you tested positive for CDiff; 
we started you on oral vancomycin four times a day. You will 
slowly decrease the amount of vancomycin, your treatment will 
continue until until ___. 
- You developed mucositis, which resolved.

WHAT SHOULD I DO AFTER I LEAVE THE HOSPITAL?  
- Continue to take all your medicines and keep your 
appointments.  

We wish you the best.

Sincerely,  
Your ___ Team  

 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=14679785-DS-34 | hadm_id=23999855

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___.
 
Major Surgical or Invasive Procedure:
None

attach
 
Pertinent Results:
Pertinent studies and discharge labs:

___ 12:00AM BLOOD WBC-7.9 RBC-1.99* Hgb-6.8* Hct-20.8* 
MCV-105* MCH-34.2* MCHC-32.7 RDW-20.1* RDWSD-75.0* Plt Ct-36*
___ 12:00AM BLOOD Plt Ct-36*
___ 12:00AM BLOOD Glucose-152* UreaN-12 Creat-0.7 Na-131* 
K-3.7 Cl-97 HCO3-23 AnGap-11
___ 12:00AM BLOOD ALT-20 AST-21 AlkPhos-63 TotBili-<0.2
___ 12:00AM BLOOD Calcium-7.6* Phos-2.7 Mg-1.6
___ 12:00AM BLOOD tacroFK-<2.0*
___ 01:40PM URINE RBC-4* WBC-7* Bacteri-FEW* Yeast-NONE 
Epi-0 TransE-<1
___ 01:40PM URINE Blood-NEG Nitrite-NEG Protein-50* 
Glucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NORMAL pH-6.0 
Leuks-NEG

___ 1:40 pm STOOL     CONSISTENCY: NOT APPLICABLE
      Source: Stool. 

   FECAL CULTURE (Final ___:    NO SALMONELLA OR SHIGELLA 
FOUND. 

   CAMPYLOBACTER CULTURE (Final ___:    NO CAMPYLOBACTER 
FOUND. 

   FECAL CULTURE - R/O VIBRIO (Final ___:    NO VIBRIO 
FOUND. 

   FECAL CULTURE - R/O YERSINIA (Preliminary): 

   FECAL CULTURE - R/O E.COLI 0157:H7 (Final ___: 
      No E. coli O157:H7 found. 

 
___ 1:40 pm URINE

                            **FINAL REPORT ___

   URINE CULTURE (Final ___:    NO GROWTH. 

KUB ___:
FINDINGS:  
  
There are no abnormally dilated loops of large or small bowel. 
There is no free intraperitoneal air. 
Moderate degenerative changes at L5-S1 and inferior sacroiliac 
joints 
bilaterally. 
Round metallic densities projecting in the lower abdomen are 
related to a 
mesh. 
  
IMPRESSION:  
  
No evidence of free intraperitoneal air. 
  
___ CXR:
IMPRESSION:  
  
Comparison to ___.  The patient has received a new 
left-sided 
PICC line.  The course of the line is unremarkable, the tip of 
the line 
projects over the mid SVC.  No complications, notably no 
pneumothorax. 

 
Brief Hospital Course:
Brief summary:  
___ with AML s-p allo ___ complicated by 
refractory
GVHD of the GI, C. difficile colitis, CMV viremia, recent VRE
bacteremia and multifocal fungal pneumonia who presents with
diarrhea and lactic acidosis.  His diarrhea improved with 
supportive care.

Transitional issues:
[ ] Please recheck sodium at 3-day ___.  If continues to 
downtrend without diarrhea/hypovolemia, more likely SIADH ISO 
pulmonary nodules and may need fluid restriction.
[ ] Please recheck CBC, need for RBC transfusion at 3-day 
___
[ ] Overdue for CMV viral load; was supposed to have it ___
[ ] Continue to adjust immunosuppression regimen for GVHD as 
needed
[ ] ___ results of outpatient bronchoscopy

#DIARRHEA
#Lactic Acidosis: 
#Leukocytosis
 Presentation concerning for infectious etiology vs. GI
GVHD flare given recent decrease in immunosuppresive medication
regimen. Patient has long history of GVHD of the GI tract that
has been steroid refractory. Has been on Jakofi 5 mg twice daily
and tacrolimus and prednisone (dose
recently decreased from 10 mg daily to 7.5 mg). He also has a 
history of recurrent C.
difficile colitis.  Stool negative for C. difficile colitis and 
GI PCR negative for other infectious causes as well Patient with 
elevated WBC on
admission, though also noted to be clinically dry in setting of
diarrhea; therefore suspect hemoconcentration.  Bland UA.  
Patient was treated supportively with IV fluids.  His 
immunosuppression was continued: Jakafi 5 mg twice daily and
Tacro 0.5mg qday, pred 7.5mg qday

#RECENT ENTEROCOCCUS BACTEREMIA: Patient was treated on prior
admissions for enterococcus bacteremia with unclear source. 
Could
be gut given GVHD. TTE ___ neg for vegetations. PICC was pulled
and cultured. He was discharged with antibiotics to be 
continued.
- c/w Linezolid ___ IV BID x 6 weeks from first negative blood
culture (D1: ___
- will f/u with ID outpatient ___

#RECENT MULTIFOCAL PNEUMONIA AND CAVITARY PULMONARY NODULES:
Patient is currently being treated with isavuconazole given c/f
aspergillus. Recent BAL ___ growing mold (described as a
contaminant but ID concerned about true mold infection). Repeat
chest CT ___ showed complete resolution of multifocal
pneumonia. Chest CT also shows short interval density and mild
size increase in multiple bilateral peribronchovascular solid
and cavitating nodules as well as appearance of a new nodule in
the
left lower lobe with concern for lung involvement from primary
disease. However last admission w increase in serum aspergillis
prompting repeating Chest CT which showed increased size of
pulmonary
nodules. s/p bronch ___ with biopsies, path pending
-Continued isavuconazole

#AML s/p allogeneic MRD HSCT (Day 0 = ___:
#THROMBOYCTOPENIA:
AML initially with favorable mutational profile (normal
karyotype; FLT3 negative, NPM1 positive, IDH2 positive, RAD21
positive, CEBPA negative). He relapsed after chemo-consolidation
(7+3, 3C HIDAC & MEC/Revlimid) then underwent an MRD allogeneic
SCT as above. In remission following his transplant with slow
count recovery most likely due to valganciclovir. BMBX during
recent admission showed no evidence of recurrence w/ 100%
chimerism. 
-Continued Tacrolimus 0.5mg qday
-Continued ruxolitinib 5mg PO BID
-prednisone tapered to 7.5mg ___
-Continued ACV
-Continued Bactrim SS PO QD

#HYPONATREMIA: noted for Na 133 on admission. Possibly component
of hypovolemic hyponatremia in setting of diarrhea versus SIADH 
ISO pulmonary nodules.  Down trended to 131 after IV fluid 
resuscitation.

#CMV VIREMIA: History of CMV viremia with positive viral load
___ (peak 2.2log), and he completed course of
valganciclovir last admission. CMV VL ND since ___ and was
changed ACV at time of DC last admission. ___ CMV VL 
negative

#Macrocytic anemia:
B12 and folate ok during previous admission.  Monitored and 
transfuse for Hgb less than 7

 
Medications on Admission:
The Preadmission Medication list is accurate and complete.
1. Acyclovir 400 mg PO Q8H 
2. PredniSONE 7.5 mg PO DAILY 
3. Linezolid ___ mg IV Q12H 
4. Budesonide 3 mg PO TID 
5. FoLIC Acid 1 mg PO DAILY 
6. LORazepam 1 mg PO BID: PRN anxiety 
7. Pantoprazole 40 mg PO Q12H 
8. Sulfameth/Trimethoprim SS 1 TAB PO DAILY 
9. Tacrolimus 0.5 mg PO DAILY 
10. Vitamin D ___ UNIT PO 1X/WEEK (WE) 
11. Magnesium Oxide 800 mg PO BID 
12. Isavuconazonium Sulfate 372 mg PO DAILY 
13. Ruxolitinib 5 mg PO BID 

 
Discharge Medications:
1.  Acyclovir 400 mg PO Q8H  
2.  Budesonide 3 mg PO TID  
3.  FoLIC Acid 1 mg PO DAILY  
4.  Isavuconazonium Sulfate 372 mg PO DAILY  
5.  Linezolid ___ mg IV Q12H  
6.  LORazepam 1 mg PO BID: PRN anxiety  
7.  Magnesium Oxide 800 mg PO BID  
8.  Pantoprazole 40 mg PO Q12H  
9.  PredniSONE 7.5 mg PO DAILY  
10.  Ruxolitinib 5 mg PO BID  
11.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  
12.  Tacrolimus 0.5 mg PO DAILY  
13.  Vitamin D ___ UNIT PO 1X/WEEK (WE)  

 
Discharge Disposition:
Home With Service
 
Facility:
___
 
Discharge Diagnosis:
Graft-versus-host disease of the gastrointestinal tract

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Dear Mr. ___,

Why you are admitted to the hospital?
-For severe diarrhea and abdominal pain

What happened when you are in the hospital?
-Your stool was analyzed for any signs of infection
-You were given fluids to treat her dehydration

Which do you when you go home?
-Please continue to take her immunosuppression medicines: 
Tacrolimus, prednisone, Jakofi
-If you were to develop worsening abdominal pain or diarrhea 
please contact your doctor ___ you feel dizzy or lightheaded and dehydrated, please contact 
your doctor ___ with hematology oncology this ___ or 
___, as we need to monitor your blood counts

It was a pleasure to participate in your care,

___ medicine
 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=14679785-DS-25 | hadm_id=24529140

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___.
 
Chief Complaint:
febrile neutropenia
 
Major Surgical or Invasive Procedure:
none

 
History of Present Illness:
___ PMH of AML (s/p 7+3 and recently received C3 HiDAC ___,
Perianal Abscess (s/p I&D), Marijuana Use, who presented with
neutropenic fever, admitted to ___ for further workup/treatment

Pt received last cycle of HiDAC on ___ with neulasta on
___. He noted that on ___ he was called by clinic 
staff
and instructed to start flagyl/cipro prophylaxis and he did so
accordingly. The next day he had fever up to 100.6, and his
daughter was nervous given her cytopenias so had him call the
fellow who rec'd ED evaluation.

Pt noted that despite the single episode of fever, he has been
without cough, sore throat, mucositis, headache, neck stiffness,
nausea, vomiting, diarrhea, abdominal pain, rash, dysuria,
diarrhea. He noted that he had occasional hemorrhoidal pain but
nothing that felt like the perianal abscess he had in the past. 

In the ED, initial vitals: 98.9 113 117/80 18 100% RA. Labs
included WBC of 0.2 (2% Neutrophils), 9 plt, Hgb 8.5, chem wnl,
lactate 1.1. UA negative. Bcx were drawn. CXR was negative for
acute change. Patient was seen by ___ in the emergency room.
Patient received Cefepime, vancomycin, flagyl and later had
voriconazole added as per  discussion with ___ fellow. Plt  were
transfused for  count of 9

 
Past Medical History:
PAST ONCOLOGIC HISTORY (per OMR):
___ INITIAL BM/BXAML
___ Consented to protocol ___ INDUCTION DAUNOrubicin  (90 mg/m2)  Cytarabine  (100
mg/m2) (RHP: +NPM1, +IDH2,+ RAD21)
___ D+14 BMBx ablated, 
___ D+26 remission, NPM1 negative
___ C1D1 HIDAC
--___ admitted for fever
--___ CT showed perianal abscess, drained, improved with
antibiotics
--___ C2D1 HIDAC

PAST MEDICAL HISTORY (per OMR):
AS ABOVE
 
Social History:
___
Family History:
Mother had lung cancer
Father had some type of metastatic cancer extensively involving
the bones
No history of any hematologic disorders including leukemia or
lymphoma
 
Physical Exam:
ADMISSION PHYSICAL EXAM:  
Vitals:   97.9 
PO 104 / 67
R Sitting 82 18 99 Ra 
GENERAL: laying in bed, appears comfortable, smiling, pleasant
EYES: PERRLA, anicteric
HEENT: OP clear, no lesions or mucositis, MMM
NECK: supple
LUNGS:  CTA b/l without qheezes/rales/rhonchi, normal RR
CV: RRR no m/r/g, no peripheral edema
ABD: soft, NT, ND, normoactive BS
GENITOURINARY: no foley
EXT: warm, dry, no rash no deformity, normal muscle bulk
SKIN: warm, dry, no rash  
NEURO:  AOx3, fluent speech
ACCESS: port in right chest which is accessed, clean dry, and
intact

DISCHARGE PHYSICAL EXAM:
VS: 98.1 119/76 85 18 98%RA
I/O: ___/BRP
Wt: 90.54 kg
GEN: sitting on side of bed, comfortable, pleasant
EYES: PERRLA, anicteric
HEENT: OP clear, no lesions or mucositis, MMM
NECK: Supple
LUNGS: CTA b/l without wheezes/rales/rhonchi, normal RR
CV: RRR no m/r/g, no peripheral edema
ABD: soft, NT/ND, normoactive BS
GENITOURINARY: No foley
EXT: warm, dry, no rash/deformity, normal muscle bulk
SKIN: warm, dry, no rash or lesions  
NEURO: AOx3, fluent speech
ACCESS: Right chest POC C/D/I
 
Pertinent Results:
___ 05:10AM BLOOD WBC-4.5# RBC-2.34* Hgb-7.8* Hct-22.4* 
MCV-96 MCH-33.3* MCHC-34.8 RDW-15.8* RDWSD-54.8* Plt Ct-29*
___ 09:33PM BLOOD WBC-0.2* RBC-2.49* Hgb-8.5* Hct-25.0* 
MCV-100* MCH-34.1* MCHC-34.0 RDW-16.3* RDWSD-60.3* Plt Ct-9*#
___ 05:10AM BLOOD Neuts-62 Bands-2 ___ Monos-11 Eos-0 
Baso-0 Atyps-1* Metas-2* Myelos-0 Promyel-1* AbsNeut-2.88 
AbsLymp-0.99* AbsMono-0.50 AbsEos-0.00* AbsBaso-0.00*
___ 09:33PM BLOOD Neuts-2* Bands-0 Lymphs-89* Monos-8 Eos-0 
Baso-1 ___ Myelos-0 AbsNeut-0.00* AbsLymp-0.18* 
AbsMono-0.02* AbsEos-0.00* AbsBaso-0.00*
___ 05:10AM BLOOD Glucose-104* UreaN-9 Creat-0.8 Na-136 
K-3.8 Cl-99 HCO3-23 AnGap-14
___ 09:33PM BLOOD Glucose-109* UreaN-14 Creat-0.7 Na-138 
K-3.7 Cl-100 HCO3-22 AnGap-16
___ 05:10AM BLOOD ALT-16 AST-16 LD(___)-211 AlkPhos-66 
TotBili-0.3
___ 07:00AM BLOOD ALT-13 AST-11 LD(___)-103 AlkPhos-61 
TotBili-0.9
___ 05:10AM BLOOD Albumin-3.6 Calcium-9.2 Phos-3.3 Mg-1.8
___ 06:37AM BLOOD Calcium-8.6 Phos-3.4 Mg-1.8
 
Brief Hospital Course:
 Mr. ___ is a ___ PMH of AML (s/p 7+3 and
recently received C3 HiDAC ___, Perianal Abscess (s/p I&D),
Marijuana Use, who presented with neutropenic fever.

#Febrile Neutrapenia: resolved. Neutropenia was likely due to
recent chemotherapy HiDAC regimen. He received neulasta on
___. He was started on prophylactic antibiotics on ___
(ciprofloxacin and flagyl) once his ANC < 500; unfortunately, he
developed fever 1 day after initiation of PPX antibiotics.
Patient has a history of vaping marijuana and has been on
voriconazole in the past to prevent fungal infection.

Fortunately, patient without any localizing symptoms, now with
count recovery and afebrile >72 hrs with no source found. POC
without any evidence of infection.

-F/U UCx/Bcx: negative to date
-Flu swab negative, viral panel neg
-Home cipro/flagyl ppx give were held for systemic IV ABX 
-Initiated on Vancomycin/Cefepime/Flagyl/Voriconazole on 
___
for empiric coverage. Changed from Voricnazole to Posaconazole
per discussion with AST. 
-now peeling off ABX with count recovery. d/c vanc ___, plan 
to
d/c cefe ___ if remains afebrile and d/c home. will d/c flagyl
___ and d/c vori ___ at home if remains afebrile.

#AML (+NPM1, +IDH2,+ RAD21): Considered favorable risk based on
IDH2 and NPM1 status, although presence of RAD21 not well
understood. He did achieve MRD negative status based on his
negative NPM1 by PCR testing and is considered favorable AML. He
is currently s/p cycle #3 of HIDAC. Today is D+ 18. 

#Anemia: At baseline, likely ___ BM suppression in setting of
chemotherapy and AML
-Trend daily
-Maintain T&S
-Transfuse for hgb<7 and or active bleeding
-Received 1U PRBCS ___ 

#Thrombocytopenia: likely ___ BM suppression in setting of 
recent
chemotherapy and AML as has nadired to similar counts in the 
past
on last cycle of HiDAC. No schistos on smear.
-Coags  WNL to r/o consumptive process such as DIC given fever
(despite lower likelihood given smear witout shistos)
-Maintain T&S
-Transfuse for plt<10 and/or active bleeding
-Needs pre-medications w/ Tylenol, Benadryl and Pepcid 

#Marijuana Use: Continues although he is using vaporizer, will
need to take prophylactic fungal therapy during his neutropenic
periods.

=
================================================================

CORE MEASURES: 
============== 
#FEN: IVF prn/replete electrolytes/neutropenic diet/precautions
#Prophylaxis:  
-DVT: pboots given thrombocytopenia  
#Access: PORT
#HCP/Contact: ___ 
Relationship: Ex-wife 
Phone number: ___ 
Cell phone: ___  
#Code: Full Code
#Disposition: Given count recovery, will discharge home today
with cipro/metronidazole. Will f/u with Dr. ___ on ___.

 
Medications on Admission:
The Preadmission Medication list is accurate and complete.
1. Vitamin D ___ UNIT PO DAILY 
2. PrednisoLONE Acetate 1% Ophth. Susp. 1 DROP BOTH EYES TID 
3. LORazepam 0.5-1 mg PO Q8H:PRN 
anxiety/nausea/vomiting/insomnia 
4. Ciprofloxacin HCl 500 mg PO Q12H 
5. MetroNIDAZOLE 500 mg PO TID 

 
Discharge Medications:
1.  Ciprofloxacin HCl 500 mg PO Q12H  
2.  LORazepam 0.5-1 mg PO Q8H:PRN 
anxiety/nausea/vomiting/insomnia  
3.  MetroNIDAZOLE 500 mg PO TID 
you can stop this medication on ___ as long as you have no 
fevers  
4.  PrednisoLONE Acetate 1% Ophth. Susp. 1 DROP BOTH EYES TID  
5.  Vitamin D ___ UNIT PO DAILY  
6.  Voriconazole 200 mg PO Q12H 
Take through ___. If you do not have a fever, then you can 
stop this.  

 
Discharge Disposition:
Home
 
Discharge Diagnosis:
lymphoma
febrile neutropenia

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Mr. ___,

You were admitted for fever when your blood counts were low. 
Your infectious work up was negative and your fevers resolved 
and your counts recovered. You will continue ciprofloxacin and 
metronidazole. You will follow up with Dr. ___ as stated 
below. It was a pleasure taking care of you.
 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=14679785-DS-19 | hadm_id=24541766

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___
 
Chief Complaint:
fevers, decreased exercise tolerance, throat pain
 
Major Surgical or Invasive Procedure:
Bone marrow biopsy ___ and ___

 
History of Present Illness:
Mr. ___ is a ___ year-old gentleman with no significant past
medical history who is referred from an OSH for concern for 
acute
leukemia. 

Five weeks prior to admission, Mr. ___ began with an episode
of chills/fever and sore throat. He saw a physician in urgent
care and received a course of antibiotics (unclear which). His
fevers/chills subsided and the sore throat improved but about 3
weeks prior to admission his sore throat and fevers returned, 
his
sore throat was severe enough to prevent him from eating much. 
He
seen in urgent care again, was tested for mononucleosis and 
strep
which were negative and was given another course of antibiotics
(cephalexin) with no improvement. Three days prior to admission
he was noticed to have a hoarse voice, neck pain prompting him 
to
see a dental surgeon who removed 'an infected tooth' and started
him on amoxicillin-clavulanate. Given worsening of his 
hoarseness
and some throat pressure as well as fevers as high as 103 he
decided to go to an OSH ED were he was found to have WBC 67 and
tonsillar abscess on CT neck prompting transfer to ___. Prior
to transfer he received 2L IVF, ampicillin-sulbactam, amikacin,
fluconazole. 
 
ED initial vitals were   96.2 112 127/73 16 95% RA 
Prior to transfer vitals were  98.5 100 101/59 18 97% RA 

Exam in the ED showed : "HEENT: Notable for large cervical LAD,
non-tender; Poor dentition CV: Normal S1, S2, no m/r/g
Resp: clear lung sounds bilaterally to auscultation"
 
ED work-up significant for:
-CBC: WBC: 77.1* HGB: 6.0*. Plt Count: 95* . Neuts%: 9* Other%
73*
-Chemistry: Na: 137. K: 3.4. Cl: 103. CO2: 21*. BUN: 13. Creat:
1.2. Ca: 7.8*. Mg: 1.9. PO4: 1.9*. 
-Lactate: 1.1
-Coags: INR: 1.3*. PTT: 25.5. FBG 478
-LFTs: ALT: 12. AST: 17. Alk Phos: 62. Total Bili: 0.4. 

ED management significant for:
-Medications: cefepime 2g, vancomycin 1g, allopurinol ___,
hydroxyurea 2g,  
-Transfusions: None
-Procedures: Bone Marrow Biopsy by ___ Fellow
-Consult: ___

On arrival to the floor, patient reports feeling much better
since he received steroids

Patient denies headache, vision changes,
dizziness/lightheadedness, weakness/numbnesss, shortness of
breath, cough, hemoptysis, chest pain, palpitations, abdominal
pain, nausea/vomiting, diarrhea, hematemesis,
hematochezia/melena, dysuria, hematuria, and new rashes. 
 
Past Medical History:
None
 
Social History:
___
Family History:
No family history of cancer to the best of his recollection
 
Physical Exam:
ADMISSION PHYSICAL EXAM:
VS: 98.1 PO 130 / 60 71 20 100 RA 
GENERAL: Pale appearing gentleman in no distress lying, in bed
comfortably.
HEENT: Anicteric, PERLL, Mucous membranes moist, bilaterally
enlarged and erythematous tonsils protruding close to midline
with prominent yellow exudates.
LYMPH: 3x4cm enlarged non-tender bilateral posterior cervical
nodes, no supraclavicular / axillary / inguinal lymphadenopathy.
CARDIAC: Regular rate and rhythm, normal heart sounds, systolic
multifocal ejection murmur. No rubs or gallops.
LUNG: Appears in no respiratory distress, bibasilar wheezing, no
crackles or rhonchi.
ABD: Non-distended, normal bowel sounds, soft, non-tender, no
guarding, no palpable masses, no organomegaly.
EXT: Warm, well perfused. No lower extremity edema. No erythema
or tenderness.
NEURO: A&Ox3, good attention and linear thought, CN II-XII
intact. Strength full throughout. Sensation to light touch
intact.
SKIN: No significant rashes.

DISCHARGE PHYSICAL EXAM:
VS: 98.0, 106 / 64, 103, 20, 98 RA 

GENERAL: Well-appearing middle-aged male in no acute distress
resting comfortably in bed.
HEENT: Anicteric sclerae.  Moist mucous membranes. Palatine
tonsils with minimal edema and white exudate.
CV: Regular rate and rhythm, normal S1 and S2, no murmurs, rubs,
gallops, or thrills.
LUNG: Clear to auscultation bilaterally, no wheezes, rales, or
rhonchi.  Good respiratory effort.
ABD: No scars.  Normal bowel sounds.  Soft, nontender,
nondistended.  No rebound tenderness or guarding.  No
hepatosplenomegaly.
EXT: Warm and well perfused.  No clubbing, cyanosis, or lower
extremity edema.
NEURO: A&O 3. Moving all 4 extremities with purpose.
SKIN: Moderate pallor.  Bilateral petechial rash on the inner
left and right thighs resolved.
 
Pertinent Results:
ADMISSION LABS:
___ 05:00PM   WBC-77.1* RBC-1.86* HGB-6.0* HCT-18.2* MCV-98 
MCH-32.3* MCHC-33.0 RDW-16.2* RDWSD-56.5*
___ 05:00PM   NEUTS-9* BANDS-2 LYMPHS-14* MONOS-26* EOS-0 
BASOS-0 ___ MYELOS-0 BLASTS-49* OTHER-0 
AbsNeut-8.48* AbsLymp-10.79* AbsMono-20.05* AbsEos-0.00* 
AbsBaso-0.00*
___ 05:00PM   HYPOCHROM-NORMAL ANISOCYT-1+* 
POIKILOCY-OCCASIONAL MACROCYT-OCCASIONAL MICROCYT-OCCASIONAL 
POLYCHROM-NORMAL OVALOCYT-OCCASIONAL TEARDROP-OCCASIONAL
___ 05:00PM   GLUCOSE-144* UREA N-13 CREAT-1.2 SODIUM-137 
POTASSIUM-3.4 CHLORIDE-103 TOTAL CO2-21* ANION GAP-13
___ 05:00PM   ALT(SGPT)-12 AST(SGOT)-17 LD(LDH)-443* ALK 
PHOS-62 TOT BILI-0.4
___ 05:00PM   ALBUMIN-3.4* CALCIUM-7.8* PHOSPHATE-1.9* 
MAGNESIUM-1.9 URIC ACID-6.5
___ 05:00PM   HBsAg-NEG HBs Ab-NEG HBc Ab-NEG
___ 05:00PM   HIV Ab-NEG
___ 05:00PM   HCV Ab-NEG
___ 05:09PM   LACTATE-1.1
___ 05:29PM   ___
___ 05:29PM   ___ PTT-25.5 ___

PERTINENT LABS:
___ 01:29PM BLOOD WBC-62.3* RBC-2.08* Hgb-6.8* Hct-19.3* 
MCV-93 MCH-32.7* MCHC-35.2 RDW-17.0* RDWSD-57.1* Plt Ct-71*
___ 10:00PM BLOOD WBC-36.0* RBC-2.11* Hgb-6.8* Hct-19.5* 
MCV-92 MCH-32.2* MCHC-34.9 RDW-17.2* RDWSD-57.2* Plt Ct-68*
___ 02:40PM BLOOD WBC-14.5* RBC-2.24* Hgb-7.1* Hct-20.5* 
MCV-92 MCH-31.7 MCHC-34.6 RDW-16.6* RDWSD-54.7* Plt Ct-49*
___ 06:00AM BLOOD WBC-3.2*# RBC-2.03* Hgb-6.3* Hct-18.6* 
MCV-92 MCH-31.0 MCHC-33.9 RDW-16.2* RDWSD-53.3* Plt Ct-43*
___ 05:02AM BLOOD WBC-0.6* RBC-2.14* Hgb-6.8* Hct-19.3* 
MCV-90 MCH-31.8 MCHC-35.2 RDW-15.9* RDWSD-52.0* Plt Ct-30*
___ 12:00AM BLOOD WBC-0.5* RBC-2.44* Hgb-7.5* Hct-21.3* 
MCV-87 MCH-30.7 MCHC-35.2 RDW-15.3 RDWSD-48.2* Plt Ct-5*#
___ 12:00AM BLOOD WBC-0.3* RBC-2.11* Hgb-6.6* Hct-18.8* 
MCV-89 MCH-31.3 MCHC-35.1 RDW-14.8 RDWSD-48.0* Plt Ct-10*#
___ 12:00AM BLOOD WBC-0.5* RBC-2.47* Hgb-7.4* Hct-21.7* 
MCV-88 MCH-30.0 MCHC-34.1 RDW-13.9 RDWSD-45.2 Plt Ct-29*#
___ 11:30PM BLOOD Neuts-4* Bands-0 Lymphs-8* Monos-48* 
Eos-0 Baso-0 ___ Myelos-0 Blasts-40* Other-0 
AbsNeut-3.30 AbsLymp-6.61* AbsMono-39.65* AbsEos-0.00* 
AbsBaso-0.00*
___ 01:29PM BLOOD Neuts-12* Bands-0 Lymphs-13* Monos-38* 
Eos-0 Baso-0 ___ Myelos-3* Blasts-34* AbsNeut-7.48* 
AbsLymp-8.10* AbsMono-23.67* AbsEos-0.00* AbsBaso-0.00*
___ 09:38PM BLOOD Neuts-35 Bands-0 ___ Monos-15* 
Eos-1 Baso-0 ___ Myelos-0 Blasts-30* AbsNeut-3.05 
AbsLymp-1.65 AbsMono-1.31* AbsEos-0.09 AbsBaso-0.00*
___ 03:15PM BLOOD Neuts-36 Bands-1 Lymphs-62* Monos-0 Eos-0 
Baso-0 ___ Myelos-0 Blasts-1* AbsNeut-0.26* 
AbsLymp-0.43* AbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*
___ 12:00AM BLOOD Neuts-0.0* Lymphs-98.0* Monos-2.0* 
Eos-0.0* Baso-0.0 AbsNeut-0.00*# AbsLymp-0.49* AbsMono-0.01* 
AbsEos-0.00* AbsBaso-0.00*
___ 12:00AM BLOOD Neuts-12* Bands-0 Lymphs-88* Monos-0 
Eos-0 Baso-0 ___ Myelos-0 AbsNeut-0.05* 
AbsLymp-0.35* AbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*
___ 12:00AM BLOOD Neuts-29* Bands-1 Lymphs-69* Monos-0 
Eos-0 Baso-0 Atyps-1* ___ Myelos-0 NRBC-1* AbsNeut-0.15* 
AbsLymp-0.35* AbsMono-0.00* AbsEos-0.00* AbsBaso-0.00*
___ 02:40PM BLOOD ALT-21 AST-18 LD(___)-441* AlkPhos-46 
TotBili-0.4
___ 10:00PM BLOOD ALT-22 AST-13 LD(___)-303* AlkPhos-44 
TotBili-0.8
___ 12:00AM BLOOD ALT-21 AST-14 LD(___)-281* AlkPhos-36* 
TotBili-0.9
___ 12:00AM BLOOD ALT-19 AST-14 LD(___)-158 AlkPhos-37* 
TotBili-0.4
___ 03:15PM BLOOD Hapto-232*
___ 06:14AM BLOOD TSH-4.7*
___ 12:00AM BLOOD 25VitD-22*
___ 12:00AM BLOOD CMV VL-NOT DETECT

DISCHARGE LABS:
___ 12:00AM BLOOD WBC-1.8* RBC-2.81* Hgb-8.6* Hct-25.5* 
MCV-91 MCH-30.6 MCHC-33.7 RDW-14.4 RDWSD-46.9* Plt ___
___ 12:00AM BLOOD Neuts-63.2 ___ Monos-6.0 Eos-0.0* 
Baso-0.0 Im ___ AbsNeut-1.15*# AbsLymp-0.54* AbsMono-0.11* 
AbsEos-0.00* AbsBaso-0.00*
___ 12:00AM BLOOD Glucose-136* UreaN-10 Creat-0.5 Na-136 
K-3.9 Cl-99 HCO3-22 AnGap-15
___ 12:00AM BLOOD ALT-42* AST-23 LD(___)-167 AlkPhos-59 
TotBili-0.4
___ 12:00AM BLOOD Albumin-3.2* Calcium-7.9* Phos-2.5* 
Mg-2.0 UricAcd-2.5*
___ 12:00AM BLOOD Hapto-230*

IMAGING/STUDIES:
TTE (___): Preserved biventricular systolic function. Mildy 
dilated aortic root and ascending aorta. Borderline pulmonary 
artery systolic hypertension. 

CT Neck (___): 1. No evidence of rim enhancing abscess or 
drainable fluid collection.
2. significant interval decrease in bilateral lymphadenopathy 
since ___ with slightly enlarged lymph nodes remaining at cervical 
level 2 a.

CT C/A/P (___): 1. Acute colonic diverticulitis as 
described.  No free air or abscess.
2. Part solid pulmonary nodule measuring 7 mm.  Please follow up 
per
guidelines below.

CT Sinus (___): 
1. Mild chronic paranasal sinus disease, as described above.  No 
evidence of
fluid collection concerning for abscess formation.
2. Left maxillary premolar dental ___ and ___ maxillary molar 
periodontal
disease.  Formal dental evaluation is advised.

CT Chest (___): 
1. Diffuse millimetric peribronchovascular ___ 
nodularity,
nonspecific, suggestive of infection or inflammation.
2. Interval increase in size and solid appearance of a 
previously described
partially solid ground-glass nodule in the right upper lobe, 
with solid
component measuring approximately 8-9 mm, since ___.
3. Upper lobe predominance of mild centrilobular emphysema.
4. The ascending thoracic aorta is mildly prominent, measuring 
up to 3.8 cm.
5. Partially visualized hypodense lesions in the liver, possibly 
hepatic
cysts.

 
Brief Hospital Course:
Mr. ___ is a ___ male with no significant past 
medical
history who was referred from an outside hospital with new acute 
myelogenous leukemia in the setting of subacute fevers, 
shortness of breath, and peritonsillar phlegmon. He received 
induction chemotherapy with 7+3. His course was complicated by 
acute diverticulitis and fever of unknown origin. He was 
ultimately deemed stable for discharge.

ACTIVE ISSUES
============
#Acute myelogenous leukemia: The patient was transferred from 
___ in the setting of several months of 
intermittent fevers, decreased exercise tolerance, and new 
peritonsillar phlegmons. A CBC at the OSH showed a white blood 
cell count of 67,000 and 30% myeloid blasts on smear. He was 
transferred to ___ for further workup. A bone marrow biopsy on 
admission at ___ was consistent with AML, normal karyotype, 
FLT3(-), IDH2(+), NPM1(+), RAD21(+), CEBPA (-). The patient was 
initially started on Hydrea, steroids, and fluids before 
beginning 7+3 on ___. He tolerated chemotherapy well with 
only mild nausea, grade 2 mucositis, a petechial rash on the 
bilateral thighs, and increased fatigue. Bone marrow biopsy on 
day 14 of his chemotherapy cycle showed chemoablation. He 
otherwise remained stable. Pt was discharged after his D28 bone 
marrow biopsy, results pending on DC. 

#Peritonsillar phlegmon/abscess
#Acute diverticulitis
#Neutropenic fever: The patient initially presented with 
subacute fevers. These were likely due to a combination of his 
AML and peritonsillar phlegmons. He was initially started on 
Zosyn with subsequent decrease in tonsil size and exudate. 
However, on ___, the patient became febrile to 100.9. He was 
subsequently switched to cefepime and Flagyl. The patient 
continued to be febrile, Vancomycin was added on ___. 
Throughout these febrile episodes, the patient otherwise 
remained HDS, +diarrhea, C. diff negative. CT Chest/A/P on 
___ showed findings consistent with acute sigmoid 
diverticulitis and stable peritonsillar phlegmons. Pt continued 
to be intermittently febrile between ___ and ___, Vanc was DC'd 
on ___, switched from cefepime to meropenem on ___ due to 
concern for drug fever. Pt ultimately defervesced on ___. 
Blood and urine cultures remained negative throughout the 
entirety of the patient's febrile episodes. It was thought that 
the last week of fevers may have been drug-related (vancomycin 
vs. cefepime).

CHRONIC ISSUES
NONE

TRANSITIONAL ISSUES:
#NEW MEDS

[]Has AML with favorable mutation profile; plan is for HiDAC 
with curative intent
[]Will need follow-up of day ___ bone marrow biopsy
[]CT chest showed incidental pulmonary nodule, will need CT or 
PET follow-up in 3 months to monitor for interval change

FULL CODE
Contact: ___ ___
 
Medications on Admission:
The Preadmission Medication list is accurate and complete.
1. This patient is not taking any preadmission medications

 
Discharge Medications:
1.  Vitamin D ___ UNIT PO 1X/WEEK (TH) Duration: 8 Doses  

 
Discharge Disposition:
Home
 
Discharge Diagnosis:
Primary:
acute myelogenous leukemia
peritonsillar phlegmon
acute diverticulitis

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Dear Mr. ___,

It was a pleasure taking care of you at ___ 
___.

Why was I in the hospital?
- You had swollen tonsils; lab tests also showed you had a very 
high number of white blood cells that were concerning for 
leukemia

What was done while I was in the hospital?
- You had a bone marrow biopsy that showed you had a cancer 
called acute myeloid leukemia
- You were started on chemotherapy; a repeat of your bone marrow 
biopsy after chemotherapy showed that there were no visible 
leukemia cells
- You began to have fevers and were started on antibiotics; we 
then found that you had an infection in your colon called acute 
diverticulitis that was being treated with the antibiotics
- You kept having fevers, but otherwise felt fine; we think they 
were due to one of the medications that you were taking in the 
hospital
- Your counts slowly recovered and you were determined to be 
safe to go home
- You had a repeat bone marrow biopsy on the day before you 
left, the results of which are pending. 

What should I do when I get home from the hospital?
- Be sure to take all of your medications as prescribed, 
especially your medications to prevent infections
- Go to all of your follow-up appointments with your oncologist. 
Your first follow up appointment is next ___. 
- If you have fevers, chills, or generally feel unwell, please 
call your oncologist or go to the emergency room

Sincerely,
Your ___ Treatment Team
 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=14679785-DS-30 | hadm_id=25396761

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___.
 
Major Surgical or Invasive Procedure:
None

attach
 
Pertinent Results:
ADMISSION LABS  
==============================
___ 12:15PM BLOOD WBC-9.1 RBC-2.62* Hgb-9.4* Hct-28.1* 
MCV-107* MCH-35.9* MCHC-33.5 RDW-20.0* RDWSD-77.8* Plt Ct-46*
___ 12:15PM BLOOD Neuts-81.9* Lymphs-6.6* Monos-6.6 
Eos-0.0* Baso-0.1 NRBC-0.4* Im ___ AbsNeut-7.46* 
AbsLymp-0.60* AbsMono-0.60 AbsEos-0.00* AbsBaso-0.01
___ 12:15PM BLOOD  WBC-9.1 Lymph-7* Abs ___ CD3%-79 Abs 
CD3-506* CD4%-16 Abs CD4-105* CD8%-63 Abs CD8-401 CD4/CD8-0.26*
___ 11:40AM BLOOD UreaN-29* Creat-0.8 Na-138 K-3.4* Cl-105 
HCO3-20* AnGap-13
___ 11:40AM BLOOD ALT-29 AST-16 LD(LDH)-313* AlkPhos-73 
TotBili-0.6
___ 11:40AM BLOOD Calcium-8.4 Phos-3.0 Mg-1.5*

DISCHARGE LABS
==============================
___ 09:45AM BLOOD WBC-3.5* RBC-2.50* Hgb-8.5* Hct-26.3* 
MCV-105* MCH-34.0* MCHC-32.3 RDW-21.9* RDWSD-82.0* Plt Ct-34*
___ 09:45AM BLOOD Neuts-45 Bands-13* ___ Monos-10 
Eos-0* Baso-0 Atyps-3* Metas-3* Myelos-3* NRBC-6.2* AbsNeut-2.03 
AbsLymp-0.91* AbsMono-0.35 AbsEos-0.00* AbsBaso-0.00*
___ 09:45AM BLOOD Glucose-91 UreaN-23* Creat-0.7 Na-143 
K-3.5 Cl-106 HCO3-24 AnGap-13
___ 09:45AM BLOOD ALT-39 AST-28 AlkPhos-79 TotBili-0.4
___ 09:45AM BLOOD Calcium-7.5* Phos-3.0 Mg-1.3*
___ 09:45AM BLOOD tacroFK-5.5
___ 06:10AM BLOOD CMV VL-NOT DETECT
___ 06:25AM BLOOD CMV VL-NOT DETECT

PERTINENT STUDIES
==============================
___ CT CHEST W/ CONTRAST
1. Interval development of bilateral peribronchial nodules, 
concerning for 
infection. 
2. Moderate diffuse bronchial wall thickening and irregularity 
with mucous 
plugging, consistent with chronic airway disease. 
3. Mild centrilobular emphysema. 

___ CT ABD/PELVIS WITH CONTRAST
1. Bladder wall edema with mucosal hyperenhancement.  
Correlation with UA for cystitis is recommended. 
2. Circumferential mural thickening involving the entire large 
bowel, as well as the distal ileum, is most suggestive of acute 
graft-versus-host disease and infectious enterocolitis, as on 
prior. 

___ RESPIRATORY VIRAL PANEL, PCR
Rhinovirus positive by NP swab, others negative

___ BILATERAL LOWER EXTREMITY VEINS
No evidence of deep venous thrombosis in the right or left lower 
extremity 
veins. 

___ TISSUE (BONE MARROW BIOPSY), IMMUNOPHENOTYPING
HYPOCELLULAR BONE MARROW WITH TRILINEAGE HEMATOPOIESIS.
NO MORPHOLOGIC EVIDENCE OF INVOLVEMENT BY THE PATIENT'S KNOWN 
ACUTE
MYELOID LEUKEMIA. SEE NOTE

INTERPRETATION:
Diagnostic immunophenotypic features of involvement by acute 
myeloid leukemia are not seen in this specimen. Correlation with 
clinical, morphologic (see separate pathology report 
___, cytogenetic studies (see separate cytogenetics 
report ___), and other ancillary findings is recommended. 
Flow cytometry immunophenotyping may not detect all abnormal 
populations due to topography, sampling or artifacts of sample 
preparation.

An apparently normal 46,XY male chromosome complement was 
observed in 20 mitotic cells examined in detail. Chromosome band 
resolution was 400-450. A karyogram was prepared on 5 cells

___ TRANSTHORACIC ECHO
EF 59% Normal left ventricular wall thickness and biventricular 
cavity sizes and regional/global biventricular systolic 
function. Trace-mild aortic regurgitation. No 2D 
echocardiographic evidence for endocarditis.

 
Brief Hospital Course:
================================================
TRANSITIONAL ISSUES 
================================================
- continue Daptomycin (10mg/kg dosing) 750mg IV Q24H 
(___)
- continue Ceftriaxone 2g IV q24h ___ s/p 
cefepime (___)
- continue C.Diff prophylaxis with oral Vancomycin 125mg PO BID 
until completion or antibiotics (___) 
- consider restarting ciprofloxacin prophylaxis following 
antibiotics, to be reassessed in transplant ___ clinic
- CT Chest imaging and ID follow-up scheduled for ___ 
reassess indication for outpatient bronchoscopy
- f/u ___ bone marrow biopsy results
- re-assess indication for CMV prophylaxis 

================================================
BRIEF HOSPITAL COURSE
================================================
___ with relapsed acute myeloid leukemia in remission s/p 
reinduction with MEC/lenalidomide on protocol ___, s/p 
allogeneic MRD stem cell transplant c/b acute GVHD of the gut, 
presenting with BK Cystitis and diarrhea (GVHD) and started on 
___. He was also found to have pulmonary nodules concerning 
for fungal etiology for which he has repeat imaging scheduled 
for ___ prior to ID follow-up with Dr. ___. He was 
found to have asymptomatic Enterococcal (vanc/amp resistant) and 
E. Coli bacteremia, for which he will continue antibiotics via 
___ following hospital discharge.

ACTIVE ISSUES
# Dysuria
# BK Virus cystitis
Dysuria, hematuria with trouble with continuing flow. UA 
consistent with UTI and Urine BK virus PCR with >50 million 
copies (other infectious etiologies negative). No suggestion of 
pyelonephritis. Some initial concern for memory lapses/ 
?confusion which historically was present iso past infection, 
however family denying acute process but rather chronic 
intermittent forgetfulness. Patient provided pain relief with 
phenazopyridine; urology consult not finding indication for 3 
way foley. 

# Diarrhea
# Recurrent C Diff infection
# Acute GVHD
On tacrolimus and steroids (prednisone/budesonide) with ongoing 
diarrhea concerning for GVH (C Diff negative). Started jakafi 
5mg BID while inpatient with subjective improvement. 

#Enterococcus Bacteremia, Vancomycin/Ampicillin Resistant
Patient without clinical stigmata of a bloodstream infection (no 
fevers/chills, vital signs stable, no malaise) but iso severe 
immunosuppression. TTE without vegetations appreciated. 
Enterococcus sensitive to daptomycin (dose-dependent) and 
provided PICC on ___ for outpatient completion of 
antibiotics. 
- continue Daptomycin (10mg/kg dosing) 750mg IV Q24H 
(___)
- continue C.Diff prophylaxis with oral Vancomycin 125mg PO BID 
until completion or antibiotics (___) 
- consider restarting ciprofloxacin prophylaxis following 
antibiotics, to be reassessed in transplant ___ clinic

#E. Coli Bacteremia
Completed ciprofloxacin course on ___ while inpatient for foot 
ecthyma and history of pseudomonal bacteremia, and on ___ with 
blood cultures growing E. Coli bacteremia sensitive to 
ceftriaxone. Likely is gut translocation iso significant 
immunosuppression alongside jakafi initiation this admission. 
Provided PICC on ___ for outpatient completion of 
antibiotics. 
- continue Ceftriaxone 2g IV q24h ___ s/p 
cefepime (___)
- continue C.Diff prophylaxis with oral Vancomycin 125mg PO BID 
until completion or antibiotics (___) 
- consider restarting ciprofloxacin prophylaxis following 
antibiotics, to be reassessed in transplant ___ clinic

# Lower Extremity Edema
Patient reports lower extremity swelling is secondary to 
steroids and relieves (minorly) with elevation; denies history 
of heart disease. Dr. ___ prednisone taper while 
admitted; prednisone was decreased from 30->20->15 by discharge. 
His 15mg dosing was started on ___. 

# Cough
# Pulmonary nodules
Recent sick contact exposure with 1 week of cough and phlegm 
production. CT chest suggesting pulmonary nodules and B-Glucan 
224 / galactomannan negative concerning for fungal etiology. 
Pulmonary consult finding transient nodules in past likely 
related to ongoing marijuana vaping use and without infectious 
symptoms or stigmata and does not favor urgent bronchoscopy this 
admission with repeat imaging in 6 weeks; ID consult 
recommending bronchoscopy or potential repeat imaging in 2 
weeks. Given lack of patient symptoms, plan for discharge with 
ID follow-up evaluation with repeat CT imaging scheduled. Of 
note, patient was rhinovirus positive by nasopharyngeal swab and 
sputum cultures grew stenotrophomonas maltophilia, serratia 
marcescens. 
- CT Chest imaging and ID follow-up scheduled for ___ 
reassess indication for outpatient bronchoscopy

# Acute myeloid leukemia, in remission
___ continues to remain in a complete remission count slow most 
likely due to valganciclovir, slowly thrombocytopenia is 
improving. Bone marrow biopsy ___ without AML recurrence 
(Blast cells 1%, no discrete blast population in blast gate). 
Continued on prophylaxis: atovaquone, high dose PPI.
- f/u ___ bone marrow biopsy results

# CMV Viremia, history of reactivation
History of viremia on maintenance dosing; viral loads checked 
through admission not detected. ID consult appreciated 
significant immunosuppression in this asymptomatic host and 
recommended continuing valganciclovir 900 mg daily through 
admission. Planned ___ weeks of therapy which can be reduced to 
prophylaxis pending outpatient plan.
- re-assess indication for CMV prophylaxis 

CHRONIC/RESOLVED ISSUES: 
# Cellulitis with Pseudomonas bacteremia
Per outpatient ID note on ___, pseudomonal foot ulcer was 
healing well and ciprofloxacin was to be continued for ~2 weeks 
with re-evaluation. Maintained on ciprofloxacin while admitted 
with well-healing tissue by exam. 

# EBV Viremia, history of reactivation
s/p one dose of Rituximab ___.

# Nicotine dependence
# Marijuana use
Provided nicotine patch while admitted.

 
Medications on Admission:
The Preadmission Medication list is accurate and complete.
1. Atovaquone Suspension 1500 mg PO DAILY 
2. Ciprofloxacin HCl 500 mg PO BID 
3. Posaconazole Delayed Release Tablet 300 mg PO DAILY 
4. ValGANCIclovir 900 mg PO DAILY 
5. Budesonide 3 mg PO TID 
6. LORazepam 1 mg PO BID:PRN anxiety 
7. Multivitamins 1 TAB PO DAILY 
8. Tacrolimus 0.5 mg PO QAM 
9. Tacrolimus 0.5 mg PO QPM 
10. FoLIC Acid 1 mg PO DAILY 
11. LOPERamide 2 mg PO QID diarrhea 
12. PredniSONE 30 mg PO DAILY 
13. Vitamin D ___ UNIT PO 1X/WEEK (WE) 
14. Nicotine Patch 21 mg/day TD DAILY 
15. Pantoprazole 40 mg PO Q12H 

 
Discharge Medications:
1.  CefTRIAXone 2 gm IV Q 24H 
RX *ceftriaxone in dextrose,iso-os 2 gram/50 mL 2 g IV once a 
day Disp #*15 Intravenous Bag Refills:*0 
2.  Daptomycin 750 mg IV Q24H  
3.  LOPERamide 2 mg PO QID:PRN Diarrhea  
4.  ruxolitinib 5 mg PO BID  
5.  Vancomycin Oral Liquid ___ mg PO BID  
6.  PredniSONE 15 mg PO DAILY  
7.  Atovaquone Suspension 1500 mg PO DAILY  
8.  Budesonide 3 mg PO TID  
9.  FoLIC Acid 1 mg PO DAILY  
10.  LORazepam 1 mg PO BID:PRN anxiety  
11.  Multivitamins 1 TAB PO DAILY  
12.  Nicotine Patch 21 mg/day TD DAILY  
13.  Pantoprazole 40 mg PO Q12H  
14.  Posaconazole Delayed Release Tablet 300 mg PO DAILY  
15.  Tacrolimus 0.5 mg PO QPM  
16.  Tacrolimus 0.5 mg PO QAM  
17.  ValGANCIclovir 900 mg PO DAILY  
18.  Vitamin D ___ UNIT PO 1X/WEEK (WE)  

 
Discharge Disposition:
Home With Service
 
Facility:
___
 
Discharge Diagnosis:
PRIMARY DIAGNOSES
===============================
# BK Virus Cystitis
# Graft vs Host Disease
# Enterococcus Bacteremia, Vancomycin/Ampicillin Resistant
# E. Coli Bacteremia
# Diarrhea
# Pulmonary Nodules
# Lower Extremity Edema

SECONDARY DIAGNOSES
===============================
# Recurrent C Diff infection
# Acute myeloid leukemia, in remission
# Cellulitis with Pseudomonas bacteremia
# CMV Viremia, history of reactivation
# EBV Viremia, history of reactivation
# Nicotine dependence
# Marijuana use

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
================================================  
PATIENT DISCHARGE INSTRUCTIONS
================================================  
Dear Mr. ___,

It was a pleasure taking care of you at the ___ 
___!  

WHY WAS I IN THE HOSPITAL?  
- You were admitted because you had pain with urination, had a 
recent cold and cough, and also had ongoing diarrhea.

WHAT HAPPENED IN THE HOSPITAL?  
- You were started on a medication (jakafi) to help suppress the 
inflammation in your bowels and treat your diarrhea.
- Lab tests showed that your bladder was infected with BK Virus, 
a virus that can cause common bladder infections and pain in 
immunosuppressed hosts.
- You were found to have pulmonary nodules that could be 
infection, and it was decided these would be monitored when you 
leave.
- You were found to have bloodstream infections and you were 
started on antibiotics. 

WHAT SHOULD I DO WHEN I LEAVE THE HOSPITAL?  
- You should follow-up with your Oncologist, Dr. ___ on 
___. 
- You should follow-up with your Infectious Disease physician, 
___, on ___ for outpatient evaluation of your 
pulmonary nodules/infection. The morning before you see Dr. 
___ will have CT imaging of your chest. 
- Continue your antibiotic infusions as instructed, with an end 
date of ___. 
- Be sure to take your medications as prescribed and attend the 
appointments listed below. 

Thank you for allowing us to be involved in your care, we wish 
you all the best!  

 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=14679785-DS-28 | hadm_id=26153993

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___
 
Chief Complaint:
Fever
 
Major Surgical or Invasive Procedure:
None

 
History of Present Illness:
___ yo M w/relapsed AML s/p reinduction w/ MEC/lenalidomide per
protocol ___, now s/p allogeneic MRD stem cell transplant,
(day +62 on admission), non-neutropenic, now admitted w/ 1 day 
of
fever, nasal congestion, and diarrhea.

Patient overall had been doing well until two days prior to
admission when he developed fatigue, mild nasal congestion, and
dry cough. He believes he may have caught something from his
daughter, who has had a URI. His symptoms were initially mild,
and he was seen in outpatient ___ clinic on ___ for a
previously scheduled follow-up. He subsequently developed
worsening fatigue, and on evening prior to admission developed
fever to 100.8. Overnight at home he also developed loose 
stools;
he reports ___ stools that were loose (not watery), non-bloody,
with ~4 BM total in past 24H. Consistently of stools has been
improving per patient. He denies subjective fevers (even when
temp elevated), chills, night sweats, light-headedness,
dizziness, vision changes, neck stiffness, sore throat, mouth or
neck pain, SOB, productive cough, abdominal pain, nausea,
vomiting, myalgias, rashes or new skin changes, swelling, pain 
or
other changes at his TLC site, or any bleeding. Temperatures
remained elevated with Tmax 101.8, prompting him to call his
oncologist.

He initially presented to ___ clinic, where he was 
evaluated
by Dr. ___ recommended admission for infectious work-up,
IV fluids, and monitoring to assess need for antibiotics. 

On arrival to the floor, patient reports continued fatigue and
mild nasal congestion. He reports that cough has resolved. He
also reports a mild HA this morning, resolved spontaneously 
prior
to admission. He denies any other current symptoms, full ROS
obtained as above.

 
Past Medical History:
PAST ONCOLOGIC HISTORY:  
TREATMENT COURSE:
-------------------
___ INITIAL BMBX  AML
___ Consented to  protocol ___  INDUCTION DAUNOrubicin  (90 mg/m2)  Cytarabine  (100
mg/m2)  (RHP: +NPM1, +IDH2,+ RAD21)
___  D+14 BMBx ablated, 
___  D+26 remission, NPM1 negative
___ C1D1 HIDAC
___ admitted for fever
___ CT showed perianal abscess, drained, improved with
antibiotics
___ - C2D1 HIDAC, complicated by fevers and rash after 4 
of 6 doses attributed to possible cytarabine syndrome, all
resolved with higher dexamethasone premedication. also received
neulasta on D9
___ - C3D1 HIDAC, complicated by neutropenic fever, 
empiric antibiotics without complications or infectious source
___ - taken off of active study protocol (control arm) due
to patient preference to avoid frequent visits and tests;
consented to be followed by the study for survival/outcome data
___ - initiation of therapy for relapsed AML on trial
___
----lenalidomide 50 mg D1-10
----MEC D4-8
___ - admitted for alloHSC transplant
- Flu/Bu ablation chemotherapy ___
- Allogeneic stem cell transplant ___
- Discharged ___ - Bone marrow biopsy w/no morphologic evidence of AML,
negative NPM1 and myeloid sequencing panels
---- COMPLICATIONS: neutropenic fever, c.diff colitis, SCoN
bacteremia, ___ abscess

PAST MEDICAL HISTORY: 
AML (onc history as above)
___ abscess
C. difficile

 
Social History:
___
Family History:
Mother had lung cancer. Father had some type of metastatic 
cancer
extensively involving the bones. No history of any hematologic
disorders including leukemia or lymphoma. 
 
Physical Exam:
ADMISSION PHYSICAL EXAM: 
==========================
___ 1458 Temp: 99.0 PO BP: 110/97 HR: 86 RR: 20 O2 sat: 98%
O2 delivery: RA 
GENERAL: ___ adult man in NAD
HEENT: NCAT, sclerae anicteric, normal conjunctivae, PERRL, 
EOMI,
oropharynx clear without evident ulceration, erythema, exudates,
or bleeding. S/P extraction of two teeth #27, #28
LYMPHATICS: No appreciable lymphadenopathy
PULMONARY: CTAB, no increased work of breathing
HEART: RRR, normal S1/S2, no m/r/g
ABDOMEN:  Soft, nontender, nondistended, normoactive BS, no
hepatosplenomegaly
EXTREMITIES: Warm, DP pulses 2+ bilaterally, no edema
SKIN: No evident petechiae, ecchymosis, or rashes
NEURO: A&Ox3, CNII-XII intact, strength ___ in upper and lower
extremities bilaterally, normal sensation throughout
LINES: Tunneled RIJ in place without erythema or tenderness

DISCHARGE PHYSICAL EXAM:
===========================
___ 0524 Temp: 98.4 PO BP: 117/81 HR: 77 RR: 18 O2 sat: 
100%
O2 delivery: RA 
GENERAL: ___ adult man in NAD
HEENT: NCAT, sclerae anicteric, oropharynx clear without evident
ulceration, erythema, exudates, or bleeding
PULMONARY: CTAB, no increased work of breathing
HEART: RRR, normal S1/S2, no m/r/g
ABDOMEN:  Soft, nontender, nondistended, normoactive BS, no
hepatosplenomegaly
EXTREMITIES: Warm, DP pulses 2+ bilaterally, no edema
SKIN: No evident petechiae, ecchymosis, or rashes
NEURO: A&Ox3, CN grossly intact
 
Pertinent Results:
ADMISSION LABS
================
___ 09:30AM BLOOD WBC-8.8 RBC-3.66* Hgb-12.3* Hct-37.2* 
MCV-102* MCH-33.6* MCHC-33.1 RDW-15.6* RDWSD-58.7* Plt Ct-97*
___ 09:30AM BLOOD Neuts-26.7* Lymphs-59.1* Monos-11.5 
Eos-2.0 Baso-0.5 Im ___ AbsNeut-2.35 AbsLymp-5.21* 
AbsMono-1.01* AbsEos-0.18 AbsBaso-0.04
___ 09:30AM BLOOD Plt Ct-97*
___ 09:30AM BLOOD UreaN-13 Creat-1.2 Na-137 K-4.4 Cl-104 
HCO3-23 AnGap-10
___ 09:30AM BLOOD ALT-17 AST-25 LD(LDH)-178 AlkPhos-65 
TotBili-0.3
___ 09:30AM BLOOD TotProt-6.5 Albumin-4.1 Globuln-2.4 
Calcium-9.4 Phos-3.2 Mg-1.4*
___ 09:30AM BLOOD tacroFK-6.1
___ 09:30AM BLOOD CMV VL-DETECTED, 
___ 06:31PM URINE Color-Yellow Appear-Clear Sp ___
___ 06:31PM URINE Blood-NEG Nitrite-NEG Protein-30* 
Glucose-NEG Ketone-10* Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG
___ 06:31PM URINE RBC-0 WBC-<1 Bacteri-NONE Yeast-NONE 
Epi-0
___ 04:01PM OTHER BODY FLUID FluAPCR-POSITIVE* 
FluBPCR-NEGATIVE

DISCHARGE LABS
=================
___ 05:30AM BLOOD WBC-7.1 RBC-3.63* Hgb-12.0* Hct-35.6* 
MCV-98 MCH-33.1* MCHC-33.7 RDW-15.1 RDWSD-54.4* Plt Ct-84*
___ 05:30AM BLOOD Neuts-35.0 ___ Monos-9.6 Eos-4.8 
Baso-0.3 Im ___ AbsNeut-2.48 AbsLymp-3.54 AbsMono-0.68 
AbsEos-0.34 AbsBaso-0.02
___ 05:30AM BLOOD Glucose-87 UreaN-14 Creat-0.9 Na-139 
K-4.2 Cl-106 HCO3-18* AnGap-15
___ 05:30AM BLOOD ALT-22 AST-29 AlkPhos-53 TotBili-0.2
___ 05:30AM BLOOD Calcium-9.0 Phos-4.2 Mg-1.5*
___ 09:30AM BLOOD tacroFK-5.9

MICROBIOLOGY
==================
___ 04:01PM OTHER BODY FLUID FluAPCR-POSITIVE* 
FluBPCR-NEGATIVE
                            **FINAL REPORT ___

   C. difficile PCR (Final ___: 
      Reported to and read back by ___ AT 2322 ON 
___. 
      POSITIVE.              (Reference Range-Negative). 
         The C. difficile PCR is highly sensitive for toxigenic 
strains of
         C. difficile and detects both C. difficile infection 
(CDI) and
         asymptomatic carriage. Therefore, positive C. diff PCR 
tests
         trigger reflex C. difficile toxin testing, which is 
highly
         specific for CDI. 

   C. difficile Toxin antigen assay (Final ___: 
      POSITIVE.              (Reference Range-Negative).  
PERFORMED BY EIA. 
         This result indicates a high likelihood of C. difficile 
infection
         (CDI). 

                            **FINAL REPORT ___

   Legionella Urinary Antigen  (Final ___: 
      NEGATIVE FOR LEGIONELLA SEROGROUP 1 ANTIGEN. 
           (Reference Range-Negative). 
      Performed by Immunochromogenic assay. 
      A negative result does not rule out infection due to other 
L.
      pneumophila serogroups or other Legionella species. 
Furthermore, in
      infected patients the excretion of antigen in urine may 
vary. 

Test                          Result              Reference 
Range/Units
S. PNEUMONIAE ANTIGENS,       Not Detected        Not Detected
URINE   

IMAGING
==========
CXR ___
No acute intrathoracic process.

CXR ___
Successful removal of a right chest tunneled line.
 
Brief Hospital Course:
ASSESSMENT/PLAN: 
___ yo M w/relapsed AML s/p reinduction w/ MEC/lenalidomide per
protocol ___, now s/p allogeneic MRD stem cell transplant,
(day +62 on admission), non-neutropenic, admitted w/ 1 day of
fever, nasal congestion, and diarrhea.

TRANSITIONAL ISSUES

[ ] Osteltamavir course to complete ___
[ ] Bezlotoxumab infusion to be given on ___
[ ] Fidaxomicin to be continued at current dose until ID 
follow-up

ACUTE CONDITIONS
===================
#Fever
#C. difficile infection
#Diarrhea
Fevers and 1 day of diarrhea prior to admission. C. diff 
positive. Infectious work-up also notable for influenza A 
infection (see below); no growth on blood cultures at time of 
discharge. CXR clear. Patient remained hemodynamically stable. 
Consulted ID based on history of recurrent C. diff, recommended 
transition from PO vancomycin to fidaxomicin. Also recommended 
treatment with bezlotoxumab, with infusion scheduled for ___. 
Given patient's history of BMT and diarrhea, monitored for 
evidence of GVHD; patient had no RUQ pain or hyperbilirubinemia, 
stool output improving prior to discharge. Fidaxomicin to be 
continued at current dose post-discharge until ID follow-up, 
with plan for likely prolonged taper.

#Influenza A
2 days of fatigue, upper respiratory symptoms prior to 
admission,
fever to 101.8 on ___. Influenza A positive. Started Tamiflu on
___ with 5 day course to complete ___. Patient remained 
hemodynamically stable. C. diff positive as above. CXR clear, no 
evidence to date of superimposed bacterial respiratory 
infection. Urine legionella and strep negative. Expanded 
respiratory viral panel negative except for influenza A. Fungal 
studies pending at discharge.

#Relapsed AML s/p BMT: 
In remission since allogenic BMT, D+62 on admission. CBC on ___
with WBC 8.8, ANC 2.35, Hgb stable at 12.3, platelets stable at
97. Had been doing well post-transplant prior to recent 
symptoms.
Last bone marrow biopsy on ___ with no morphologic evidence of
AML, doing well post transplant until recent symptoms (see
above). While inpatient continued home tacrolimus 0.5MG BID, 
monitored tacrolimus levels. Ursodiol was discontinued given 
time since transplant. Continue outpatient prophylaxis regimen 
with acyclovir 400 TID, fluconazole 400 daily, 
trimethoprim-sulfamethoxazole 400-80 daily.

CHRONIC/RESOLVED CONDITIONS
============================
# Hx of C diff: 
Treated with PO vancomycin for C. diff infection in ___. 
Not
on prophylaxis as outpatient. Recurrent C. difficile infections 
managed as above.

 
Medications on Admission:
The Preadmission Medication list is accurate and complete.
1. Acyclovir 400 mg PO Q8H 
2. LORazepam 0.5 mg PO DAILY:PRN anxiety 
3. Fluconazole 400 mg PO Q24H 
4. FoLIC Acid 1 mg PO DAILY 
5. Multivitamins 1 TAB PO DAILY 
6. Sulfameth/Trimethoprim SS 1 TAB PO DAILY 
7. Ursodiol 300 mg PO BID 
8. Vitamin D 1000 UNIT PO DAILY 
9. Tacrolimus 0.5 mg PO QPM 
10. Tacrolimus 0.5 mg PO QAM 
11. Magnesium Oxide 800 mg PO TID 

 
Discharge Medications:
1.  Fidaxomicin 200 mg PO BID 
RX *fidaxomicin [Dificid] 200 mg 1 tablet(s) by mouth twice a 
day Disp #*60 Tablet Refills:*0 
2.  OSELTAMivir 75 mg PO BID 
RX *oseltamivir 75 mg 1 capsule(s) by mouth twice a day Disp #*3 
Capsule Refills:*0 
3.  Acyclovir 400 mg PO Q8H  
4.  Fluconazole 400 mg PO Q24H  
5.  FoLIC Acid 1 mg PO DAILY  
6.  LORazepam 0.5 mg PO DAILY:PRN anxiety  
7.  Magnesium Oxide 800 mg PO TID  
8.  Multivitamins 1 TAB PO DAILY  
9.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  
10.  Tacrolimus 0.5 mg PO QPM  
11.  Tacrolimus 0.5 mg PO QAM  
12.  Vitamin D 1000 UNIT PO DAILY  

 
Discharge Disposition:
Home
 
Discharge Diagnosis:
PRIMARY DIAGNOSES
Recurrent C. difficile Infection
Influenza A

SECONDARY DIAGNOSES
Acute Myeloid Leukemia
History of Bone Marrow Transplant

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Dear Mr. ___,  

It was a privilege caring of you at ___.  

WHY WAS I IN THE HOSPITAL?  
- You were admitted for fever, fatigue, and diarrhea

WHAT HAPPENED TO ME IN THE HOSPITAL?  
- You tested positive for influenza A and were started on 
oseltamivir (Tamiflu)
- You tested positive for C. difficile. You were evaluated by 
the infectious disease specialists, who recommended treatment 
with fidaxomicin based on your history of recurrent C. 
difficile. They also recommended an additional treatment, 
bezlotoxumab, which you will receive after discharge.
- Your symptoms improved and you were well enough to go home.

WHAT SHOULD I DO AFTER I LEAVE THE HOSPITAL?  
- Continue to take your oseltamivir until the course is 
completed on ___
- Continue to take fidaxomicin until you
- Continue to take all your medicines and keep your 
appointments.  

We wish you the best.

Sincerely,  
Your ___ Team  
 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=14679785-DS-23 | hadm_id=27202053

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___
 
Chief Complaint:
Fever
 
Major Surgical or Invasive Procedure:
None

 
History of Present Illness:
Mr. ___ is a pleasant ___ w/ intermediate-risk cytogenetics
and favorable risk AML (normal karyotype, FLT3-, NPM1+, IDH2+,
RAD21+, CEBPA-) in ___ remission after successful induction 7+3
now s/p C2D1 of HiDAC consolidation therapy on ___. His ___
cycle of HIDAC was complicated by relatively prolonged
neutropenia along with fever and subsequent ___ abscess,
fortunately now all resolved. C2 was complicated by morbilliform
eruption associated w/ cytarabine. 

Today he was in clinic feeling "fantastic." He was found to be
anemic and thrombocytopenic. He received 1U plts and 15 min into
his 1st unit PRBC, (received premeds w/ apap, benadryl, pepcid),
developed rigors and required demerol x 2 and apap. However
developed temp of 101.1 1hr. Transfusion reaction workup
completed and sent to blood bank. Received 2gm Cefepime. I spoke
w/ the RN who was there and she noted that aside from the 
rigors,
VSS, he appeared well and the "best he's looked."

On arrival to ___, pt noted he felt "like a million dollars." He
states he feels the "best he's felt," and requesting to go home
in the am. 
 
Past Medical History:
PAST ONCOLOGIC HISTORY (per OMR):
___ INITIAL BM/BXAML
___ Consented to protocol ___ INDUCTION DAUNOrubicin  (90 mg/m2)  Cytarabine  (100
mg/m2) (RHP: +NPM1, +IDH2,+ RAD21)
___ D+14 BMBx ablated, 
___ D+26 remission, NPM1 negative
___ C1D1 HIDAC
--___ admitted for fever
--___ CT showed perianal abscess, drained, improved with
antibiotics
--___ C2D1 HIDAC

PAST MEDICAL HISTORY (per OMR):
AS ABOVE
 
Social History:
___
Family History:
Mother had lung cancer
Father had some type of metastatic cancer extensively involving
the bones
No history of any hematologic disorders including leukemia or
lymphoma
 
Physical Exam:
ADMISSION EXAM
=============================
VITAL SIGNS: 98.5 PO 101 / 62 77 18 100
General:  NAD, Resting in bed comfortably, appears well
HEENT:  MMM, no OP lesions, no cervical/supraclavicular
adenopathy
CV:  RR, NL S1S2 no S3S4 No MRG
PULM:  CTAB, No C/W/R, No respiratory distress
ABD:  BS+, soft, NTND, no palpable masses or HSM
LIMBS: WWP, no ___, no tremors
SKIN:  No rashes on the extremities
NEURO:  Grossly normal
 
DISCHARGE EXAM
=============================
Vital signs stable 
GEN: NAD  
HEENT: MMM. 
Cards: RR S1/S2 normal. no murmurs/gallops/rubs.  
Pulm: CTAB no crackles or wheezes  
Abd: BS+, soft, NT, NABS
Extremities: WWP, no edema.   
Skin: no rashes or bruising  
Neuro: AOx3, CNs II-XII intact.
 
Pertinent Results:
ADMISSION LABS
===========================
___ 09:15AM BLOOD WBC-1.0* RBC-2.06* Hgb-6.7* Hct-19.7* 
MCV-96 MCH-32.5* MCHC-34.0 RDW-17.2* RDWSD-59.7* Plt Ct-7*#
___ 09:15AM BLOOD Neuts-27* Bands-2 Lymphs-56* Monos-9 
Eos-5 Baso-0 Atyps-1* ___ Myelos-0 AbsNeut-0.29* 
AbsLymp-0.57* AbsMono-0.09* AbsEos-0.05 AbsBaso-0.00*
___ 09:15AM BLOOD Hypochr-1+* Anisocy-1+* Poiklo-1+* 
Macrocy-OCCASIONAL Microcy-OCCASIONAL Polychr-NORMAL 
Ovalocy-OCCASIONAL Schisto-OCCASIONAL Tear Dr-1+* Ellipto-1+*
___ 09:15AM BLOOD Plt Smr-RARE* Plt Ct-7*#
___ 01:10PM BLOOD LD(LDH)-133 TotBili-0.5 DirBili-<0.2 
IndBili-0.5
___ 01:10PM BLOOD Hapto-205*
___ 04:35PM URINE Color-Straw Appear-Clear Sp ___
___ 03:23PM URINE Color-Yellow Appear-Clear Sp ___
___ 04:35PM URINE Blood-NEG Nitrite-NEG Protein-NEG 
Glucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG
___ 03:23PM URINE Blood-NEG Nitrite-NEG Protein-NEG 
Glucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-6.0 Leuks-NEG
 
PERTINENT LABS
===========================
___ 10:45AM BLOOD WBC-6.2 RBC-2.28* Hgb-7.4* Hct-21.2* 
MCV-93 MCH-32.5* MCHC-34.9 RDW-17.6* RDWSD-59.8* Plt Ct-11*
___ 12:00AM BLOOD Neuts-40 Bands-7* ___ Monos-22* 
Eos-3 Baso-0 ___ Myelos-0 AbsNeut-2.07 AbsLymp-1.23 
AbsMono-0.97* AbsEos-0.13 AbsBaso-0.00*
___ 12:00AM BLOOD ___ PTT-27.1 ___
___ 12:00AM BLOOD Glucose-88 UreaN-8 Creat-0.7 Na-142 K-3.8 
Cl-103 HCO3-25 AnGap-14
___ 12:00AM BLOOD ALT-13 AST-11 LD(LDH)-117 AlkPhos-57 
TotBili-0.3
___ 01:10PM BLOOD LD(LDH)-133 TotBili-0.5 DirBili-<0.2 
IndBili-0.5
___ 01:10PM BLOOD Hapto-205*
___ 12:00AM BLOOD Hapto-180
___ 12:00AM BLOOD Hapto-160
 
DISCHARGE LABS
===========================
___ 10:45AM BLOOD WBC-6.2 RBC-2.28* Hgb-7.4* Hct-21.2* 
MCV-93 MCH-32.5* MCHC-34.9 RDW-17.6* RDWSD-59.8* Plt Ct-11*
___ 12:00AM BLOOD Neuts-40 Bands-7* ___ Monos-22* 
Eos-3 Baso-0 ___ Myelos-0 AbsNeut-2.07 AbsLymp-1.23 
AbsMono-0.97* AbsEos-0.13 AbsBaso-0.00*
___ 12:00AM BLOOD Hypochr-NORMAL Anisocy-NORMAL Poiklo-1+* 
Macrocy-1+* Microcy-NORMAL Polychr-NORMAL Ovalocy-1+*
___ 10:45AM BLOOD Plt Ct-11*
___ 12:00AM BLOOD Plt Smr-RARE* Plt Ct-10*
___ 12:00AM BLOOD Glucose-88 UreaN-8 Creat-0.7 Na-142 K-3.8 
Cl-103 HCO3-25 AnGap-14
___ 12:00AM BLOOD LD(LDH)-183
___ 12:00AM BLOOD ALT-13 AST-11 LD(LDH)-117 AlkPhos-57 
TotBili-0.3
___ 12:00AM BLOOD Calcium-8.8 Phos-3.4 Mg-1.6
___ 12:00AM BLOOD Hapto-160
 
MICRO
===========================
___ BLOOD CULTURE Blood Culture, Routine-PENDING 

___ BLOOD CULTURE Blood Culture, Routine-PENDING 

UCx ___ NO GROWTH
 
PERTINENT STUDIES
===========================
CXR (___)
Heart size and mediastinum are stable.  Central venous line tip 
is at the 
level of lower SVC.  Lungs are essentially clear.  No pleural 
effusion or 
pneumothorax is seen. 
 
Brief Hospital Course:
___ man with PMHx notable for acute myeloid leukemia 
with intermediate-risk cytogenetics and favorable risk (normal 
karyotype, FLT3-, NPM1+, IDH2+, RAD21+, CEBPA-) in ___ remission 
after successful induction 7+3 now s/p C2D16 of HiDAC 
consolidation therapy, admitted for neutropenic fever in setting 
of pRBC and platelet transfusion in clinic.  

# NEUTROPENIC FEVER: 
Admitted for neutropenic fever to 101.1 that occurred during 
pRBC and platelet transfusion in clinic despite having received 
acetaminophen, diphenhydramine, and Pepcid. Started on broad 
spectrum antibiotics with cefepime. Was otherwise feeling 
completely well without localizing signs/symptoms of infection. 
Negative blood and urine cultures, CXR clear, port site without 
erythema or purulence, history of gluteal abscess however this 
has resolved. Workup of transfusion reaction notable for 
normal/negative LDH, haptoglobin, direct Coombs test, and HLA 
antibody screen. Most likely represented febrile non-hemolytic 
reaction. Neutrophil counts recovered on D17 of HiDAC. Received 
additional 1u platelets prior to discharge without reaction.

# ACUTE MYELOLOID LEUKEMIA:
# PANCYTOPENIA
Notable for intermediate-risk cytogenetics and favorable risk 
(normal karyotype, FLT3-, NPM1+, IDH2+, RAD21+, CEBPA-) in ___ 
remission after successful induction 7+3 now s/p C2D1 of HiDAC 
consolidation therapy on ___. Pancytopenia expected s/p HiDAC. 
Previously on home Cipro/Flagyl prophylaxis which was stopped at 
discharge given resolution of neutropenia. Continued home 
voriconazole prophylaxis. Received 1 additional unit platelets 
prior to discharge without febrile reaction.

TRANSITIONAL ISSUES
===============================

 [ ] Recommend repeat CBC/diff to ensure maintaining WBC and 
platelet count.

 [ ] Discontinued home Cipro/Flagyl prophylaxis given rapid 
resolution of neutropenia and absence of fever.

CODE: full (presumed)
CONTACT: ___ (ex-wife: ___
 
Medications on Admission:
The Preadmission Medication list is accurate and complete.
1. LORazepam 0.5-1 mg PO Q8H:PRN 
anxiety/nausea/vomiting/insomnia 
2. Vitamin D ___ UNIT PO DAILY 
3. Ciprofloxacin HCl 500 mg PO Q12H 
4. Voriconazole 200 mg PO Q12H 
5. MetroNIDAZOLE 500 mg PO TID 

 
Discharge Medications:
1.  LORazepam 0.5-1 mg PO Q8H:PRN 
anxiety/nausea/vomiting/insomnia  
2.  Vitamin D ___ UNIT PO DAILY  
3.  Voriconazole 200 mg PO Q12H  

 
Discharge Disposition:
Home
 
Discharge Diagnosis:
PRIMARY DIAGNOSIS:
Neutropenic fever (most likely due to non-hemolytic blood 
transfusion reaction)

SECONDARY DIAGNOSES:
Acute myeloid leukemia
Pan-cytopenia

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Dear Mr. ___,

It was a pleasure taking care of you at ___.

Why you were in the hospital:
 - fever that occurred during a blood transfusion in the clinic
 - low white blood cell count (neutropenia)

What was done for you in the hospital:
 - we gave you IV antibiotics in case there was a serious 
infection
 - we monitored your fever and white blood cell counts
 - we obtained blood tests and imaging to determine if there was 
any evidence of infection

What you should do when you get home:
 - continue to monitor for any fevers/chills, and if so please 
call your doctor or go to the emergency room
 - attend your follow up appointments as scheduled in the 
discharge papers
 - take your medications as prescribed in the discharge papers

We wish you the best!

Sincerely,
Your ___ Care Team
 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=14679785-DS-33 | hadm_id=27811444

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___.
 
Chief Complaint:
positive blood culture
 
Major Surgical or Invasive Procedure:
___ line ___

 
History of Present Illness:
Mr ___ is a ___ yo gentleman with a history of relapsed AML 
treated with multiple rounds chemotherapy and MRD alloHSCT with 
MAC (D0 ___ complicated by steroid-refractory GI-GVHD, C. 
difficile colitis, CMV viremia, and recent VRE/E.coli bacteremia
with recent admission with multifocal pneumonia, progressive 
cavitary pulmonary nodules, and worsening lower extremity edema 
found to have aspergillosis despite prophylaxis with 
posaconazole with adequate levels, treated with isavuconazole. 
He was admitted ___ for recurrent VRE bacteremia
and discharge on daptomycin.  

Unfortunately his blood culture from ___ returned positive for
GRAM POSITIVE COCCI.  He was contacted by phone and instructed 
to
go to the ED where he started on Linezolid. 

 
Past Medical History:
Past Medical History:
ONCOLOGIC HISTORY:
___ INITIAL BMBX  AML
___ Consented to  protocol ___  INDUCTION DAUNOrubicin  (90 mg/m2)  Cytarabine  (100
mg/m2)  (RHP: +NPM1, +IDH2,+ RAD21)
___  D+14 BMBx ablated, 
___  D+26 remission, NPM1 negative
___ C1D1 HIDAC
___ admitted for fever
___ CT showed perianal abscess, drained, improved with
antibiotics
___ - C2D1 HIDAC, complicated by fevers and rash after 4 
of 6 doses attributed to possible cytarabine syndrome, all
resolved with higher dexamethasone premedication. also received
neulasta on D9
___ - C3D1 HIDAC, complicated by neutropenic fever, 
empiric antibiotics without complications or infectious source
___ - taken off of active study protocol (control arm) due
to patient preference to avoid frequent visits and tests;
consented to be followed by the study for survival/outcome data
___ - initiation of therapy for relapsed AML on trial
___
----lenalidomide 50 mg D1-10
----MEC D4-8
___ - admitted for alloHSC transplant
- Flu/Bu ablation chemotherapy ___
- Allogeneic stem cell transplant ___
- Discharged ___ - Bone marrow biopsy w/no morphologic evidence of AML,
negative NPM1 and myeloid sequencing panels
---- COMPLICATIONS: neutropenic fever, c.diff colitis, SCoN
bacteremia, ___ abscess, steroid-refractory GI-GVHD, C. 
difficile colitis, CMV viremia, and recent VRE/E.coli bacteremia 


PAST MEDICAL HISTORY:
- Recurrent clostridioides colitis
- genital warts
- Hernia s/p mesh ___ years ago

 
Social History:
___
Family History:
Mother had lung cancer
Father had some type of metastatic cancer extensively involving
the bones
No history of any hematologic disorders including leukemia or
lymphoma
 
Physical Exam:
ADMISSION PHYSICAL EXAM: 
24 HR Data (last updated ___ @ 1628)
    Temp: 97.7 (Tm 97.7), BP: 164/88, HR: 82, RR: 18, O2 sat: 
98%

GEN: Pleasant. NAD
NEURO: A&Ox3, non-focal
HEENT: No conjunctival pallor. No icterus. MMM. OP clear.  
NECK: Supple. JVP not elevated
LYMPH: No cervical or supraclavicular LAD
CV: Nl rate, regular rhythm. No MRG.   
LUNGS: No incr WOB. CTA
fields. No wheezes, rales, or rhonchi.  
ABD: ND, nl bowel sounds. Tenderness to palpation in the
suprapubic region has now resolved 
EXT: WWP. 1+ edema to the shins bilaterally
SKIN: Right upper extremity with areas of ecchymosis in the
entecubital fossae. No rash or erythema.

DISCHARGE PHSYICAL EXAM:
VSS
GENERAL: Pleasant. NAD
NEURO: A&Ox3, non-focal
HEENT: No conjunctival pallor. No icterus. MMM. OP clear.  
NECK: Supple. JVP not elevated
LYMPH: No cervical or supraclavicular LAD
CV: Nl rate, regular rhythm. No MRG.   
LUNGS: No incr WOB. CTA
fields. No wheezes, rales, or rhonchi.  
ABD: ND, nl bowel sounds. No tenderness. 
EXT: WWP. 1+ edema bilaterally
SKIN: Right upper extremity with areas of ecchymosis in the
entecubital fossae. No rash or erythema.

 
Pertinent Results:
ADMISSION LABORATORY STUDIES:
___ 01:45PM BLOOD WBC: 4.4 RBC: 2.43* Hgb: 8.5* Hct: 25.2*
MCV: 104* MCH: 35.0* MCHC: 33.7 RDW: 23.1* RDWSD: 83.9* Plt Ct:
60* 
___ 05:14AM BLOOD Neuts: 65 Bands: 4 Lymphs: 18* Monos: 7
Eos: 0* Baso: ___ Metas: 6* NRBC: 1.6* AbsNeut: 2.62 AbsLymp: 
0.68*
AbsMono: 0.27 AbsEos: 0.00* AbsBaso: 0.00* 
___ 05:14AM BLOOD Glucose: 110* UreaN: 12 Creat: 0.8 Na: 
137
K: 3.6 Cl: 103 HCO3: 24 AnGap: 10 
___ 05:14AM BLOOD ALT: 16 AST: 22 AlkPhos: 67 TotBili: <0.2 

___ 05:14AM BLOOD Calcium: 7.7* Phos: 3.5 Mg: 1.4* 
___ 01:18PM BLOOD Lactate: 1.2 

___ aspergillus Pending
___ B-Glucan pending. 

___ 06:30AM BLOOD VitB12: 988* Folate: 15 
___ 06:20AM BLOOD Osmolal: 270* 

 MICROBIOLOGY: Reviewed in OMR. 
Pertinent results include:
___ 9:00 am BLOOD CULTURE
  
   Blood Culture, Routine (Preliminary): 
      ENTEROCOCCUS FAECIUM.    FINAL SENSITIVITIES. 
         Daptomycin MIC OF 16 MCG/ML = NON-SUSCEPTIBLE. 
         SENSITIVITIES: MIC expressed in MCG/ML
                     
_________________________________________________________
                             ENTEROCOCCUS FAECIUM
                             |   
AMPICILLIN------------  =>32 R
PENICILLIN G----------  =>64 R
VANCOMYCIN------------ <=0.5 S

   Aerobic Bottle Gram Stain: GPC IN PAIRS AND CHAINS. 
 
___ 1:10 pm BLOOD CULTURE
     Blood Culture, Routine (Pending):    No growth to date. 
 
___ 1:30 pm BLOOD CULTURE
     Blood Culture, Routine (Preliminary): 
      ENTEROCOCCUS FAECIUM. 
      Aerobic Bottle Gram Stain: GPC IN PAIRS AND CHAINS.

___ 6:49 pm CATHETER TIP-IV      Source: PICC. 
   WOUND CULTURE (Final ___:    No significant growth. 
 
___ 9:29 am URINE      Source: ___. 
   URINE CULTURE (Pending): 
 
Imaging CT A&P ___:
1. Persistent inflammatory changes in the terminal ileum, which
may represent graft-versus-host disease or enteritis.
2. Persistent bladder wall thickening and mild surrounding fat
stranding, which is concerning for cystitis.  Correlation with
urinalysis is recommended.
3. Scattered colonic diverticulosis without evidence of
diverticulitis.

DISCHARGE LABS:

___ 12:00AM BLOOD WBC-5.0 RBC-2.28* Hgb-8.0* Hct-24.1* 
MCV-106* MCH-35.1* MCHC-33.2 RDW-21.5* RDWSD-82.1* Plt Ct-72*
___ 12:00AM BLOOD Neuts-56 Bands-10* Lymphs-18* Monos-10 
Eos-0* ___ Myelos-6* NRBC-0.8* AbsNeut-3.30 AbsLymp-0.90* 
AbsMono-0.50 AbsEos-0.00* AbsBaso-0.00*
___ 12:00AM BLOOD Glucose-149* UreaN-12 Creat-0.8 Na-132* 
K-4.6 Cl-96 HCO3-22 AnGap-14
___ 12:00AM BLOOD ALT-20 AST-21 LD(LDH)-395* AlkPhos-77 
TotBili-<0.2
___ 12:00AM BLOOD Albumin-3.0* Calcium-7.9* Phos-3.0 
Mg-1.5*
 
Brief Hospital Course:
Mr. ___ is a ___ yo man w/ relapsed AML s/p
MRD allogeneic HSCT (D0 ___ complicated by
steroid-refractory GI-GVHD, multiple infectious complications
admit with enterococcus bacteremia and found to have progressive
fungal pneumonia. 

ACTIVE ISSUES
========================
#ENTEROCOCCUS BACTEREMIA: Unclear source. Could be gut given
GVHD. TTE ___ neg for vegetations. PICC was pulled and 
cultured.
Repeat CT AP w/ some c/f cystitis so repeated UA and urine cx 
and
negative
- Linezolid ___ IV BID x 6 weeks from first negative blood
culture (D1: ___  
- will f/u with ID outpatient ___

#RECENT MULTIFOCAL PNEUMONIA AND CAVITARY PULMONARY NODULES:
Patient is currently being treated with isavuconazole given c/f
aspergillus. Recent BAL ___ growing mold (described as a
contaminant but ID concerned about true mold infection). Repeat
chest CT ___ shows complete resolution of multifocal
pneumonia. Chest CT also shows short interval density and mild
size increase in multiple bilateral peribronchovascular solid 
and
cavitating nodules as well as appearance of a new nodule in the
left lower lobe with concern for lung involvement from primary
disease. This admission increase in serum aspergillis prompting 
repeating Chest CT which showed increased size of pulmonary
nodules. Discussed with ID and consulted IP for bronch with
biopsies. changed isavuconazole to IV ___ concern may be poor
absorption with history of GVDH while inhouse.
-Can not administer IV isavuconazole 372mg daily outpatient due 
to drug stability, resume po isavuconazole at discharge 
-follow up isavuconazole level. 
-plan for outpatient bronchoscopy with biopsies ___
-ID follow up ___

#AML s/p allogeneic MRD HSCT (Day 0 = ___: 
#THROMBOYCTOPENIA:
AML initially with favorable mutational profile (normal
karyotype; FLT3 negative, NPM1 positive, IDH2 positive, RAD21
positive, CEBPA negative). He relapsed after chemo-consolidation
(7+3, 3C HIDAC & MEC/Revlimid) then underwent an MRD allogeneic
SCT as above. In remission following his transplant with slow
count recovery most likely due to valganciclovir. BMBX during
recent admission showed no evidence of recurrence w/ 100%
chimerism. His immunosuppression agents are:
-Continue Tacrolimus 0.5mg BID; repeat trough ___ <2.0. No
adjustments in light of starting Jakafi. 
-Continue ruxolitinib 5mg PO BID
-prednisone 10mg PO QD, tapered to 7.5mg ___ 
-Continue ACV
-Continue Bactrim SS PO QD

#HYPONATREMIA: noted for Na ___ with lytes indicative of
SIADH likely in setting of persistent pulmonary nodules. rec
1L fluid restriction and monitor outpatient.

#CMV VIREMIA: History of CMV viremia with positive viral load
___ (peak 2.2log), and he completed course of 
valganciclovir
last admission.  CMV VL ND since ___ and was changed ACV at
time of DC last admission. 
- ___ CMV VL negative repeat ___ outpatient

#GI GVHD: Remains on tacrolimus, prednisone, budesonide and 
Jakafi as above.   
-Continue ID prophylaxis with bactrim
-Continue PPI, vitamin D and folic acid supplementation
- clarify tacro target level
- taper pred from 10 mg to 7.5 mg on ___

#Macrocytic anemia: 
B12 and folate ok. Likely med related.  
-transfuse hgb < 7. 

Prophylaxes:
# Access: ___ placed ___
# FEN: regular diet
# Disposition: home with PICC/IV ABX use

# Code status: full
 
Medications on Admission:
The Preadmission Medication list is accurate and complete.
1. Budesonide 3 mg PO TID 
2. FoLIC Acid 1 mg PO DAILY 
3. LORazepam 1 mg PO BID: PRN anxiety 
4. Nicotine Patch 21 mg/day TD DAILY 
5. Pantoprazole 40 mg PO Q12H 
6. PredniSONE 10 mg PO DAILY 
7. Sulfameth/Trimethoprim SS 1 TAB PO DAILY 
8. Tacrolimus 0.5 mg PO Q12H 
9. Vitamin D ___ UNIT PO 1X/WEEK (WE) 
10. Isavuconazonium Sulfate 372 mg PO DAILY 
11. Acyclovir 400 mg PO Q8H 
12. Jakafi (ruxolitinib) 5 mg oral BID 
13. Magnesium Oxide 800 mg PO BID 

 
Discharge Medications:
1.  Linezolid ___ mg IV Q12H 
RX *linezolid in dextrose 5% 600 mg/300 mL 600 mg iv every 
twelve (12) hours Disp #*60 Intravenous Bag Refills:*1 
2.  PredniSONE 7.5 mg PO DAILY  
3.  Acyclovir 400 mg PO Q8H  
4.  Budesonide 3 mg PO TID  
5.  FoLIC Acid 1 mg PO DAILY  
6.  Isavuconazonium Sulfate 372 mg PO DAILY  
7.  Jakafi (ruxolitinib) 5 mg oral BID  
8.  LORazepam 1 mg PO BID: PRN anxiety  
9.  Magnesium Oxide 800 mg PO BID  
10.  Nicotine Patch 21 mg/day TD DAILY  
11.  Pantoprazole 40 mg PO Q12H  
12.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  
13.  Tacrolimus 0.5 mg PO Q12H  
14.  Vitamin D ___ UNIT PO 1X/WEEK (WE)  

 
Discharge Disposition:
Home With Service
 
Facility:
___
 
Discharge Diagnosis:
VRE Bacteremia
Cavitary pulmonary nodules secondary to aspergillosis

SECONDARY DIAGNOSIS
======================
-Acute myelogenous leukemia
-Graft versus host disease

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Mr. ___,

You were admitted due to concern for blood stream infection. We 
did extensive infectious workup which showed bacteremia. We 
started you on antibiotics and your infection has cleared. You 
will continue on antibiotics as instructed for 6 weeks. You were 
also found to have presumed progressive fungal pneumonia. You 
will continue po antibiotics for this and follow up with ID as 
stated below. Please continue to take all of your medications as 
instructed.

Sincerely, 
Your ___ TEAM
 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=14679785-DS-20 | hadm_id=28324760

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___.
 
Chief Complaint:
planned admission for chemotherapy 
 
Major Surgical or Invasive Procedure:
Port placement ___
 
History of Present Illness:
Mr. ___ is a ___ year-old gentleman with newly diagnosed AML, 
s/p 7+3 induction chemotherapy (completed ___ who reports 
as a direct admission today for port placement and initiation of 
HiDAC therapy. Patient had a complete remission following 7+3 
therapy with minimal complications (nausea, grade 2 mucositis, a 
petechial rash on the bilateral thighs, and increased fatigue). 
Has been well since discharge with any acute illnesses or 
hospitalizations.

On arrival to the floor, patient is stable and doing well. 
States he has had some facial dryness at home, but otherwise no 
complaints. Denies nausea, vomiting, diarrhea, or constipation. 
Has had a good appetite. Denies any fevers or chills. Denies any 
sore throat or cough. Vitals were stable and WNL.

 
Past Medical History:
None
 
Social History:
___
Family History:
No family history of cancer to the best of his recollection
 
Physical Exam:
 ADMISSION PHYSICAL EXAM:  
 VS: T 98.3 PO 124 / 74 HR 84 RR 18 O2 100% RA
 GENERAL: Pleasant, sitting up in bed comfortably in NAD  
 HEENT: Some skin dry skin and mild erythema on cheeks, neck 
supple with FROM, no tonsillar swelling or exudate
 CARDIAC: Regular rate and rhythm, no murmurs, rubs, or gallops  

 LUNG: Appears in no respiratory distress, clear to auscultation 
bilaterally, no crackles, wheezes, or rhonchi  
 ABD: Normal bowel sounds, soft, nontender, nondistended, no 
hepatomegaly, no splenomegaly  
 EXT: Warm, well perfused, no lower extremity edema   
 NEURO: Alert, oriented, motor and sensory function grossly 
intact
 LYMPH: No supraclavicular, axillary,  posterior cervical
  nodes lymphadenopathy.  
 SKIN: Mild skin erythema on cheeks, otherwise WNL

DISCHARGE PHYSICAL EXAM:
 VS: 98.0 PO 104 / 64 73 18 98 R  RA
 GENERAL: Pleasant, sitting up in bed comfortably in NAD  
 HEENT: Some mild erythema on cheeks, no oral ulcers
 CARDIAC: Regular rate and rhythm, no murmurs, rubs, or gallops  

 LUNG: Appears in no respiratory distress, clear to auscultation
bilaterally, no crackles, wheezes, or rhonchi  
 ABD: Normal bowel sounds, soft, nontender, nondistended
 EXT: Warm, well perfused, no lower extremity edema   
 NEURO: Alert, oriented, motor and sensory function grossly
intact. Normal finger to nose, heal to shin, no truncal ataxia,
speech pattern
 SKIN: Mild skin erythema on cheeks, otherwise WNL
 
Pertinent Results:
ADMISSION LABS:
==========================
___ 09:23PM BLOOD WBC-7.1 RBC-3.32* Hgb-10.3* Hct-31.0* 
MCV-93 MCH-31.0 MCHC-33.2 RDW-16.9* RDWSD-56.5* Plt ___
___ 09:23PM BLOOD Neuts-63.5 ___ Monos-12.2 Eos-3.7 
Baso-0.8 Im ___ AbsNeut-4.51 AbsLymp-1.40 AbsMono-0.87* 
AbsEos-0.26 AbsBaso-0.06
___ 09:23PM BLOOD ___ PTT-29.0 ___
___ 09:23PM BLOOD Glucose-95 UreaN-11 Creat-0.7 Na-143 
K-3.6 Cl-102 HCO3-26 AnGap-15
___ 09:23PM BLOOD ALT-20 AST-14 LD(LDH)-135 AlkPhos-72 
TotBili-0.8
___ 09:23PM BLOOD Albumin-4.2 Calcium-9.0 Phos-3.7 Mg-1.7 
UricAcd-6.2

MICRO:
==========================
None

IMAGING:
==========================
___ Port Placement:  
Successful placement of a double lumen chest power Port-a-cath 
via the right internal jugular venous approach. The tip of the 
catheter terminates in the right atrium. The catheter is ready 
for use. 

DISCHARGE LABS:
==========================
___ 05:23AM BLOOD WBC-4.6 RBC-3.23* Hgb-9.9* Hct-29.9* 
MCV-93 MCH-30.7 MCHC-33.1 RDW-16.1* RDWSD-54.6* Plt ___
___ 05:23AM BLOOD Neuts-95.6* Lymphs-3.2* Monos-0.6* 
Eos-0.0* Baso-0.2 Im ___ AbsNeut-4.43# AbsLymp-0.15* 
AbsMono-0.03* AbsEos-0.00* AbsBaso-0.01
___ 05:23AM BLOOD Glucose-138* UreaN-14 Creat-0.6 Na-139 
K-4.4 Cl-101 HCO3-25 AnGap-13
___ 05:23AM BLOOD ALT-41* AST-19 AlkPhos-66 TotBili-0.6
___ 05:23AM BLOOD Albumin-3.9 Calcium-8.9 Phos-4.0 Mg-1.___ man with newly diagnosed AML presented for planned port 
placement & HiDAC consolidation. He received the port without 
issues. He started HiDAC Day 1: ___, and had no acute 
complications. Cerebellar examinations remained normal. He 
received some docusate & senna for mild constipation, but 
otherwise had no acute inpatient issues. He was discharged home 
with stable vital signs and no home services needed. 

TRANSITIONAL ISSUES:
- Patient should follow up with his outpatient oncologist. They 
are working to schedule an appointment and will call you with 
the date and time of this appointment. 
- Patient was discharged with eye drops to take for 48 hours 
after completion of HIDAC
- Patient had some mild constipation in the hospital, so was 
given scripts for Docusate & Senna at discharge
- Pt also had some anxiety and nausea, which was treated with 
ativan 0.5mg PRN
- ANC at discharge: ___

CODE: Full
Proxy name: ___ 
Relationship: Ex-wife Phone: ___ 

 
___ on Admission:
The Preadmission Medication list is accurate and complete.
1. LORazepam 0.5 mg PO Q8H:PRN anxiety 
2. Vitamin D ___ UNIT PO DAILY 

 
Discharge Medications:
1.  Docusate Sodium 100 mg PO BID:PRN constipation 
RX *docusate sodium 100 mg 1 capsule(s) by mouth BID prn Disp 
#*30 Capsule Refills:*0 
2.  PrednisoLONE Acetate 1% Ophth. Susp. 1 DROP BOTH EYES TID 
Take for 2 days after you leave the hospital 
RX *prednisolone acetate 1 % 1 drop in each eye three times a 
day Refills:*0 
3.  Senna 8.6 mg PO BID:PRN constipation 
RX *sennosides [senna] 8.6 mg 8.6 mg by mouth BID prn Disp #*30 
Tablet Refills:*0 
4.  LORazepam 0.5 mg PO Q8H:PRN anxiety 
RX *lorazepam [Ativan] 0.5 mg 1 tablet by mouth every eight (8) 
hours Disp #*21 Tablet Refills:*0 
5.  Vitamin D ___ UNIT PO DAILY  

 
Discharge Disposition:
Home
 
Discharge Diagnosis:
PRIMARY DIAGNOSIS
- AML

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Dear Mr. ___, 

It was a pleasure taking care of you.

Why was I admitted to the hospital?
- You had a scheduled admission to receive consolidation therapy 
to treat your AML

What happened in the hospital?
- Your got your port
- Your received "HIDAC" chemotherapy

What do I need to do when I go home?
- Take all of your medicines as prescribed. This includes the 
new eye drops, which you should take for 2 more days 
- Go to all of your follow up appointments (listed below)
- Call Dr. ___ office if you have any fevers, chills, 
nausea, vomiting, vision changes, confusion, or anything 
worrisome to you

We wish you the best in the future!

Sincerely,
Your ___ Care Team 
 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=14679785-DS-24 | hadm_id=28664852

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___
 
Chief Complaint:
HiDAC
 
Major Surgical or Invasive Procedure:
none

 
History of Present Illness:
Mr. ___ is a ___
male with history of intermediate-risk cytogenetics and 
favorable
risk AML (normal karyotype, FLT3-, NPM1+, IDH2+, RAD21+, CEBPA-)
in ___ remission after successful induction 7+3 chemotherapy who
presents for C3 of HiDAC consolidation therapy.
His ___ cycle of HIDAC was complicated by relatively prolonged
neutropenia along with fever and subsequent ___ abscess.
During his C2, he developed hypersensitivity that was attributed
to cytarabine which all resolved with pre-medications. Following
C2, he was admitted briefly for fever in the setting of PRBCs
transfusion. Otherwise, he has been doing well. He will receive  

Neulasta again on D9 of treatment to help reduce duration of
neutropenia and infection risk.

 
Past Medical History:
PAST ONCOLOGIC HISTORY (per OMR):
___ INITIAL BM/BXAML
___ Consented to protocol ___ INDUCTION DAUNOrubicin  (90 mg/m2)  Cytarabine  (100
mg/m2) (RHP: +NPM1, +IDH2,+ RAD21)
___ D+14 BMBx ablated, 
___ D+26 remission, NPM1 negative
___ C1D1 HIDAC
--___ admitted for fever
--___ CT showed perianal abscess, drained, improved with
antibiotics
--___ C2D1 HIDAC

PAST MEDICAL HISTORY (per OMR):
AS ABOVE
 
Social History:
___
Family History:
Mother had lung cancer
Father had some type of metastatic cancer extensively involving
the bones
No history of any hematologic disorders including leukemia or
lymphoma
 
Physical Exam:
ADMISSION PHYSICAL EXAM:
VS: TC 98.0 133/73 72 18 99%RA 
WT: 211 LBS
GEN: well-appearing man, pleasant, conversive, and interactive.
HEENT: anicteric sclerae. MM moist and pink. 
LYMPH: no adenopathy in cervical, submandibular, submental,
___ chains
LUNGS: clear bilaterally, non-labored.
HEART: normal rate, regular rhythm, no m/r/g
ABDOMEN: soft, non-tender/non-distended, NABS. no splenomegaly
EXTREMITIES: warm. no petechiae or skin rash
RECTAL: inspection notable for absence of abscess or ___
skin irritation/ulceration. Small non-inflamed external
hemorrhoids present.
ACCESS: POC C/D/I

DISCHARGE PHYSICAL EXAM:
VS: TC 98.0 126/80 65 18 100%RA 
WT: 206.1LBS
GEN: well-appearing man, pleasant, conversive, and interactive.
HEENT: anicteric sclerae. MM moist and pink. 
LYMPH: no adenopathy in cervical, submandibular, submental,
___ chains
LUNGS: clear bilaterally, non-labored.
HEART: normal rate, regular rhythm, no m/r/g
ABDOMEN: soft, non-tender/non-distended, NABS. no splenomegaly
EXTREMITIES: warm. no petechiae or skin rash
ACCESS: POC C/D/I
NEURO: PERRLA EOMI no nystagmus rapid hand movements intact
finger to nose intact, tandem gait appropriate
 
Pertinent Results:
___ 12:00AM BLOOD WBC-3.1*# RBC-2.78* Hgb-9.2* Hct-29.0* 
MCV-104* MCH-33.1* MCHC-31.7* RDW-19.3* RDWSD-74.4* Plt ___
___ 09:40AM BLOOD WBC-6.3 RBC-2.82* Hgb-9.4* Hct-30.0* 
MCV-106* MCH-33.3* MCHC-31.3* RDW-22.7* RDWSD-86.7* Plt ___
___ 12:00AM BLOOD Neuts-95.5* Lymphs-2.3* Monos-1.3* 
Eos-0.0* Baso-0.3 Im ___ AbsNeut-2.95# AbsLymp-0.07* 
AbsMono-0.04* AbsEos-0.00* AbsBaso-0.01
___ 09:40AM BLOOD Neuts-27* Bands-0 Lymphs-60* Monos-12 
Eos-0 Baso-1 ___ Myelos-0 AbsNeut-1.70 AbsLymp-3.78* 
AbsMono-0.76 AbsEos-0.00* AbsBaso-0.06
___ 12:00AM BLOOD Glucose-157* UreaN-18 Creat-0.6 Na-141 
K-4.4 Cl-101 HCO3-25 AnGap-15
___ 09:40AM BLOOD UreaN-9 Creat-0.6 Na-143 K-4.4 Cl-106 
HCO3-27 AnGap-10
___ 12:00AM BLOOD ALT-34 AST-22 LD(LDH)-142 AlkPhos-54 
TotBili-0.5
___ 09:40AM BLOOD ALT-26 AST-24 AlkPhos-64 TotBili-0.3
___ 12:00AM BLOOD Albumin-3.8 Calcium-8.6 Phos-4.1 Mg-2.0
___ 09:40AM BLOOD TotProt-6.0* Albumin-4.0 Globuln-2.0 
Calcium-9.1 Phos-3.4 Mg-2.___ is a ___ year old male with
intermediate-risk cytogenetics and favorable risk AML (normal
karyotype, FLT3-, NPM1+, IDH2+, RAD21+, CEBPA-) in ___ remission
presenting for C3 of HiDAC consolidation therapy.

ACUTE ISSUES:
=============

#AML (+NPM1, +IDH2,+ RAD21): Considered favorable risk based on
IDH2 and NPM1 status, although presence of RAD21 not
well-understood. He did achieve MRD negative status based on his
negative NPM1 by PCR testing and is considered favorable AML.
Given hypersensitivity he developed during C2, he will receive
additional IV dexamethasone q12hrs x 6 doses on D1, D3 and D5. 
-Cytarabine 6480 mg IV Q12H on Days 1, 3 and 5. ___ and ___ mg/m2) 
-Cerebellar testing prior to each dose of cytarabine
-IVF/Antiemetics per protocol 
-Neulasta following chemotherapy completion on ___ then 
f/u scheduled ___
-When ANC < 500, will initiate prophylaxis with ciprofloxacin,
voriconazole and flagyl given prior ___ abscess during C1

CHRONIC/RESOLVED ISSUES:
========================

#Perianal abscess s/p I&D: Resolved. 

#Marijuana Use: Continues although he is using vaporizer, will
need to take prophylactic voriconazole during his neutropenic
periods.

FEN: Regular/IVF/Encourage PO/Replete Electrolytes PRN
PPX: Refusing Lovenox PPX
ACCESS: POC
CODE: Full Code 
COMMUNICATION: Patient
EMERGENCY CONTACT HCP: ___ (ex-wife/HCP) 
___
(home) ___ (cell)
DISPO: home

 
Medications on Admission:
The Preadmission Medication list is accurate and complete.
1. LORazepam 0.5-1 mg PO Q8H:PRN 
anxiety/nausea/vomiting/insomnia 
2. Vitamin D ___ UNIT PO DAILY 
3. Voriconazole 200 mg PO Q12H 
4. Ciprofloxacin HCl 500 mg PO Q12H 
5. MetroNIDAZOLE 500 mg PO TID 

 
Discharge Medications:
1.  Pegfilgrastim 6 mg SC ONCE Duration: 1 Dose  
2.  PrednisoLONE Acetate 1% Ophth. Susp. 1 DROP BOTH EYES TID 
continue through ___ then stop  
3.  LORazepam 0.5-1 mg PO Q8H:PRN 
anxiety/nausea/vomiting/insomnia  
4.  Vitamin D ___ UNIT PO DAILY  

 
Discharge Disposition:
Home
 
Discharge Diagnosis:
AML

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Mr. ___,

You were admitted to receive your third cycle of consolidation 
therapy (HIDAC) as part of your leukemia treatment and you 
tolerated this well. You will receive your neulasta injection 
and follow up with Dr. ___ as below. It was a pleasure 
taking care of you.
 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=14679785-DS-29 | hadm_id=29493454

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___.
 
Chief Complaint:
Abdominal cramping and diarrhea
 
Major Surgical or Invasive Procedure:
EGD with biopsies
Flexible sigmoidoscopy with biopsies

 
History of Present Illness:
HPI:  
___ is a ___ man with relapsed acute myeloid
leukemia currently in remission status post reinduction with
MEC/lenalidomide on protocol ___, now status post allogeneic
MRD stem cell transplant, currently day+211 on vaccine protocol
___ who presents to clinic with dry mouth, abdominal cramping
and diarrhea concerning for GVHD.

Following transplant in ___, patient had been on tacrolimus
and had tolerated decreasing doses. On ___, decision was 
made
to taper patient off completely. At that time, his only symptoms
of GVHD were minimal dry skin and dry mouth. (per chart-early
lichenoid buccal mucosal changes)
He was then seen in clinic on ___ for symptoms of worsening dry
mouth, requiring more frequent hydration. He was also having 
some
mild intermittent, dull achy stomach pain, lasting a few 
minutes,
and several loose stools per day for a week or so. He was 
started
on Budesonide 3mg TID and Dexamethasone swish/spit 10mls tid,
on/off 2wks/1wk. Since ___, he has been taking these as
prescribed. He reports that the rinse had helped a little bit,
but the next day he had increased abdominal "tightness" with
loose stools. On ___ he began having frequent diarrhea and
worsening pain. Reports 10+ small volume stools without blood or
foam. Has been increasing his PO fluid intake (gatorade) to keep
his mouth dry and stay hydrated. However, wasn't able to eat as
much food because it would cause worsening cramping several 
hours
later. No recent abx use other than prophylactic Bactrim. 

Denies any other rash, blisters, desquamation, skin tightening,
N/V, bloating, hematochezia, melena, BRBPR, itching, jaundice,
RUQ pain. Reports about 8lb weight loss in the past week. Denies
any constitutional symptoms including fevers, chills, night
sweats.

Upon arrival to the floor, patient stable and talkative with his
two daughters. 

Review of Systems:  
(+) Per HPI.
Denies headache, vision changes, rhinorrhea, congestion, sore
throat, cough, shortness of breath, chest pain, dysuria,
hematuria. 
 
PAST ONCOLOGIC HISTORY:  
___ INITIAL BMBX  AML
___ Consented to  protocol ___  INDUCTION DAUNOrubicin  (90 mg/m2)  Cytarabine  (100
mg/m2)  (RHP: +NPM1, +IDH2,+ RAD21)
___  D+14 BMBx ablated, 
___  D+26 remission, NPM1 negative
___ C1D1 HIDAC
___ admitted for fever
___ CT showed perianal abscess, drained, improved with
antibiotics
___ - C2D1 HIDAC, complicated by fevers and rash after 4 
of 6 doses attributed to possible cytarabine syndrome, all
resolved with higher dexamethasone premedication. also received
neulasta on D9
___ - C3D1 HIDAC, complicated by neutropenic fever, 
empiric antibiotics without complications or infectious source
___ - taken off of active study protocol (control arm) due
to patient preference to avoid frequent visits and tests;
consented to be followed by the study for survival/outcome data
___ - initiation of therapy for relapsed AML on trial
___
----lenalidomide 50 mg D1-10
----MEC D4-8
___ - admitted for alloHSC transplant
- Flu/Bu ablation chemotherapy ___
- Allogeneic stem cell transplant ___
- Discharged ___ - Bone marrow biopsy w/no morphologic evidence of AML,
negative NPM1 and myeloid sequencing panels
---- COMPLICATIONS: neutropenic fever, c.diff colitis, SCoN
bacteremia, ___ abscess
 
Past Medical History:
PAST MEDICAL HISTORY:
- AML as above
- C-diff infection
- Genital warts
- Hernia s/p mesh ___ years ago
 
Social History:
___
Family History:
Mother had lung cancer. Father had some type of metastatic 
cancer
extensively involving the bones. No history of any hematologic
disorders including leukemia or lymphoma. 
 
Physical Exam:
ADMISSION PHYSICAL EXAM:
========================
Vitals: ___ 1454 Temp: 98.3 PO BP: 104/67 HR: 87 RR: 18 O2
sat: 98% O2 delivery: RA 
Gen: sitting upright in NA
NEURO: A&Ox3.
HEENT: No conjunctival pallor. No icterus. MMM. Several buccal
mucosal lesions.  
NECK: No JVP 
LYMPH: No cervical or supraclav LAD
CV: Regular rate, regular rhythm. No MRG.   
LUNGS: No incr WOB. CTAB. No wheezes, rales, or rhonchi.  
ABD: Very mild tenderness to deep palpation in blt lower
quadrants. Soft, ND, nl bowel sounds, no HSM. No RUQ tenderness
EXT: WWP. No ___ edema. 
Rectum: no evidence of hemorrhoids or fistula. Multiple small 
SKIN: No rashes/lesions, petechiae/purpura ecchymoses.  

DISCHARGE PHYSICAL EXAM:
========================
 
Pertinent Results:
ADMISSION LABS:
===============

___ 01:52PM BLOOD WBC-9.4 RBC-4.31* Hgb-13.9 Hct-40.2 
MCV-93 MCH-32.3* MCHC-34.6 RDW-13.8 RDWSD-47.6* Plt ___
___ 01:52PM BLOOD Neuts-41.9 ___ Monos-12.3 
Eos-0.6* Baso-0.2 Im ___ AbsNeut-3.94 AbsLymp-4.21* 
AbsMono-1.16* AbsEos-0.06 AbsBaso-0.02
___ 05:45AM BLOOD ___ PTT-26.3 ___
___ 01:52PM BLOOD UreaN-9 Creat-0.9 Na-134* K-3.8 Cl-98 
HCO3-22 AnGap-14
___ 01:52PM BLOOD ALT-28 AST-23 LD(LDH)-134 AlkPhos-90 
TotBili-0.5
___ 01:52PM BLOOD Calcium-9.1 Phos-3.9 Mg-1.7
___ 01:52PM BLOOD Albumin-3.5 Calcium-9.0
___ 01:52PM BLOOD CMV VL-NOT DETECT

CT A/P WITH CONTRAST ___
Marked circumferential mural thickening and mucosal 
hyperenhancement involving the entire large bowel terminal and 
distal ileum and the antrum of the stomach.  The appearances are 
more suggestive of acute graft-versus-host disease than an 
infectious enterocolitis. 

UPPER ENDOSCOPY ___
- Grade B esophagitis in the distal esophagus
- Ulcers in the antrum (biopsy)
- Erythema in the gastro-esophageal junction (biopsy)
- Normal mucosa in the whole examined duodenum with small 
polypoid lesions (biopsy)

Surgical Pathology Report ___
Gastrointestinal mucosal biopsies, four:
1. Gastroesophageal junction:
- Cardiac mucosa with changes suggestive of mild 
graft-versus-host-disease (GVHD).
- Squamous epithelium within normal limits.
2. Stomach:
- Corpus mucosa with changes suggestive of mild GVHD.
- Immunohistochemical stains for Helicobacter and CMV are 
negative with adequate controls.
3. Duodenum:
- Duodenal mucosa with changes suggestive of minimal GVHD.
4. Descending colon and rectum:
- Colonic mucosa with changes of moderate to severe GVHD.
- Immunohistochemical stain for CMV is negative with adequate 
controls.

PET SCAN ___
IMPRESSION: 1. Diffuse colonic wall thickening, fat stranding 
and mild colonic FDG uptake are suggestive of colitis. 2. No 
suspicious lymphadenopathy. 3. Stable, non FDG avid 7 mm 
ground-glass nodule in the right lung apex dating back to at 
least ___. 4. Mild centrilobular and paraseptal emphysema. 


RUQUS ___
Ill-defined mild hyperechogenicity in segment 2 in a periportal 
location could represent graft-versus-host disease. 
Redemonstration of extensive gallbladder sludge with moderate 
distension, 
slightly increased from prior study.  No evidence of wall 
thickening, 
pericholecystic fluid, or sonographic ___ sign to suggest 
acute 
cholecystitis. 
  
MICROBIOLOGY:
=============
Blood Culture, Routine (Final ___: 
      PSEUDOMONAS PUTIDA .    FINAL SENSITIVITIES. 

                              SENSITIVITIES: MIC expressed in 
MCG/ML
                      
_________________________________________________________
                             PSEUDOMONAS PUTIDA 
                             |   
CEFEPIME--------------   <=1 S
CEFTAZIDIME-----------     4 S
CEFTRIAXONE-----------    16 I
CIPROFLOXACIN---------<=0.25 S
GENTAMICIN------------   <=1 S
LEVOFLOXACIN----------     1 S
MEROPENEM-------------     2 S
PIPERACILLIN/TAZO-----     8 S
TOBRAMYCIN------------   <=1 S
TRIMETHOPRIM/SULFA----  =>16 R

   Aerobic Bottle Gram Stain (Final ___: 
      Reported to and read back by ___. ___ ON ___ AT 0350. 

      GRAM NEGATIVE ROD(S).

DISCHARGE LABS:
===============
___ 12:05AM BLOOD WBC-4.4 RBC-2.42* Hgb-8.3* Hct-24.1* 
MCV-100* MCH-34.3* MCHC-34.4 RDW-22.1* RDWSD-76.3* Plt Ct-35*
___ 12:00AM BLOOD Neuts-88* Bands-1 Lymphs-8* Monos-3* 
Eos-0* Baso-0 NRBC-0.9* AbsNeut-3.03 AbsLymp-0.27* AbsMono-0.10* 
AbsEos-0.00* AbsBaso-0.00*
___ 12:05AM BLOOD Glucose-165* UreaN-18 Creat-0.7 Na-136 
K-4.3 Cl-101 HCO3-21* AnGap-14
___ 12:05AM BLOOD ALT-40 AST-15 LD(LDH)-235 AlkPhos-115 
TotBili-1.1
___ 12:05AM BLOOD Albumin-3.1* Calcium-7.8* Phos-3.1 Mg-1.6
___ 09:00AM BLOOD tacroFK-5.___RIEF HOSPITAL COURSE:
=======================
___ is a ___ man with AML s/p allogeneic MRD stem cell 
transplant who presented with signs of GI GVHD, with course 
complicated by EBV and CMV viremia, right foot cellulitis, and 
transaminitis.

ACTIVE ISSUES:
==============
#GVHD of GI tract
Patient had biopsy proven GVHD of his esophagus, stomach and 
distal colon and was treated with high dose steroids at 2mg/kg, 
tacrolimus and budesonide. Throughout his admission, his CMV 
viral load and EBV viral load turned positive and he was treated 
with Valganciclovir and Rituximab. His C dif PCR and stool 
cultures were negative. He was also started on a PPI and Vitamin 
D supplementation, and required TPN while NPO. His diarrhea 
eventually began to improve, his diet was slowly advanced and 
his steroids were weaned down. His current medications include 
prednisone 50 mg QD, tacrolimus 0.5 BID, and budesonide 3 mg 
TID.

# Elevated AST/ALT/T. bili: patient's AST/ALT/direct bili were 
elevated at times during this admission. This was likely 
multifactorial, due to medication effect with posaconazole 
therapy, his TPN, possible extraintestinal GVHD, CMV infection. 
After holding the lipids in his TPN, his transaminitis improved. 
He had a RUQ US on ___ without acute cholecystitis.

# Acute myeloid leukemia:  in complete remission. Initially with 
favorable mutational profile (normal karyotype; FLT3 negative, 
NPM1 positive, IDH2 positive, RAD21 positive, CEBPA negative). 
Relapsed AML now in remission s/p allo-SCT (___) on vaccine 
protocol ___ (decision for vaccine per Dr. ___. 
Patient was initially continued on his prophylactic bactrim, 
acyclovir (transitioned to valganciclovir after CMV +) and was 
started on antifungal prophylaxis after receiving high dose 
steroids for GVHD. Of note, he became thrombocytopenic during 
his stay (possibly related to his Bactrim and valganciclovir 
therapy), and Bactrim was switched to Atovaquone on ___.

#CMV viremia
On ___, patient had positive CMV of 2.1, with repeat of 2.2 on
___. He was started on PO valganciclovir 900mg bid on ___. CMV 
VL was monitored weekly and became undetectable on ___. After 2 
negative VLs, he was decreased to 900mg valganciclovir qd on 
___.

#EBV viremia
Patient had elevated EBV on ___. Repeat on ___ still
elevated at 1589 with ___ repeat significantly higher at 5147.
Back down to 1483 on ___. 
- ___ PET scan without any suspicious LAD
- s/p Rituximab on ___. Recheck on ___ was pending at time of 
discharge.

#R foot cellulitis
Patient with erythema of R medial ankle on ___ that rapidly 
extended into his foot and up his lower leg, concerning for 
rapidly evolving infection in the setting of immunosuppression. 
CT ___ without subcutaneous gas, drainable fluid collection or 
bony involvement and US lower extremity ___ without evidence 
clot. Started on Vancomycin, Cefepime and Clindamycin, ID was 
consulted. ___ blood culture showed Pseudomonas putida, 
sensitive to Cefepime. Per ID, cellulitis is likely 
monomicrobial infection due to pseudomonas. Vancomycin and 
Flagyl were discontinued and he remained on Cefepime from ___ - 
___. He was transitioned to ciprofloxacin 500mg BID and 
discharged to finish a ___nding on ___. His last 
positive blood culture was on ___.

# History of genital lesion: not present on admission. Had 
resolved after cryotherapy, most consistent with genital warts. 

#Thrush - patient was found to have thrush of his oral mucosa on 
___ and was treated with clotrimazole troches

#Peripheral edema
#Hypoalbuminemia
Patient had increased weight and ___ edema in the setting of 
hypoalbuminemia. Was diuresed intermittently with 40mg Lasix and 
albumin.
 
Medications on Admission:
The Preadmission Medication list is accurate and complete.
1. Acyclovir 400 mg PO Q8H 
2. LORazepam 0.5 mg PO DAILY:PRN anxiety 
3. Multivitamins 1 TAB PO DAILY 
4. Sulfameth/Trimethoprim SS 1 TAB PO DAILY 
5. Budesonide 3 mg PO TID 
6. Dexamethasone Oral Soln (0.1mg/1mL) 10 mL ORAL TID 

 
Discharge Medications:
1.  Atovaquone Suspension 1500 mg PO DAILY 
RX *atovaquone 750 mg/5 mL 10 ml by mouth once a day Refills:*0 
2.  Ciprofloxacin HCl 500 mg PO BID Duration: 6 Days 
RX *ciprofloxacin HCl 500 mg 1 tablet(s) by mouth twice a day 
Disp #*5 Tablet Refills:*0 
3.  FoLIC Acid 1 mg PO DAILY 
RX *folic acid 1 mg 1 tablet(s) by mouth once per day Disp #*30 
Tablet Refills:*0 
4.  LOPERamide 2 mg PO QID diarrhea 
Decrease frequency if you become constipated 
RX *loperamide [Anti-Diarrheal (loperamide)] 2 mg 1 tablet by 
mouth 4 times per day Disp #*120 Tablet Refills:*0 
5.  Nicotine Patch 21 mg/day TD DAILY 
RX *nicotine 21 mg/24 hour  Once per day Disp #*30 Patch 
Refills:*0 
6.  Pantoprazole 40 mg PO Q12H 
RX *pantoprazole 40 mg 1 tablet(s) by mouth Twice per day Disp 
#*60 Tablet Refills:*0 
7.  Posaconazole Delayed Release Tablet 300 mg PO DAILY 
RX *posaconazole 100 mg 3 tablet(s) by mouth once a day Disp 
#*30 Tablet Refills:*0 
8.  PredniSONE 50 mg PO DAILY 
Your doctor ___ work with you to slowly decrease the dose you 
are taking 
RX *prednisone 10 mg 50 mg by mouth Take 5 tablets (50 mg) by 
mouth once per day Disp #*150 Tablet Refills:*0 
9.  Tacrolimus 0.5 mg PO QAM  
10.  Tacrolimus 0.5 mg PO QPM  
11.  ValGANCIclovir 900 mg PO DAILY 
RX *valganciclovir 450 mg 2 tablet(s) by mouth once a day Disp 
#*28 Tablet Refills:*0 
12.  Vitamin D ___ UNIT PO 1X/WEEK (WE)  
13.  Budesonide 3 mg PO TID  
14.  LORazepam 0.5 mg PO DAILY:PRN anxiety 
RX *lorazepam 0.5 mg 0.5 (One half) mg by mouth Every 8 hours as 
needed Disp #*60 Tablet Refills:*0 
15.  Multivitamins 1 TAB PO DAILY  

 
Discharge Disposition:
Home
 
Discharge Diagnosis:
Primary diagnosis: GVHD of the GI tract

Secondary diagnosis:
- Cellulitis
- CMV viremia
- EBV viremia 
- Oral candidiasis
- Hypoalbuminemia
- Severe malnutrition

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Dear Mr. ___,  

It was a privilege taking care of you at ___ 
___.  

WHY WAS I IN THE HOSPITAL?  
- You were admitted to the hospital for abdominal cramping and 
diarrhea and were found to have graft versus host disease 
affecting your intestines.

WHAT HAPPENED TO ME IN THE HOSPITAL?  
- We treated you with steroids and other medications to suppress 
your immune system so that your intestines could heal. We gave 
you nutrition through the IV while you were resting your gut and 
then slowly introduced back foods.
- While your immune system was suppressed, you had a virus that 
became reactivated in your body (called EBV). We gave you a 
medication for this called Rituximab. You also developed an 
infection from another virus called CMV. We gave you a 
medication called valgancyclovir for this.
- You developed an infection in your foot. We treated you with 
IV antibiotics for this. We transitioned you to oral antibiotics 
before you left.

WHAT SHOULD I DO AFTER I LEAVE THE HOSPITAL?  
- Continue to take all your medicines and keep your 
appointments. Your doctor ___ work with you to slowly decrease 
the steroids that are treating your graft versus host disease.

We wish you the best.

Sincerely,  
Your ___ Team  
 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=14679785-DS-22 | hadm_id=29541922

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___.
 
Chief Complaint:
admission for cycle 2 of HIDAC
 
Major Surgical or Invasive Procedure:
none

 
History of Present Illness:
Mr. ___ is a ___ male with history of 
intermediate-risk cytogenetics and favorable risk AML (normal 
karyotype, FLT3-, NPM1+, IDH2+, RAD21+, CEBPA-) in ___ remission 
after successful induction 7+3 chemotherapy who
presented for C2 of HiDAC consolidation therapy. His ___ cycle 
of HIDAC was complicated by relatively prolonged neutropenia 
along with fever and subsequent ___ abscess, fortunately 
now all resolved. We will therefore provide Neulasta therapy on 
D10 of treatment to help reduce duration of neutropenia and 
infection risk.

ROS: On arrival to the floor, patient denies headache, vision 
changes, dizziness, lightheadedness, weakness, numbness, 
shortness of breath, cough, hemoptysis, chest pain, 
palpitations, abdominal pain, nausea, vomiting, diarrhea, 
hematemesis, hematochezia, melena, dysuria, hematuria, and new 
rashes. All other ROS negative. 
 
 
Past Medical History:
TREATMENT COURSE:
___ INITIAL BM/BXAML
___ Consented to protocol ___ INDUCTION DAUNOrubicin  (90 mg/m2)  Cytarabine  (100
mg/m2) (RHP: +NPM1, +IDH2,+ RAD21)
___ D+14 BMBx ablated, 
___ D+26 remission, NPM1 negative
___ C1D1 HIDAC
--___ admitted for fever
--___ CT showed perianal abscess, drained, improved with
antibiotics
--___ C2D1 HIDAC
 
Social History:
___
Family History:
Mother had lung cancer. Father had some type of
metastatic cancer extensively involving the bones. No history of
any hematologic disorders including leukemia or lymphoma.
 
Physical Exam:
ADMISSION PHYSICAL EXAM:
VS: TC 98.5 PO 116/74 84 18 100%RA 
GEN: well-appearing adult man sitting comfortably on the exam
table. pleasant, conversive, and interactive. accompanied by 1
daughter
___: anicteric sclerae. MM moist and pink. hair is starting to
grow back
LYMPH: no adenopathy in cervical, submandibular, submental,
___ chains
LUNGS: clear bilaterally
HEART: normal rate, regular rhythm, no m/r/g
ABDOMEN: soft, non-tender, non-distended, NABS. no splenomegaly
EXTREMITIES: warm. no petechiae or skin rash
RECTAL: inspection notable for absence of abscess or ___
skin irritation/ulceration. Small non-inflamed external
hemorrhoids present.
ACCESS: POC C/D/I

DISCHARGE PHYSICAL EXAM:
VS: TC 98.5 94-120/55-64 82-100 ___ 94-100%RA
GEN: well-appearing adult man in no acute distress
___: anicteric sclerae. MM moist and pink. Hair growing back
LYMPH: no adenopathy in cervical, submandibular, submental,
___ chains
LUNGS: clear bilaterally, non-labored
HEART: normal rate, regular rhythm, no m/r/g
ABDOMEN: soft, non-tender, non-distended, NABS. No splenomegaly
SKIN: erythematous macules and papules coalescing into diffuse
blanchable erythema on trunk and proximal extremities now 
resolved. 
EXTREMITIES: WWP, no tremors
RECTAL: inspection notable for absence of abscess or ___
skin irritation/ulceration. Small non-inflamed external
hemorrhoids present.
ACCESS: POC C/D/I
 
Pertinent Results:
ADMISSION LABS:
___ 12:00PM   PLT COUNT-398
___ 12:00PM   NEUTS-60.9 ___ MONOS-18.3* EOS-0.2* 
BASOS-0.8 IM ___ AbsNeut-3.64# AbsLymp-1.15* AbsMono-1.09* 
AbsEos-0.01* AbsBaso-0.05
___ 12:00PM   WBC-6.0 RBC-2.83* HGB-9.2* HCT-28.0* MCV-99*# 
MCH-32.5* MCHC-32.9 RDW-20.5* RDWSD-68.4*
___ 12:00PM   TOT PROT-5.9* ALBUMIN-4.0 GLOBULIN-1.9* 
CALCIUM-9.4 PHOSPHATE-3.8 MAGNESIUM-1.9
___ 12:00PM   ALT(SGPT)-17 AST(SGOT)-18 ALK PHOS-54 TOT 
BILI-0.3
___ 12:00PM   estGFR-Using this
___ 12:00PM   GLUCOSE-96 UREA N-10 CREAT-0.7 SODIUM-143 
POTASSIUM-4.3 CHLORIDE-105 TOTAL CO2-27 ANION GAP-11
___ 12:00AM   PLT COUNT-391
___ 12:00AM   NEUTS-86.6* LYMPHS-9.1* MONOS-3.0* EOS-0.1* 
BASOS-0.6 IM ___ AbsNeut-7.77*# AbsLymp-0.82* AbsMono-0.27 
AbsEos-0.01* AbsBaso-0.05
___ 12:00AM   WBC-9.0 RBC-2.81* HGB-9.2* HCT-28.0* MCV-100* 
MCH-32.7* MCHC-32.9 RDW-20.4* RDWSD-69.7*
___ 12:00AM   ALBUMIN-3.7 CALCIUM-8.5 PHOSPHATE-1.6* 
MAGNESIUM-1.8
___ 12:00AM   ALT(SGPT)-16 AST(SGOT)-17 LD(LDH)-193 ALK 
PHOS-56 TOT BILI-0.2
___ 12:00AM   GLUCOSE-151* UREA N-9 CREAT-0.5 SODIUM-138 
POTASSIUM-3.6 CHLORIDE-106 TOTAL CO2-24 ANION GAP-8*

DISCHARGE LABS:
___ 12:00AM BLOOD WBC-3.1*# RBC-2.87* Hgb-9.3* Hct-27.8* 
MCV-97 MCH-32.4* MCHC-33.5 RDW-19.2* RDWSD-67.4* Plt ___
___ 12:00AM BLOOD Neuts-96.5* Lymphs-1.3* Monos-0.3* 
Eos-0.3* Baso-0.3 Im ___ AbsNeut-3.02# AbsLymp-0.04* 
AbsMono-0.01* AbsEos-0.01* AbsBaso-0.01
___ 12:00AM BLOOD Plt ___
___ 12:00AM BLOOD Glucose-148* UreaN-16 Creat-0.5 Na-138 
K-4.5 Cl-100 HCO3-23 AnGap-15
___ 12:00AM BLOOD ALT-17 AST-15 LD(LDH)-164 AlkPhos-53 
TotBili-0.6
___ 12:00AM BLOOD Albumin-4.0 Calcium-8.6 Phos-3.7 Mg-2.1

IMAGING:

CXR ___ IMPRESSION: No radiographic evidence of acute 
cardiopulmonary disease. 
 
Brief Hospital Course:
ASSESSMENT AND PLAN: ___ is a ___ year old male with 
intermediate-risk cytogenetics and favorable risk AML (normal 
karyotype, FLT3-, NPM1+, IDH2+, RAD21+, CEBPA-) in ___ remission 
presenting for C2 of HiDAC consolidation therapy.

ACUTE ISSUES:
=================

#Rash: Concerning for drug rash likely due to cytarabine. 
Dermatology consulted ___ and thinks that the characteristics 
of the rash is most likely consistent with an exanthematous or 
morbilliform eruption. He has no LFT abnormalities or
eosinophilia. Albeit, he has received previous cytarabine 
infusions without any skin eruptions, exanthematous reaction is 
common with cytarabine. DERM recommendations are as follows:
-Clobetasol 0.05% ointment BID (day 1: ___ for up to 2 wks. 
-Loratidine daily and Benadryl as needed

#Fever, non-neutrapenia: Fever spike to 102.8 on ___ in the 
absence of localizing symptoms of infection. Potentially also 
due to idiosyncratic reaction to cytarabine in the context of a 
rash as above. UA is bland. Urine and blood cultures without 
growth at discharge. Chest x-ray without acute cardiopulmonary 
process. Deferred
antibiotics at this time given he is not neutropenic and there 
is no localizing source of infection. He did not have any other 
recurrences of fever prior to discharge. 

#AML (+NPM1, +IDH2,+ RAD21): Considered favorable risk based on 
IDH2 and NPM1 status, although presence of RAD21 not 
well-understood. He did achieve MRD negative status based on his 
negative NPM1 by PCR testing and is considered favorable AML
based on ___. Except as described, he did not develop any 
other acute complications during cycle 2 of HIDAC. Today is D+6. 
He will receive Neulasta following chemotherapy completion 
___. He will follow up with Dr. ___ on D11 
(___). 

CHRONIC/RESOLVED ISSUES:
===========================

#Perianal abscess s/p I&D: Resolved. 

#Marijuana Use: Continues although he is using vaporizer, will 
need prophylactic voriconazole while neutropenic.

ACCESS: POC
CODE: Full Code 
COMMUNICATION: Patient
EMERGENCY CONTACT HCP: ___ (ex-wife/HCP) 
___ (cell)
DISPO: Discharged ___. RTC ___ and ___
 
Medications on Admission:
The Preadmission Medication list is accurate and complete.
1. Ciprofloxacin HCl 500 mg PO Q12H 
2. LORazepam 0.5-1 mg PO Q8H:PRN 
anxiety/nausea/vomiting/insomnia 
3. Vitamin D ___ UNIT PO DAILY 
4. Voriconazole 200 mg PO Q12H 

 
Discharge Medications:
1.  Clobetasol Propionate 0.05% Ointment 1 Appl TP BID affected 
areas on the body, spare face/groin/axilla 
do not use more than 2 weeks  
2.  Loratadine 10 mg PO DAILY:PRN rash  
3.  Pegfilgrastim 6 mg SC ONCE Duration: 1 Dose 
You will receive this injection on ___  
4.  PrednisoLONE Acetate 1% Ophth. Susp. 1 DROP BOTH EYES TID 
continue for the next ___ hours and then discontinue  
5.  LORazepam 0.5-1 mg PO Q8H:PRN 
anxiety/nausea/vomiting/insomnia  
6.  Vitamin D ___ UNIT PO DAILY  
7. HELD- Ciprofloxacin HCl 500 mg PO Q12H Duration: 7 Days  This 
medication was held. Do not restart Ciprofloxacin HCl until Dr. 
___ you to do so
8. HELD- Voriconazole 200 mg PO Q12H  This medication was held. 
Do not restart Voriconazole until Dr. ___ you to 
do so

 
Discharge Disposition:
Home
 
Discharge Diagnosis:
#Rash
#AML

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Mr. ___,

You were admitted to receive your second cycle of consolidation 
therapy (HIDAC) as part of your leukemia treatment. You 
developed fever and rash which we think is a side effect of your 
chemotherapy. Your symptoms are resolved. You will receive your 
neulasta injection and follow up with Dr. ___ as below. It 
was a pleasure taking care of you.
 
Followup Instructions:
___


-----
===== DISCHARGE NOTE =====
note_id=14679785-DS-35 | hadm_id=29843937

 
Name:  ___                  Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
No Known Allergies / Adverse Drug Reactions
 
Attending: ___.
 
Major Surgical or Invasive Procedure:
None

attach
 
Pertinent Results:
ADMISSION LABS
==============
___ 11:40AM   ANISOCYT-1+* POIKILOCY-1+* MICROCYT-1+* 
SCHISTOCY-1+* TEARDROP-1+* RBCM-SLIDE REVI
___ 11:40AM   NEUTS-53 ___ MONOS-1* EOS-0* BASOS-0 
AbsNeut-2.49 AbsLymp-2.16 AbsMono-0.05* AbsEos-0.00* 
AbsBaso-0.00*
___ 11:40AM   WBC-4.7 RBC-2.69* HGB-9.1* HCT-26.7* MCV-99* 
MCH-33.8* MCHC-34.1 RDW-19.0* RDWSD-68.7*
___ 11:40AM   OSMOLAL-269*
___ 11:40AM   TOT PROT-4.6* ALBUMIN-3.4* GLOBULIN-1.2* 
PHOSPHATE-3.8 MAGNESIUM-1.6
___ 11:40AM   estGFR-Using this
___ 11:40AM   UREA N-11 CREAT-0.7 SODIUM-133* POTASSIUM-3.7 
CHLORIDE-96 TOTAL CO2-23 ANION GAP-14
___ 08:31PM OTHER BODY FLUID  FluAPCR-NEG FluBPCR-NEG

OTHER PERTINENT LABS
====================
___ 12:00AM BLOOD TotProt-3.9* Albumin-2.8* Globuln-1.1* 
Calcium-7.3* Phos-2.7 Mg-2.1
___ 08:31PM OTHER BODY FLUID FluAPCR-NEG FluBPCR-NEG

DISCHARGE LABS
===============
___ 12:00AM BLOOD WBC-6.8 RBC-2.27* Hgb-7.6* Hct-23.2* 
MCV-102* MCH-33.5* MCHC-32.8 RDW-18.7* RDWSD-70.0* Plt Ct-45*
___ 12:00AM BLOOD Neuts-50.1 ___ Monos-5.0 Eos-0.3* 
Baso-0.3 NRBC-0.7* Im ___ AbsNeut-3.43 AbsLymp-2.90 
AbsMono-0.34 AbsEos-0.02* AbsBaso-0.02
___ 12:00AM BLOOD Glucose-151* UreaN-11 Creat-0.7 Na-130* 
K-4.2 Cl-95* HCO3-23 AnGap-12
___ 12:00AM BLOOD ALT-17 AST-16 LD(LDH)-255* AlkPhos-65 
TotBili-<0.2
___ 12:00AM BLOOD Albumin-2.6* Calcium-7.5* Phos-3.0 Mg-1.7

MICRO
=======
___ 7:50 pm BLOOD CULTURE      Source: Line-PICC. 

   Blood Culture, Routine (Preliminary): 
      ANAEROBIC GRAM NEGATIVE ROD(S).    BETA LACTAMASE 
POSITIVE. 

   Anaerobic Bottle Gram Stain (Final ___: 
      GRAM NEGATIVE ROD(S). 
      Reported to and read back by ___ (___), 
___ @
      10:36AM. 

 
Brief Hospital Course:
PATIENT SUMMARY STATEMENT FOR ADMISSION
=========================================
Mr. ___ is a ___ yo gentleman with a history of relapsed AML 
treated with multiple rounds chemotherapy and MRD alloHSCT with 
MAC (D0 ___ complicated by steroid-refractory GI-GVHD, C. 
difficile colitis, CMV viremia, and recent VRE/E.coli 
bacteremia, and fungal pneumonia. Patient presented after ___ 
BAL results with positive galactomannan and stenotrophomonas

TRANSITIONAL ISSUES
=====================
Discharge weight: 69.67 kg - 153.59 lb  
Discharge Hgb: 7.6
Discharge WBC: 6.8
Discharge ANC: 3.43
Discharge platelets: 45
Discharge Cr: 0.7

[ ] The plan is to continue dual treatment with micafungin and 
isavuconazole for at least 8 weeks. However this plan could 
change depending on ID and imaging follow-up.
[ ] Follow-up chest CT has been schewduled in 4 weeks 
(___).
[ ] Continue metronidazole for current anaerobe bacteremia until 
___.
[ ] Continue linezolid for prior VRE bacteremia until ___.
[ ] Consider repeating CMV viral load.

ACUTE MEDICAL ISSUES ADDRESSED
=================================
#Aspergillus pneumonia
Patient with recent episode of multifocal pneumonia and VRE 
bacteremia. Multiple CT scans in the interval have shown 
development and progression of cavitating nodules concerning for 
pulmonary aspergillosis. Patient underwent BAL on ___ as an 
outpatient and had a positive galactomannan despite
being on isavuconazole treatment. . Initially patient 
transitioned to IV isavuconazole given concern for poor PO 
absorption due to GI-GVHD. However, isavuconazole levels 
adequate and per ID recs patient placed on PO isavuconazole and 
micafungin. Plan for at least 8 week treatment but will undergo 
ID follow-up and repeat imaging in 4 weeks.

#Positive stenotrophomonas in BAL
Cultures from BAL grew Stenotrophomonas maltophilia, sensitive 
to Bactrim. Patient remained asymptomatic throughout admission. 
ID considering this as a colonizer versus true infection given 
overall clinical stability. But decision to continue Bactrim at 
prophylactic dose.

#Gram negative bacteremia
Patient had single fever episode on ___. Blood cultures 
were drawn and gre anaerobic gram negative bacteria. Patient 
initially received empiric coverage with cefepime and 
metronidazole. However, upon final results of culture, ID 
recommended de-escalating to a 14 day course of metronidazole. 
Stop date would ___

CHRONIC ISSUES PERTINENT TO ADMISSION
=======================================
#AML s/p allogeneic MRD HSCT (Day 0 = ___:
#Thrombocytopenia:
AML initially with favorable mutational profile (normal 
karyotype; FLT3 negative, NPM1 positive, IDH2 positive, RAD21 
positive, CEBPA negative). He relapsed after chemo-consolidation 
(7+3, 3C HIDAC & MEC/Revlimid) then underwent an MRD allogeneic 
SCT. In remission following his transplant with slow count 
recovery. BMBX during recent admission showed no evidence of 
recurrence w/ 100% chimerism. 

#Recent enterococcus bacteremia
Patient was treated on prior admissions for enterococcus 
bacteremia with unclear source. Main suspicion was gut source 
given GVHD. TTE ___ negative for vegetations. He was discharged 
with Linezolid ___ BID for 6 weeks. On this admission 
Linezolid was transitions from IV to PO.

#GVHD, extensive GI involvement
-Continued immunosuppression with Jakafi 5 mg twice daily and 
Tacro 0.5mg qday, pred 7.5mg qday
-Continued ID prophylaxis with bactrim
-Continued PPI, vitamin D and folic acid supplementation

#Thrombocytopenia: 
Likely secondary to multiple infections, linezolid, Bactrim.  No 
evidence of consumptive process for splenomegaly.

#CMV viremia: 
History of CMV viremia with positive viral load ___ (peak 
2.2log), and he completed course of valganciclovir last 
admission. CMV VL ND since ___ and was changed to ACV at time 
of DC last admission. Consider repeating CMV viral load.

#Macrocytic anemia:
B12 and folate ok during previous admission. Likely med related
from Bactrim.

 
Medications on Admission:
The Preadmission Medication list is accurate and complete.
1. Acyclovir 400 mg PO Q8H 
2. Budesonide 3 mg PO TID 
3. FoLIC Acid 1 mg PO DAILY 
4. Isavuconazonium Sulfate 372 mg PO DAILY 
5. Linezolid ___ mg IV Q12H 
6. LORazepam 1 mg PO BID: PRN anxiety 
7. Magnesium Oxide 800 mg PO BID 
8. Pantoprazole 40 mg PO Q12H 
9. PredniSONE 7.5 mg PO DAILY 
10. Sulfameth/Trimethoprim SS 1 TAB PO DAILY 
11. Tacrolimus 0.5 mg PO DAILY 
12. Vitamin D ___ UNIT PO 1X/WEEK (WE) 
13. Ruxolitinib 5 mg PO BID 

 
Discharge Medications:
1.  Linezolid ___ mg PO BID 
RX *linezolid ___ mg 1 tablet(s) by mouth twice a day Disp #*34 
Tablet Refills:*0 
2.  MetroNIDAZOLE 500 mg PO/NG Q8H 
RX *metronidazole 500 mg 1 tablet(s) by mouth three times a day 
Disp #*42 Tablet Refills:*0 
3.  Micafungin 100 mg IV Q24H  
4.  Acyclovir 400 mg PO Q8H  
5.  Budesonide 3 mg PO TID  
6.  FoLIC Acid 1 mg PO DAILY  
7.  Isavuconazonium Sulfate 372 mg PO DAILY  
8.  LORazepam 1 mg PO BID: PRN anxiety 
RX *lorazepam 1 mg 1 tab by mouth twice a day Disp #*10 Tablet 
Refills:*0 
9.  Magnesium Oxide 800 mg PO BID  
10.  Pantoprazole 40 mg PO Q12H  
11.  PredniSONE 7.5 mg PO DAILY  
12.  Ruxolitinib 5 mg PO BID  
13.  Sulfameth/Trimethoprim SS 1 TAB PO DAILY  
14.  Tacrolimus 0.5 mg PO DAILY  
15.  Vitamin D ___ UNIT PO 1X/WEEK (WE)  

 
Discharge Disposition:
Home With Service
 
Facility:
___
 
Discharge Diagnosis:
PRIMARY DIAGNOSES
===================
# Aspergillus pneumonia
# Anaerobe bacteremia
# Acute myelogenous leukemia s/p allogeneic stem cell transplant

SECONDARY DIAGNOSIS
=====================
# Recent enterococcus bacteremia
# Gastrointestinal graft versus host disease

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Dear ___,  

It was a privilege taking care of you at ___ 
___.  

WHY WAS I IN THE HOSPITAL?  
- You came to the hospital because on the results of your 
bronchoalveolar lavage a test for fungal infections was 
positive.
- Additionally, while in the hospital, you had a positive blood 
culture duringan episode of fever.

WHAT HAPPENED TO ME IN THE HOSPITAL?  
- You were started on 2 different antifungals to cover the 
suspected fungal infection in your lungs.
- You had an episode of fever during which we took a blood 
culture that was positive for bacteria.
- You were started on antibiotics to cover you for bacteria and 
once we had the final result of the culture the antibiotic was 
tailored to cover the specific bacteria.

WHAT SHOULD I DO AFTER I LEAVE THE HOSPITAL?  
- Continue to take all your medicines and keep your 
appointments.  

We wish you the best.

Sincerely,  
Your ___ Team  

 
Followup Instructions:
___
